```
=> s amyloid(w)beta(w)peptide
L1       12537 AMYLOID(W) BETA(W) PEPTIDE

=> s beta(w)amyloid(w)peptide
L2        9399 BETA(W) AMYLOID(W) PEPTIDE

=> s nogo(w)receptor(w)antagonist
L3          13 NOGO(W) RECEPTOR(W) ANTAGONIST

=> d l3 1-13

L3   ANSWER 1 OF 13  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
AN   2006:436251  BIOSIS
DN   PREV200600435634
TI   Nogo goes in the pure water: Solution structure of Nogo-60 and design of
     the structured and buffer-soluble Nogo-54 for enhancing CNS regeneration.
AU   Li, Minfen; Liu, Jingxian; Song, Jianxing [Reprint Author]
CS   Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, 10 Kent Ridge
     Crescent, Singapore 119260, Singapore
     bchsj@nus.edu.sg
SO   Protein Science, (AUG 2006) Vol. 15, No. 8, pp. 1835-1841.
     ISSN: 0961-8368.
DT   Article
LA   English
ED   Entered STN: 30 Aug 2006
     Last Updated on STN: 30 Aug 2006

L3   ANSWER 2 OF 13  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:1226364  CAPLUS
DN   146:26348
TI   Neuronal degeneration treatment with Nogo receptor
     antagonists
IN   Lee, Daniel H. S.; Sah, Dinah W. Y.; So, Kwok Fai; Wu, Wutian
PA   Biogen Idec Ma Inc., USA; The University of Hong Kong
SO   PCT Int. Appl., 49pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2006124627       A2     20061123    WO 2006-US18484        20060512
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
            KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
            MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
            SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
            VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRAI US 2005-679995P     P      20050512
     US 2005-735187P     P      20051110

L3   ANSWER 3 OF 13  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:289503  CAPLUS
DN   145:241471
TI   Delayed intraventricular Nogo receptor
     antagonist promotes recovery from stroke by enhancing axonal
     plasticity
AU   Kim, Tae-Won; Lee, Jung-Kil; Joo, Sung-Pil; Kim, Tae-Sun; Kim, Jae-Hyoo;
     Kim, Soo-Han
CS   Department of Neurosurgery, Chonnam National University Hospital, Gwangji,
     S. Korea
SO   Journal of Korean Neurosurgical Society (2006), 39(2), 130-135
     CODEN: JKNSAI.
PB   Korean Neurosurgical Society
DT   Journal
LA   English
RE.CNT  25    THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 4 OF 13  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:823596  CAPLUS
DN   143:222540
TI   Treatment of conditions involving dopaminergic neuronal degeneration using
     Nogo receptor antagonists
IN   Relton, Jane K.; Engber, Thomas M.; Strittmatter, Stephen M.
PA   Biogen Idec MA Inc., USA; Yale University
SO   PCT Int. Appl., 26 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005074972       A2     20050818    WO 2005-US2535         20050128
     WO 2005074972       A3     20051222
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
            RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
            MR, NE, SN, TD, TG
     AU 2005210621       A1     20050818    AU 2005-210621         20050128
     CA 2555018          A1     20050818    CA 2005-2555018        20050128
     EP 1713494          A2     20061025    EP 2005-712127         20050128
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
            BA, HR, IS, YU
     CN 1946418          A      20070411    CN 2005-80009242       20050128
PRAI US 2004-540798P     P      20040130
     WO 2005-US2535      W      20050128

L3   ANSWER 5 OF 13  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:564795  CAPLUS
DN   143:91068
TI   Methods of stimulating axonal growth of CNS neurons using Nogo
     receptor antagonists in combination with growth factors
IN   Benowitz, Larry I.; Fischer, Dietmar
PA   Children's Medical Center Corporation, USA
SO   PCT Int. Appl., 74 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005059515       A2     20050630    WO 2004-US42255        20041216
```

	WO 2005059515	A3	20060908		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE; SN, TD, TG				
	CA 2549000	A1	20050630	CA 2004-2549000	20041216
	EP 1695061	A2	20060830	EP 2004-814439	20041216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	JP 2007514748	T	20070607	JP 2006-545428	20041216
PRAI	US 2003-529833P	P	20031216		
	WO 2004-US42255	W	20041216		

L3 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:927061 CAPLUS
DN 141:406109
TI Treatment of conditions involving amyloid plaques
IN Strittmatter, Stephen M.; Lee, Daniel H. S.; Li, Weiwei
PA USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093893	A2	20041104	WO 2004-US11728	20040416
	WO 2004093893	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004231742	A2	20041104	AU 2004-231742	20040416
	AU 2004231742	A1	20041104		
	CA 2522649	A1	20041104	CA 2004-2522649	20040416
	EP 1615654	A2	20060118	EP 2004-759905	20040416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004009562	A	20060418	BR 2004-9562	20040416
	CN 1832752	A	20060913	CN 2004-80016919	20040416
	JP 2006523708	T	20061019	JP 2006-510107	20040416
	NO 2005005392	A	20051115	NO 2005-5392	20051115
	US 2007065429	A1	20070322	US 2006-553669	20060809
PRAI	US 2003-463424P	P	20030416		
	WO 2004-US11728	W	20040416		

L3 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:142908 CAPLUS
DN 140:198086
TI ***Nogo receptor antagonists*** for promoting survival of neuron and treating multiple sclerosis, CNS neuropathy, and traumatic brain or spinal cord injury
IN Lee, Daniel H. S.; Pepinsky, R. Blake; Li, Weiwei; Rabacchi, Sylvia A.; Relton, Jane K.; Worley, Dane S.; Strittmatter, Stephen M.; Sah, Dinah Y. W.
PA Yale University, USA; Biogen, Inc.
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014311	A2	20040219	WO 2003-US25004	20030807
	WO 2004014311	A3	20040429		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2495121	A1	20040219	CA 2003-2495121	20030807
	AU 2003264033	A1	20040225	AU 2003-264033	20030807
	EP 1534736	A2	20050601	EP 2003-785123	20030807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1681838	A	20051012	CN 2003-821409	20030807
	JP 2005535329	T	20051124	JP 2004-527960	20030807
	AU 2004264405	A1	20050224	AU 2004-264405	20040130
	CA 2535007	A1	20050224	CA 2004-2535007	20040130
	WO 2005016955	A2	20050224	WO 2004-US2702	20040130
	WO 2005016955	A3	20060720		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1660517	A2	20060531	EP 2004-707073	20040130
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004013426	A	20061017	BR 2004-13426	20040130
	JP 2007501612	T	20070201	JP 2006-522535	20040130
	CN 1926147	A	20070307	CN 2004-80029412	20040130
	NO 2005000685	A	20050510	NO 2005-685	20050209
	US 2005271655	A1	20051208	US 2005-55163	20050210
	IN 2005KN00382	A	20060512	IN 2005-KN382	20050309
	NO 2006001081	A	20060418	NO 2006-1081	20060306
PRAI	US 2002-402866P	P	20020810		
	WO 2003-US25004	W	20030807		
	WO 2003-US325004	A	20030807		
	WO 2004-US2702	W	20040130		

L3 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:416397 CAPLUS

DN 139:332941
TI Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury
AU Li, Shuxin; Strittmatter, Stephen M.
CS Department of Neurology and Section of Neurobiology, Yale University School of Medicine, New Haven, CT, 06520, USA
SO Journal of Neuroscience (2003), 23(10), 4219-4227
CODEN: JNRSDS; ISSN: 0270-6474
PB Society for Neuroscience
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 13 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2006363205 EMBASE
TI Nogo goes in the pure water: Solution structure of Nogo-60 and design of the structured and buffer-soluble Nogo-54 for enhancing CNS regeneration.
AU Li M.; Liu J.; Song J.
CS J. Song, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260, Singapore. bchsj@nus.edu.sg
SO Protein Science, (2006) Vol. 15, No. 8, pp. 1835-1841.
Refs: 30
ISSN: 0961-8368 E-ISSN: 1469-896X CODEN: PRCIEI
CY United States
DT Journal; Article
FS 029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 18 Aug 2006
Last Updated on STN: 18 Aug 2006

L3 ANSWER 10 OF 13 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2005100947 EMBASE
TI The newt in us.
AU Rinaldi A.
SO EMBO Reports, (2005) Vol. 6, No. 2, pp. 113-115.
Refs: 10
ISSN: 1469-221X CODEN: ERMEAX
CY United Kingdom
DT Journal; Article
FS 008 Neurology and Neurosurgery
021 Developmental Biology and Teratology
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 17 Mar 2005
Last Updated on STN: 17 Mar 2005

L3 ANSWER 11 OF 13 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2003476128 EMBASE
TI Signaling mechanisms of the myelin inhibitors of axon regeneration.
AU Yiu G.; He Z.
CS Z. He, Division of Neuroscience, Children's Hospital, Harvard Medical School, Boston, MA 02115, United States. zhigang.he@tch.harvard.edu
SO Current Opinion in Neurobiology, (2003) Vol. 13, No. 5, pp. 545-551.
Refs: 67
ISSN: 0959-4388 CODEN: COPUEN
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 4 Dec 2003
Last Updated on STN: 4 Dec 2003

L3 ANSWER 12 OF 13 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2006:388140 TOXCENTER
CP Copyright 2007 ACS
DN CA14602026348C
TI Neuronal degeneration treatment with ***Nogo receptor antagonists***
AU Lee, Daniel H. S.; Sah, Dinah W. Y.; So, Kwok Fai; Wu, Wutian
CS ASSIGNEE: The University of Hong Kong
PI WO 2006124627 A2 23 Nov 2006
SO (2006) PCT Int. Appl., 49pp.
CODEN: PIXXD2.
CY UNITED STATES
DT Patent
FS CAPLUS
OS CAPLUS 2006:1226364
LA English
ED Entered STN: 19 Dec 2006
Last Updated on STN: 5 Jun 2007

L3 ANSWER 13 OF 13 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:192720 TOXCENTER
CP Copyright 2007 ACS
DN CA14306091068P
TI Methods of stimulating axonal growth of CNS neurons using ***Nogo receptor antagonists*** in combination with growth factors
AU Benowitz, Larry I.; Fischer, Dietmar
CS ASSIGNEE: Children's Medical Center Corporation
PI WO 2005059515 A2 30 Jun 2005
SO (2005) PCT Int. Appl., 74 pp.
CODEN: PIXXD2.
CY UNITED STATES
DT Patent
FS CAPLUS
OS CAPLUS 2005:564795
LA English
ED Entered STN: 19 Jul 2005
Last Updated on STN: 9 Jan 2007

=> s reticulon(w)family(w)peptide
L4 0 RETICULON(W) FAMILY(W) PEPTIDE

=> s nogo(w)receptor
L5 459 NOGO(W) RECEPTOR

=> s l5 (p) (l1 or l2)
L6 3 L5 (P) (L1 OR L2)

=> d l6 1-3

L6 ANSWER 1 OF 3 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2002:602313 BIOSIS
DN PREV200200602313
TI The neurotrophin receptor p75NTR: Novel functions and implications for

```
    diseases of the nervous system.
AU  Dechant, Georg; Barde, Yves-Alain [Reprint author]
CS  Friedrich Miescher Institute for Biomedical Research, Maulbeerstr. 66,
    4058, Basel, Switzerland
    yves.barde@fmi.ch
SO  Nature Neuroscience, (November, 2002) Vol. 5, No. 11, pp. 1131-1136.
    print.
    ISSN: 1097-6256.
DT  Article
    General Review; (Literature Review)
LA  English
ED  Entered STN: 27 Nov 2002
    Last Updated on STN: 27 Nov 2002

L6  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
AN  2006:152149  CAPLUS
DN  144:290750
TI  Alzheimer precursor protein interaction with the nogo-66 receptor reduces
    amyloid-β plaque deposition
AU  Park, James H.; Gimbel, David A.; GrandPre, Tadzia; Lee, Jung-Kil; Kim,
    Ji-Eun; Li, Weiwei; Lee, Daniel H. S.; Strittmatter, Stephen M.
CS  Department of Neurology, Yale University School of Medicine, New Haven,
    CT, 06510, USA
SO  Journal of Neuroscience (2006), 26(5), 1386-1395
    CODEN: JNRSDS; ISSN: 0270-6474.
PB  Society for Neuroscience
DT  Journal
LA  English
RE.CNT  36    THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6  ANSWER 3 OF 3  TOXCENTER COPYRIGHT 2007 ACS on STN
AN  2002:273799  TOXCENTER
CP  Copyright (c) 2007 The Thomson Corporation
DN  PREV200200602313
TI  The neurotrophin receptor p75NTR: Novel functions and implications for
    diseases of the nervous system
AU  Dechant, Georg; Barde, Yves-Alain [Reprint author]
CS  Friedrich Miescher Institute for Biomedical Research, Maulbeerstr. 66,
    4058, Basel, Switzerland  yves.barde@fmi.ch
SO  Nature Neuroscience, (November, 2002) Vol. 5, No. 11, pp. 1131-1136.
    print.
    ISSN: 1097-6256.
DT  Article
    General Review; (Literature Review)
FS  BIOSIS
OS  BIOSIS 2002:602313
LA  English
ED  Entered STN: 3 Dec 2002
    Last Updated on STN: 3 Dec 2002


=> s NgR1(w)antagonist
L7            2 NGR1(W) ANTAGONIST

=> d l7 1-2

L7  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
AN  2006:1226364  CAPLUS
DN  146:26348
TI  Neuronal degeneration treatment with Nogo receptor antagonists
IN  Lee, Daniel H. S.; Sah, Dinah W. Y.; So, Kwok Fai; Wu, Wutian
PA  Biogen Idec Ma Inc., USA; The University of Hong Kong
SO  PCT Int. Appl., 49pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 1
    PATENT NO.          KIND   DATE       APPLICATION NO.          DATE
    ---------------     ----   --------   --------------------     --------
PI  WO 2006124627        A2    20061123   WO 2006-US18484          20060512
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
            KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
            MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
            SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
            VN, YU, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRAI US 2005-679995P      P     20050512
    US 2005-735187P       P     20051110

L7  ANSWER 2 OF 2  TOXCENTER COPYRIGHT 2007 ACS on STN
AN  2006:388140  TOXCENTER
CP  Copyright 2007 ACS
DN  CA146020263480
TI  Neuronal degeneration treatment with Nogo receptor antagonists
AU  Lee, Daniel H. S.; Sah, Dinah W. Y.; So, Kwok Fai; Wu, Wutian
CS  ASSIGNEE: The University of Hong Kong
PI  WO 2006124627 A2 23 Nov 2006
SO  (2006) PCT Int. Appl., 49pp.
    CODEN: PIXXD2.
CY  UNITED STATES
DT  Patent
FS  CAPLUS
OS  CAPLUS 2006:1226364
LA  English
ED  Entered STN: 19 Dec 2006
    Last Updated on STN: 5 Jun 2007


=> d his

    (FILE 'HOME' ENTERED AT 15:48:48 ON 19 JUN 2007)

    FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, TOXCENTER' ENTERED AT 15:49:02 ON
    19 JUN 2007
L1        12537 S AMYLOID(W)BETA(W)PEPTIDE
L2         9399 S BETA(W)AMYLOID(W)PEPTIDE
L3           13 S NOGO(W)RECEPTOR(W)ANTAGONIST
L4            0 S RETICULON(W)FAMILY(W)PEPTIDE
L5          459 S NOGO(W)RECEPTOR
L6            3 S L5 (P) (L1 OR L2)
L7            2 S NGR1(W)ANTAGONIST

=> s l13 and alzheimer
L13 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l3 and alzheimer
L8            4 L3 AND ALZHEIMER

=> d l8 1-4
```

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:823596 CAPLUS
DN 143:222540
TI Treatment of conditions involving dopaminergic neuronal degeneration using ***Nogo receptor antagonists***
IN Relton, Jane K.; Engber, Thomas M.; Strittmatter, Stephen M.
PA Biogen Idec MA Inc., USA; Yale University
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005074972	A2	20050818	WO 2005-US2535	20050128
	WO 2005074972	A3	20051222		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005210621	A1	20050818	AU 2005-210621	20050128
	CA 2555018	A1	20050818	CA 2005-2555018	20050128
	EP 1713494	A2	20061025	EP 2005-712127	20050128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	CN 1946418	A	20070411	CN 2005-80009242	20050128
PRAI	US 2004-540798P	P	20040130		
	WO 2005-US2535	W	20050128		

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:564795 CAPLUS
DN 143:91068
TI Methods of stimulating axonal growth of CNS neurons using ***Nogo receptor antagonists*** in combination with growth factors
IN Benowitz, Larry I.; Fischer, Dietmar
PA Children's Medical Center Corporation, USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005059515	A2	20050630	WO 2004-US42255	20041216
	WO 2005059515	A3	20060908		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2549000	A1	20050630	CA 2004-2549000	20041216
	EP 1695061	A2	20060830	EP 2004-814439	20041216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	JP 2007514748	T	20070607	JP 2006-545428	20041216
PRAI	US 2003-529833P	P	20031216		
	WO 2004-US42255	W	20041216		

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:927061 CAPLUS
DN 141:406109
TI Treatment of conditions involving amyloid plaques
IN Strittmatter, Stephen M.; Lee, Daniel H. S.; Li, Weiwei
PA USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093893	A2	20041104	WO 2004-US11728	20040416
	WO 2004093893	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004231742	A2	20041104	AU 2004-231742	20040416
	AU 2004231742	A1	20041104		
	CA 2522649	A1	20041104	CA 2004-2522649	20040416
	EP 1615654	A2	20060118	EP 2004-759905	20040416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004009562	A	20060418	BR 2004-9562	20040416
	CN 1832752	A	20060913	CN 2004-80016919	20040416
	JP 2006523708	T	20061019	JP 2006-510107	20040416
	NO 2005005392	A	20051115	NO 2005-5392	20051115
	US 2007065429	A1	20070322	US 2006-553669	20060809
PRAI	US 2003-463424P	P	20030416		
	WO 2004-US11728	W	20040416		

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:142908 CAPLUS
DN 140:198086
TI ***Nogo receptor antagonists*** for promoting survival of neuron and treating multiple sclerosis, CNS neuropathy, and traumatic brain or spinal cord injury
IN Lee, Daniel H. S.; Pepinsky, R. Blake; Li, Weiwei; Rabacchi, Sylvia A.; Relton, Jane K.; Worley, Dane S.; Strittmatter, Stephen M.; Sah, Dinah Y. W.
PA Yale University, USA; Biogen, Inc.
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DT Patent
LA English

```
FAN.CNT 1
     PATENT NO.            KIND   DATE        APPLICATION NO.      DATE
     ---------------       ----   --------    -------------------  --------
PI   WO 2004014311         A2     20040219    WO 2003-US25004      20030807
     WO 2004014311         A3     20040429
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2495121            A1     20040219    CA 2003-2495121      20030807
     AU 2003264033         A1     20040225    AU 2003-264033       20030807
     EP 1534736            A2     20050601    EP 2003-785123       20030807
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1681838            A      20051012    CN 2003-821409       20030807
     JP 2005535329         T      20051124    JP 2004-527960       20030807
     AU 2004264405         A1     20050224    AU 2004-264405       20040130
     CA 2535007            A1     20050224    CA 2004-2535007      20040130
     WO 2005016955         A2     20050224    WO 2004-US2702       20040130
     WO 2005016955         A3     20060720
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1660517            A2     20060531    EP 2004-707073       20040130
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2004013426         A      20061017    BR 2004-13426        20040130
     JP 2007501612         T      20070201    JP 2006-522535       20040130
     CN 1926147            A      20070307    CN 2004-80029412     20040130
     NO 2005000685         A      20050510    NO 2005-685          20050209
     US 2005271655         A1     20051208    US 2005-55163        20050210
     IN 2005KN00382        A      20060512    IN 2005-KN382        20050309
     NO 2006001081         A      20060418    NO 2006-1081         20060306
PRAI US 2002-402866P       P      20020810
     WO 2003-US25004       W      20030807
     WO 2003-US325004      A      20030807
     WO 2004-US2702        W      20040130


=> s l5 and (l1 or l2)
L9            3 L5 AND (L1 OR L2)

=> s Lingo-1(w)antagonist
L10          10 LINGO-1(W) ANTAGONIST

=> s l10 and (l1 or l2)
L11           0 L10 AND (L1 OR L2)

=> s l10 and alzhemimer
L12.          0 L10 AND ALZHEMIMER
```

```
=> s l10 and alzheimer
L13           1 L10 AND ALZHEIMER

=> d l13

L13  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:13021  CAPLUS
DN   144:101055
TI   Protein Sp35/LINGO-1 antagonists for
     treatment of conditions involving demyelination
IN   Mi, Sha; Pepinsky, R. Blake; McCoy, John
PA   Biogen Idec Ma Inc., USA
SO   PCT Int. Appl., 183 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.            KIND   DATE        APPLICATION NO.      DATE
     ---------------       ----   --------    -------------------  --------
PI   WO 2006002437         A2     20060105    WO 2005-US22881      20050624
     WO 2006002437         A3     20061228
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
             KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM
     AU 2005258335         A1     20060105    AU 2005-258335       20050624
     CA 2572193            A1     20060105    CA 2005-2572193      20050624
     US 2006009388         A1     20060112    US 2005-165576       20050624
     EP 1776136            A2     20070425    EP 2005-764255       20050624
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
             HR, LV, MK, YU
     CN 1972707            A      20070530    CN 2005-80020998     20050624
PRAI US 2004-582966P       P      20040624
     US 2004-617297P       P      20041007
     US 2004-628435P       P      20041115
     US 2005-680475P       P      20050513
     WO 2005-US22881       W      20050624
OS   MARPAT 144:101055


=> s NEP"1-40"
L14          25 NEP"1-40"

=> d l14 1-25 kwic

L14  ANSWER 1 OF 25     MEDLINE on STN
AB   . . . the thalamus in RHRSP was observed at 1, 2 and 4 weeks after
     distal MCAO.  In addition, intracerebroventricular infusion of
     NEP1-40, a Nogo-66 receptor (NgR) antagonist peptide,
     was administered starting 24 h after MCAO and continued for 1, 2 and 4.
     . the expression of Nogo-A in oligodendrocytes increased persistently and
     its localization became redistributed around damaged axons and dendrites.
     Administration of NEP1-40 downregulated the expression
     of Nogo-A, reduced axonal injury and enhanced axonal regeneration.  Our
     data suggest that Nogo-A is involved in. . .
```

L14 ANSWER 2 OF 25 MEDLINE on STN
AB . . . inhibitors (MAI). To overcome CSPG- or myelin-induced inhibition, strategies based on extrinsic and intrinsic treatments have been developed. For example, ***NEP1-40*** is a synthetic peptide that promotes axonal regeneration by blocking Nogo-66/NgR interaction and chondroitinase ABC (ChABC), which degrades CS, thereby. . model, overexpressed CSPG and MAI impaired axon regrowth, which mimics regeneration failure in vivo. Both CS cleavage with ChABC and ***NEP1-40*** strongly facilitated the regrowth of entorhinal axons after axotomy, permitting the re-establishment of synaptic contacts with target cells. However, the combined treatment did not improve the regeneration induced by ChABC alone, and the delayed treatment of ChABC, but not ***NEP1-40***, had a less pronounced effect on axonal regrowth compared with acute treatment. These results provide insight into the development of. . .
CN 0 (Myelin Proteins); 0 (***NEP1-40*** protein, human); 0 (Nogo protein); 0 (Peptide Fragments); 0 (Proteochondroitin Sulfates); 0 (Receptors, Cell Surface); 0 (Rtn4r protein, mouse); EC. . .

L14 ANSWER 3 OF 25 MEDLINE on STN
TI Cloning of ***NEP1-40*** gene and expression of its protein.
AB OBJECTIVE: To clone the genes of nogo-66 and ***NEP1-40*** from spinal cord of rat and to realize the expression of its protein in vitro. METHODS: The nogo-66 and ***NEP1-40*** genes were cloned from the spinal cord of juvenil rat by use of RT-PCR techniques, and the objective genes were. . . express the proteins. The two proteins were purified by Ni-column and detected by using Western-blot test. RESULTS: The Nogo-66 and ***NEP1-40*** genes were successfully cloned from rat, which were 215 bp and 137 bp for each one when add the enzyme. . . the results of electrophoresis. The expression plasmids were induced by IPTG and got the purified GST fusion protein nogo-66 and ***NEP1-40***, which relative molecular weight were 33.2 x 10(3) and 30.3 x 10(3) respectively. The results of Western-blot test confirmed that the antigenicity of the two proteins was precise. CONCLUSION: Nogo-66 and ***NEP1-40*** proteins can be expressed in a high efficiency in vitro using genetic engineering, so it provides a good basis for. . .

L14 ANSWER 4 OF 25 MEDLINE on STN
AB IN-1, the monoclonal antibody against the exon 3-encoded N-terminal domain of Nogo-A, and the Nogo-66 receptor (NgR) antagonist ***NEP1-40*** have both shown efficacy in promoting regeneration in animal spinal cord injury models, the latter even when administered subcutaneously 1. . . targeted disruption of Nogo and NgR have, surprisingly, only modest regenerative capacity (if any) compared with treatment with IN-1 or ***NEP1-40***. Disruption of the Nogo gene by various groups yielded results ranging from significant regenerative improvement in young mice to number . . background, we suggest here some possible and testable explanations for the above phenomena. These possibilities include effects of IN-1 and ***NEP1-40*** on the CNS beyond neutralization of Nogo and NgR functions, and the latter's possible role in the CNS beyond that. . .

L14 ANSWER 5 OF 25 MEDLINE on STN
AB . . . approach can be adapted to systemic therapy in a postinjury therapeutic time window. Subcutaneous treatment with the NgR antagonist peptide ***NEP1-40*** (Nogo extracellular peptide, residues 1-40) results in extensive growth of corticospinal axons, sprouting of serotonergic fibers, upregulation of axonal growth. . . protein 1A), and synapse re-formation. Locomotor recovery after thoracic spinal cord injury is enhanced. Furthermore, delaying the initiation of systemic ***NEP1-40*** administration for up to 1 week after cord lesions does not limit the degree of axon sprouting and functional recovery. . .

L14 ANSWER 6 OF 25 MEDLINE on STN
AB . . . NgR. Here, we identify competitive antagonists of NgR derived from amino-terminal peptide fragments of Nogo-66. The Nogo-66(1 40) antagonist peptide (***NEP1 40***) blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro, demonstrating that NgR mediates a significant portion of axonal outgrowth inhibition by myelin. Intrathecal administration of ***NEP1 40*** to rats with mid-thoracic spinal cord hemisection results in significant axon growth of the corticospinal tract, and improves functional recovery. Thus, Nogo-66 and NgR have central roles in limiting axonal regeneration after CNS injury, and ***NEP1-40*** provides a potential therapeutic agent.

L14 ANSWER 7 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB. . . inhibitors (MAI). To overcome CSPG- or myelin-induced inhibition, strategies based on extrinsic and intrinsic treatments have been developed. For example, ***NEP1-40*** is a synthetic peptide that promotes axonal regeneration by blocking Nogo-66/NgR interaction and chondroitinase ABC (ChABC), which degrades CS, thereby. . model, overexpressed CSPG and MAI impaired axon regrowth, which mimics regeneration failure in vivo. Both CS cleavage with ChABC and ***NEP1-40*** strongly facilitated the regrowth of entorhinal axons after axotomy, permitting the re-establishment of synaptic contacts with target cells. However, the combined treatment did not improve the regeneration induced by ChABC alone, and the delayed treatment of ChABC, but not ***NEP1-40***, had a less pronounced effect on axonal regrowth compared with acute treatment. These results provide insight into the development of. . .
IT . . .
nervous system
IT Chemicals & Biochemicals
chondroitin sulfate proteoglycans; chondroitinase ABC [EC 4.2.2.4]; myelin-associated glycoprotein; Nogo-66 receptor; oligodendrocyte myelin glycoprotein; ***NEP1-40***

L14 ANSWER 8 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB IN-1, the monoclonal antibody against the exon 3-encoded N-terminal domain of Nogo-A, and the Nogo-66 receptor (NgR) antagonist ***NEP1-40*** have both shown efficacy in promoting regeneration in animal spinal cord injury models, the latter even when administered subcutaneously 1. . . targeted disruption of Nogo and NgR have, surprisingly, only modest regenerative capacity (if any) compared with treatment with IN-1 or ***NEP1-40***. Disruption of the Nogo gene by various groups yielded results ranging from significant regenerative improvement in young mice to number . . background, we suggest here some possible and testable explanations for the above phenomena. These possibilities include effects of IN-1 and ***NEP1-40*** on the CNS beyond neutralization of Nogo and NgR functions, and the latter's possible role in the CNS beyond that. . .
IT . . .
system disease, injury
Spinal Cord Injuries (MeSH)
IT Chemicals & Biochemicals
Nogo receptor; Nogo-66 receptor; neutralizing agent; IN-1; Nogo-A: N-terminal domain; ***NEP1-40***: immunologic-drug, immunostimulant-drug, subcutaneous administration

L14 ANSWER 9 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB. . . of CNS myelin than those that target specific myelin proteins e.g. the anti-NogoA antibody, IN-1 or the NogoA derived peptide, ***NEP1-40***, even though both reagents successfully promote neurite outgrowth or axonal regeneration in vitro and in vivo. Recently, two NgR1

homologues,. . .

IT . . .
CNS: nervous system; DRG neurites; DRG neurons: nervous system; neurites: nervous system

IT Chemicals & Biochemicals
CNS myelin; IN-1; MAG; ***NEP1-40***; Nogo; Nogo66; NogoA; antibodies; leucine; myelin protein; p75; rhoA

L14 ANSWER 10 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AB. . . competitive binding between AP-Nogo66 and MAG in CHO cells overexpresssing NgR1, whereas Liu et al. (2002, Science 297:1190-3) showed that ***NEP1-40*** (a peptide derived from Nogo66) was unable to block MAG binding to NgR1 but successfully blocked AP-Nogo66. We compared MAG. . .

IT . . .
Organisms
CNS: nervous system; membrane; neurons: nervous system; oligodendrocytes: nervous system

IT Chemicals & Biochemicals
GPI; GST; MAG [myelin-associated glycoprotein]; ***NEP1-40***; Nogo-A; Nogo66; SPA; glycoprotein; membrane protein; myelin protein

L14 ANSWER 11 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AB. . . conclusion about the role of Nogo-66 or its receptor (NgR). We identify a peptide antagonist .(Nogo Extracellular Peptide residues 1-40, ***NEP1-40***) of the Nogo-66 Receptor derived from amino terminal fragments of the Nogo-66 domain. This antagonist binds to the Nogo-66 Receptor. . . These findings reveal the central role of the Nogo-66 Receptor in limiting axonal regeneration after adult mammalian CNS injury, and ***NEP1-40*** provides a potential therapeutic approach to treating traumatic CNS axonal injury.

IT . . .
nervous system

IT Diseases
spinal cord injury: injury, nervous system disease, drug therapy
Spinal Cord Injuries (MeSH)

IT Chemicals & Biochemicals
NEP1-40 [Nogo extracellular peptide residues 1-40]: central stimulant-drug, neuroprotectant-drug, pharmacodynamics; Nogo-66 receptor: therapeutic recovery; myelin

L14 ANSWER 12 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AB. . . approach can be adapted to systemic therapy in a postinjury therapeutic time window. Subcutaneous treatment with the NgR antagonist peptide ***NEP1-40*** (Nogo extracellular peptide, residues 1-40) results in extensive growth of corticospinal axons, sprouting of serotonergic fibers, upregulation of axonal growth. . . protein 1A), and synapse re-formation. Locomotor recovery after thoracic spinal cord injury is enhanced. Furthermore, delaying the initiation of systemic ***NEP1-40*** administration for up to 1 week after cord lesions does not limit the degree of axon sprouting and functional recovery.. . .

IT . . .
serotonergic fiber: nervous system

IT Diseases
spinal cord injury: injury, nervous system disease
Spinal Cord Injuries (MeSH)

IT Chemicals & Biochemicals
NEP1-40 peptide; Nogo; Nogo-66 receptor antagonist: delayed systemic administration; SPRR1A [small proline-rich repeat protein 1A]

L14 ANSWER 13 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AB. . . or NgR. Here, we identify competitive antagonists of NgR derived from amino-terminal peptide fragments of Nogo-66. The Nogo-66(1-40) antagonist peptide (***NEP1-40***) blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro, demonstrating that NgR mediates a significant portion of axonal outgrowth inhibition by myelin. Intrathecal administration of ***NEP1-40*** to rats with mid-thoracic spinal cord hemisection results in significant axon growth of the corticospinal tract, and improves functional recovery. Thus, Nogo-66 and NgR have central roles in limiting axonal regeneration after CNS injury, and ***NEP1-40*** provides a potential therapeutic agent.

L14 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . the thalamus in RHRSP was observed at 1, 2 and 4 wk after distal MCAO. In addition, intracerebroventricular infusion of ***NEP1-40***, a Nogo-66 receptor (NgR) antagonist peptide, was administered starting 24 h after MCAO and continued for 1, 2 and 4. . . the expression of Nogo-A in oligodendrocytes increased persistently and its localization became redistributed around damaged axons and dendrites. Administration of ***NEP1-40*** downregulated the expression of Nogo-A, reduced axonal injury and enhanced axonal regeneration. Our data suggest that Nogo-A is involved in. . .

IT Injury
(axon; ***NEP1-40*** reduced axonal injury and enhanced axonal regeneration)

IT Axon
(disease, injury; ***NEP1-40*** reduced axonal injury and enhanced axonal regeneration)

IT Axon
(regeneration; ***NEP1-40*** reduced axonal injury and enhanced axonal regeneration)

L14 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

TI Cloning of ***NEP1-40*** gene and expression of its protein

AB The genes of nogo-66 and ***NEP1-40*** from spinal cord of rat were cloned and the expression of its protein in vitro was studied. The nogo-66 and ***NEP1-40*** genes were cloned from the spinal cord of juvenil rat by RT-PCR techniques, and the objective genes were bonded to. . . proteins. The two proteins were purified by Ni-column and detected by using Western-blot test. Results showed that the Nogo-66 and ***NEP1-40*** genes were successfully cloned from rat, which were 215 bp and 137 bp for each one when add the enzyme. . . the results of electrophoresis. The expression plasmids were induced by IPTG and got the purified GST fusion protein nogo-66 and ***NEP1-40***, which relative mol. weight were 33.2+103 and 30.3+103, resp. The results of Western-blot test confirmed that the antigenicity of the two proteins was precise. It was conclusion that Nogo-66 and ***NEP1-40*** proteins could be expressed in high efficiency in vitro using genetic engineering, which provided a good basis for further research. . .

L14 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . glycoprotein) and OMgp (oligodendrocyte-myelin glycoprotein) in spinal cord injury (SCI) and the immunotherapy for SCI with monoclonal antibodies of Nogo-A, ***NEP1-40*** and DNA vaccines, etc.

L14 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . inhibitors (MAI). To overcome CSPG- or myelin-induced inhibition, strategies based on extrinsic and intrinsic treatments have been developed. For example, ***NEP1-40*** is a synthetic

peptide that promotes axonal regeneration by blocking Nogo-66/NgR interaction and chondroitinase ABC (ChABC), which degrades CS, thereby. . . model, overexpressed CSPG and MAI impaired axon regrowth, which mimics regeneration failure in vivo. Both CS cleavage with ChABC and ***NEP1-40*** strongly facilitated the regrowth of entorhinal axons after axotomy, permitting the re-establishment of synaptic contacts with target cells. However, the combined treatment did not improve the regeneration induced by ChABC alone, and the delayed treatment of ChABC, but not ***NEP1-40***, had a less pronounced effect on axonal regrowth compared with acute treatment. These results provide insight into the development of. . .

ST regeneration entorhino hippocampal axon degrdn proteoglycan signaling; chondroitinase ABC ***NEP1 40*** entorhino hippocampal axon regeneration

L14 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

AB A review. IN-1, the monoclonal antibody against the exon 3-encoded N-terminal domain of Nogo-A, and the Nogo-66 receptor (NgR) antagonist ***NEP1-40*** have both shown efficacy in promoting regeneration in animal spinal cord injury models, the latter even when administered s.c. 1. . . targeted disruption of Nogo and NgR have, surprisingly, only modest regenerative capacity (if any) compared with treatment with IN-1 or ***NEP1-40***. Disruption of the Nogo gene by various groups yielded results ranging from significant regenerative improvement in young mice to number . . background, we suggest here some possible and testable explanations for the above phenomena. These possibilities include effects of IN-1 and ***NEP1 -40*** on the CNS beyond neutralization of Nogo and NgR functions, and the latter's possible role in the CNS beyond that. . .

L14 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . approach can be adapted to systemic therapy in a postinjury therapeutic time window. S.C. treatment with the NgR antagonist peptide ***NEP1-40*** (Nogo extracellular peptide, residues 1-40) results in extensive growth of corticospinal axons, sprouting of serotonergic fibers, upregulation of axonal growth. . . protein 1A), and synapse re-formation. Locomotor recovery after thoracic spinal cord injury is enhanced. Furthermore, delaying the initiation of systemic ***NEP1-40*** administration for up to 1 wk after cord lesions does not limit the degree of axon sprouting and functional recovery. . .

L14 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . or NgR. Here, we identify competitive antagonists of NgR derived from amino-terminal peptide fragments of Nogo-66. The Nogo-66(1-40) antagonist peptide (***NEP1-40***) blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro, demonstrating that NgR mediates a significant portion of axonal outgrowth inhibition by myelin. Intrathecal administration of ***NEP1-40*** to rats with mid-thoracic spinal cord hemisection results in significant axon growth of the corticospinal tract, and improves functional recovery. Thus, Nogo-66 and NgR have central roles in limiting axonal regeneration after CNS injury, and ***NEP1-40*** provides a potential therapeutic agent.

L14 ANSWER 21 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB . . . the thalamus in RHRSP was observed at 1, 2 and 4 weeks after distal MCAO. In addition, intracerebroventricular infusion of ***NEP1-40***, a Nogo-66 receptor (NgR) antagonist peptide, was administered starting 24 h after MCAO and continued for 1, 2 and 4. . . the expression of Nogo-A in oligodendrocytes increased persistently and its localization became redistributed around damaged axons and dendrites. Administration of ***NEP1-40*** downregulated the expression of Nogo-A, reduced axonal injury and enhanced axonal regeneration. Our data suggest that Nogo-A is involved in. . .

CT Medical Descriptors:
animal . . . localization
rat
stroke prone spontaneously hypertensive rat
thalamus ventral nucleus
Nogo 66 receptor
amyloid precursor protein: EC, endogenous compound
microtubule associated protein 2: EC, endogenous compound
nepl 40: DV, drug development
nepl 40: DT, drug therapy
nepl 40: CV, intracerebroventricular drug administration
nepl 40: PD, pharmacology
neuromodulin: EC, endogenous compound
*protein Nogo A: EC, endogenous compound
receptor blocking agent: DV, drug development
receptor blocking agent: DT, drug. . .

CN ***(1) Nepl 40***

L14 ANSWER 22 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB IN-1, the monoclonal antibody against the exon 3-encoded N-terminal domain of Nogo-A, and the Nogo-66 receptor (NgR) antagonist ***NEP1-40*** have both shown efficacy in promoting regeneration in animal spinal cord injury models, the latter even when administered subcutaneously 1. . : targeted disruption of Nogo and NgR have, surprisingly, only modest regenerative capacity (if any) compared with treatment with IN-1 or ***NEP1-40***. Disruption of the Nogo gene by various groups yielded results ranging from significant regenerative improvement in young mice to number . . background, we suggest here some possible and testable explanations for the above phenomena. These possibilities include effects of IN-1 and ***NEP1 -40*** on the CNS beyond neutralization of Nogo and NgR functions, and the letter's possible role in the CNS beyond that. . .

L14 ANSWER 23 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

CT Medical Descriptors:
*central . . .
comparison
monoclonal antibody 7B12: DV, drug development
monoclonal antibody 7B12: DT, drug therapy
monoclonal antibody 7B12: PD, pharmacology
monoclonal antibody 7B12: IV, intravenous drug administration
monoclonal antibody NEP1 40: CM, drug comparison
monoclonal antibody NEP1 40: DV, drug development
monoclonal antibody NEP1 40: DT, drug therapy
monoclonal antibody NEP1 40: PD, pharmacology
monoclonal antibody NEP1 40: IP, intraperitoneal drug administration
monoclonal antibody NEP1 40: SC, subcutaneous drug administration
monoclonal antibody AS472: CM, drug comparison
monoclonal antibody AS472: DV, drug development
monoclonal antibody AS472: DT,. . .

L14 ANSWER 24 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB . . . approach can be adapted to systemic therapy in a postinjury therapeutic time window. Subcutaneous treatment with the NgR antagonist peptide ***NEP1-40*** (Nogo extracellular peptide, residues 1-40) results in extensive growth of corticospinal axons, sprouting of serotonergic fibers, upregulation of axonal growth. . . protein 1A), and synapse re-formation. Locomotor recovery after thoracic spinal cord

injury is enhanced. Furthermore, delaying the initiation of systemic ***NEP1-40*** administration for up to 1 week after cord lesions does not limit the degree of axon sprouting and functional recovery.. . .

L14 ANSWER 25 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AB . . . or NgR. Here, we identify competitive antagonists of NgR derived from aminoterminal peptide fragments of Nogo-66. The Nogo-66(1-40) antagonist peptide (***NEP1-40***) blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro, demonstrating that NgR mediates a significant portion of axonal outgrowth inhibition by myelin. Intrathecal administration of ***NEP1-40*** to rats with midthoracic spinal cord hemisection results in significant axon growth of the corticospinal tract, and improves functional recovery. Thus, Nogo-66 and NgR have central roles in limiting axonal regeneration after CNS injury, and ***NEP1-40*** provides a potential therapeutic agent.

=> s l14 and (l1 or l2)
L15 0 L14 AND (L1 OR L2)

=> s l14 and alzheimer
L16 0 L14 AND ALZHEIMER

=> d l14 1-25

L14 ANSWER 1 OF 25 MEDLINE on STN
AN 2007239440 IN-PROCESS
DN PubMed ID: 17382469
TI Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction.
AU Wang Fang; Liang Zhijian; Hou Qinghua; Xing Shihui; Ling Li; He Meixia; Pei Zhong; Zeng Jinsheng
CS Department of Neurology and Stroke Center, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.
SO Neuroscience letters, (2007 May 7) Vol. 417, No. 3, pp. 255-60. Electronic Publication: 2007-03-12. Journal code: 7600130. ISSN: 0304-3940.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 24 Apr 2007 Last Updated on STN: 13 Jun 2007

L14 ANSWER 2 OF 25 MEDLINE on STN
AN 2006120738 MEDLINE
DN PubMed ID: 16407455
TI Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling.
AU Mingorance Ana; Sole Marta; Muneton Vilma; Martinez Albert; Nieto-Sampedro Manuel; Soriano Eduardo; del Rio Jose Antonio
CS Development and Regeneration of the CNS, Department of Cell Biology, IRB-PCB, University of Barcelona, Barcelona, Spain.
SO The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, (2006 Mar) Vol. 20, No. 3, pp. 491-3. Electronic Publication: 2006-01-11. Journal code: 8804484. E-ISSN: 1530-6860.
CY United States
DT (IN VITRO) Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200604
ED Entered STN: 2 Mar 2006 Last Updated on STN: 22 Apr 2006 Entered Medline: 21 Apr 2006

L14 ANSWER 3 OF 25 MEDLINE on STN
AN 2006071862 IN-PROCESS
DN PubMed ID: 16457436
TI Cloning of ***NEP1-40*** gene and expression of its protein.
AU Gong Fuliang; Wang Kunzheng; Yu Pengbo
CS Department of Orthopaedic Surgery, Second Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, 710004, PR China.
SO Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, (2006 Jan) Vol. 20, No. 1, pp. 9-12. Journal code: 9425194. ISSN: 1002-1892.
CY China
DT (ENGLISH ABSTRACT) Journal; Article; (JOURNAL ARTICLE)
LA Chinese
FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 7 Feb 2006 Last Updated on STN: 12 Dec 2006

L14 ANSWER 4 OF 25 MEDLINE on STN
AN 2005427718 MEDLINE
DN PubMed ID: 16092935
TI Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents?.
AU Teng Felicia Yu Hsuan; Tang Bor Luen
CS Department of Biochemistry and Programme in Neurobiology and Aging, National University of Singapore, Singapore.
SO Journal of neurochemistry, (2005 Aug) Vol. 94, No. 4, pp. 865-74. Ref: 70 Journal code: 2985190R. ISSN: 0022-3042.
CY England: United Kingdom
DT (COMPARATIVE STUDY) Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T) General Review; (REVIEW)
LA English
FS Priority Journals
EM 200509
ED Entered STN: 15 Aug 2005 Last Updated on STN: 28 Sep 2005 Entered Medline: 27 Sep 2005

L14 ANSWER 5 OF 25 MEDLINE on STN
AN 2003241538 MEDLINE
DN PubMed ID: 12764110
TI Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury.
AU Li Shuxin; Strittmatter Stephen M
CS Department of Neurology and Section of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
SO The Journal of neuroscience : the official journal of the Society for Neuroscience, (2003 May 15) Vol. 23, No. 10, pp. 4219-27. Journal code: 8102140. E-ISSN: 1529-2401.
CY United States
DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200306
ED Entered STN: 24 May 2003
Last Updated on STN: 26 Jun 2003
Entered Medline: 25 Jun 2003

L14 ANSWER 6 OF 25 MEDLINE on STN
AN 2002297070 MEDLINE
DN PubMed ID: 12037567
TI Nogo-66 receptor antagonist peptide promotes axonal regeneration.
AU GrandPre Tadzia; Li Shuxin; Strittmatter Stephen M
CS Department of Neurology and Section of Neurobiology, Yale University School of Medicine, New Haven, CT 06520, USA.
SO Nature, (2002 May 30) Vol. 417, No. 6888, pp. 547-51.
Journal code: 0410462. ISSN: 0028-0836.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200206
ED Entered STN: 31 May 2002
Last Updated on STN: 28 Jun 2002
Entered Medline: 27 Jun 2002

L14 ANSWER 7 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2006:305359 BIOSIS
DN PREV200600300324
TI Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling.
AU Mingorance, Ana; Sole, Marta; Muneton, Vilma; Martinez, Albert; Nieto-Sampedro, Manuel; Soriano, Eduardo; del Rio, Jose Antonio [Reprint Author]
CS Univ Barcelona, IRB PCB, Dept Cell Biol, Dev and Regenerat CNS, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain
jario@pcb.ub.es
SO FASEB Journal, (JAN 2006) Vol. 20, No. 1.
CODEN: FAJOEC. ISSN: 0892-6638.
DT Article
LA English
ED Entered STN: 7 Jun 2006
Last Updated on STN: 7 Jun 2006

L14 ANSWER 8 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2005:440461 BIOSIS
DN PREV200510224444
TI Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents?.
AU Hsuan, Felicia Yu; Tang, Bor Luen [Reprint Author]
CS Natl Univ Singapore, Dept Biochem, 8 Med Dr, Singapore 117597, Singapore
bchtbl@nus.edu.sg
SO Journal of Neurochemistry, (AUG 2005) Vol. 94, No. 4, pp. 865-874.
CODEN: JONRA9. ISSN: 0022-3042.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 26 Oct 2005
Last Updated on STN: 26 Oct 2005

L14 ANSWER 9 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2004:203037 BIOSIS
DN PREV200400203580
TI Neutralization of NgR1 may be sufficient to promote rat DRG neurite outgrowth in the presence of CNS myeline.
AU Li, W. [Reprint Author]; Rabacchi, S. [Reprint Author]; Liu, B.; Pepinsky, B. [Reprint Author]; Jirik, A. [Reprint Author]; Choi, E. [Reprint Author]; Worley, D. [Reprint Author]; Friedman, J. [Reprint Author]; Mullen, C. [Reprint Author]; Walus, L. [Reprint Author]; Benedettu, N. [Reprint Author]; Shao, Z. [Reprint Author]; Levesque, M. [Reprint Author]; Mi, S. [Reprint Author]; Cate, R. [Reprint Author]; Sah, D. [Reprint Author]; Strittmatter, S.; Lee, D. [Reprint Author]
CS Dept. Neurodegeneration, Biogen Inc, Cambridge, MA, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 678.3. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Apr 2004
Last Updated on STN: 14 Apr 2004

L14 ANSWER 10 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2004:203036 BIOSIS
DN PREV200400203579
TI Do MAG and Nogo66 compete for binding to NgR1?.
AU Jirik, A. P. [Reprint Author]; Li, W. [Reprint Author]; Pepinsky, B. [Reprint Author]; Walus, L. [Reprint Author]; Wang, X. [Reprint Author]; Yang, W. [Reprint Author]; Sah, D. W. Y. [Reprint Author]; Lee, D. H. S. [Reprint Author]; Rabacchi, S. A. [Reprint Author]
CS NeuroBiol., Cambridge, MA, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 678.2. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Apr 2004
Last Updated on STN: 14 Apr 2004

L14 ANSWER 11 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2003:303647 BIOSIS
DN PREV200300303647
TI NOGO - 66 RECEPTOR ANTAGONIST PEPTIDE PROMOTES AXONAL REGENERATION AND FUNCTIONAL RECOVERY AFTER SPINAL CORD INJURY.
AU Li, S. [Reprint Author]; GrandPre, T. [Reprint Author]; Strittmatter, S. M. [Reprint Author]
CS Dept of Neurology, Yale University, New Haven, CT, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 203.4. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 2 Jul 2003
Last Updated on STN: 2 Jul 2003

L14 ANSWER 12 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2003:281722 BIOSIS

DN PREV200300281722
TI Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury.
AU Li, Shuxin; Strittmatter, Stephen M. [Reprint Author]
CS Department of Neurology and Section of Neurobiology, Yale University School of Medicine, P.O. Box 208018, New Haven, CT, 06520, USA
stephen.strittmatter@yale.edu
SO Journal of Neuroscience, (May 15 2003) Vol. 23, No. 10, pp. 4219-4227. print.
ISSN: 0270-6474 (ISSN print).
DT Article
LA English
ED Entered STN: 19 Jun 2003
Last Updated on STN: 19 Jun 2003

L14 ANSWER 13 OF 25 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2002:430039 BIOSIS
DN PREV200200430039
TI Nogo-66 receptor antagonist peptide promotes axonal regeneration.
AU GrandPre, Tadzia; Li, Shuxin; Strittmatter, Stephen M. [Reprint author]
CS Department of Neurology and Section of Neurobiology, Yale University School of Medicine, P.O. Box 208018, New Haven, CT, 06520, USA
stephen.strittmatter@yale.edu
SO Nature (London), (30 May, 2002) Vol. 417, No. 6888, pp. 547-551. print.
CODEN: NATUAS. ISSN: 0028-0836.
DT Article
LA English
ED Entered STN: 14 Aug 2002
Last Updated on STN: 14 Aug 2002

L14 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:448022 CAPLUS
TI Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction
AU Wang, Fang; Liang, Zhijian; Hou, Qinghua; Xing, Shihui; Ling, Li; He, Meixia; Pei, Zhong; Zeng, Jinsheng
CS Department of Neurology and Stroke Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, Peop. Rep. China
SO Neuroscience Letters (2007), 417(3), 255-260
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Ltd.
DT Journal
LA English
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:263346 CAPLUS
TI Cloning of *NEP1-40* gene and expression of its protein
AU Gong, Fuliang; Wang, Kunzheng; Yu, Pengbo; Dang, Xiaoqian; Wang, Chunsheng; Shi, Zhibin; Yang, Pei
CS The Second Hospital, Xian Jiaotong University, Xian, Shanxi Province, 710004, Peop. Rep. China
SO Zhongguo Xiufu Chongjian Waike Zazhi (2006), 20(1), 9-12
CODEN: ZXCZEH; ISSN: 1002-1892
PB Sichuan Daxue Huaxi Yiyuan
DT Journal
LA Chinese

L14 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:475553 CAPLUS
DN 145:469446
TI Myelin-associated inhibitive molecules and immune therapy for spinal cord regeneration
AU Yin, Guodong; Tang, Xun
CS Department of Orthopaedics, Kunming General Hospital of Chengdu Military Command, Kunming, 650032, Peop. Rep. China
SO Zhonghua Chuangshang Zazhi (2005), 21(7), 551-553
CODEN: ZCZAFD; ISSN: 1001-8050
PB Zhonghua Chuangshang Zazhi Bianjibu
DT Journal; General Review
LA Chinese

L14 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:267147 CAPLUS
DN 144:445304
TI Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling
AU Mingorance, Ana; Sole, Marta; Muneton, Vilma; Martinez, Albert; Nieto-Sampedro, Manuel; Soriano, Eduardo; del Rio, Jose Antonio
CS Development and Regeneration of the Central Nervous System (CNS), Department of Cell Biology, Barcelona Science Park, University of Barcelona, Barcelona, 08028, Spain
SO FASEB Journal (2006), 20(3), 491-493, 10.1096/fj.05-5121fje
CODEN: FAJOEC; ISSN: 0892-6638
PB Federation of American Societies for Experimental Biology
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:954635 CAPLUS
DN 143:283436
TI Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents?
AU Teng, Felicia Yu Hsuan; Tang, Bor Luen
CS Department of Biochemistry and Programme in Neurobiology and Aging, National University of Singapore, Singapore, Singapore
SO Journal of Neurochemistry (2005), 94(4), 865-874
CODEN: JONRA9; ISSN: 0022-3042
PB Blackwell Publishing Ltd.
DT Journal; General Review
LA English
RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:416397 CAPLUS
DN 139:332941
TI Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury
AU Li, Shuxin; Strittmatter, Stephen M.
CS Department of Neurology and Section of Neurobiology, Yale University School of Medicine, New Haven, CT, 06520, USA
SO Journal of Neuroscience (2003), 23(10), 4219-4227
CODEN: JNRSDS; ISSN: 0270-6474
PB Society for Neuroscience
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:403264 CAPLUS
DN 137:362909

TI Nogo-66 receptor antagonist peptide promotes axonal regeneration
AU GrandPre, Tadzia; Li, Shuxin; Strittmatter, Stephen M.
CS Department of Neurology and Section of Neurobiology, Yale University School of Medicine, New Haven, CT, 06520, USA
SO Nature (London, United Kingdom) (2002), 417(6888), 547-551
CODEN: NATUAS; ISSN: 0028-0836
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 21 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2007183702 EMBASE
TI Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction.
AU Wang F.; Liang Z.; Hou Q.; Xing S.; Ling L.; He M.; Pei Z.; Zeng J.
CS J. Zeng, Department of Neurology, Stroke Center, The First Affiliated Hospital, No. 58, Zhongshan Road 2, Guangzhou, 510080, China. zengjs@pub.guangzhou.gd.cn
SO Neuroscience Letters, (7 May 2007) Vol. 417, No. 3, pp. 255-260. .
Refs: 18
ISSN: 0304-3940 CODEN: NELED5
PUI S 0304-3940(07)00245-5
CY Ireland
DT Journal; Article
FS 029 Clinical Biochemistry
037 Drug Literature Index
005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
LA English
SL English
ED Entered STN: 31 May 2007
Last Updated on STN: 31 May 2007

L14 ANSWER 22 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2005378195 EMBASE
TI Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents?.
AU Teng F.Y.H.; Tang B.L.
CS B.L. Tang, Department of Biochemistry, Programme in Neurobiology and Aging, National University of Singapore, 8 Medical Drive, Singapore 117597, Singapore. bchtbl@nus.edu.sg
SO Journal of Neurochemistry, (2005) Vol. 94, No. 4, pp. 865-874. .
Refs: 71
ISSN: 0022-3042 CODEN: JONRA
CY United Kingdom
DT Journal; (Short Survey)
FS 008 Neurology and Neurosurgery
022 Human Genetics
037 Drug Literature Index
LA English
SL English
ED Entered STN: 22 Sep 2005
Last Updated on STN: 22 Sep 2005

L14 ANSWER 23 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2005069346 EMBASE
TI Strategies for developing Nogo antagonists.
AU Prinjha R.K.; McAdam R.A.; Burbidge S.A.; Ellis J.H.
CS R.K. Prinjha, Neurology and GI-CEDD, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom. Rabinder Prinjha-1@gsk.com
SO Drug Discovery Today: Therapeutic Strategies, (2004) Vol. 1, No. 1, pp. 21-27. .
Refs: 30
ISSN: 1740-6773
PUI S 1740-6773(04)00016-6
CY United Kingdom
DT Journal; Article
FS 008 Neurology and Neurosurgery
022 Human Genetics
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
039 Pharmacy
LA English
SL English
ED Entered STN: 24 Feb 2005
Last Updated on STN: 24 Feb 2005

L14 ANSWER 24 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2003321746 EMBASE
TI Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury.
AU Li S.; Strittmatter S.M.
CS Dr. S.M. Strittmatter, Department of Neurology, Section of Neurobiology, Yale University School of Medicine, P.O. Box 208018, New Haven, CT 06520, United States. stephen.strittmatter@yale.edu
SO Journal of Neuroscience, (15 May 2003) Vol. 23, No. 10, pp. 4219-4227. .
Refs: 50
ISSN: 0270-6474 CODEN: JNRSDS
CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
LA English
SL English
ED Entered STN: 28 Aug 2003
Last Updated on STN: 28 Aug 2003

L14 ANSWER 25 OF 25 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2002199201 EMBASE
TI Nogo-66 receptor antagonist peptide promotes axonal regeneration.
AU GrandPre T.; Shuxin L.I.; Strittmatter S.M.
CS S.M. Strittmatter, Department of Neurology, Section of Neurobiology, Yale University School of Medicine, P.O. Box 208018, New Haven, CT 06520, United States. stephen.strittmatter@yale.edu
SO Nature, (30 May 2002) Vol. 417, No. 6888, pp. 547-551. .
Refs: 14
ISSN: 0028-0836 CODEN: NATUAS
CY United Kingdom
DT Journal; Article
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
LA English
SL English
ED Entered STN: 20 Jun 2002
Last Updated on STN: 20 Jun 2002

=> s alzheimer and (axonal (w)regeneration)
L17 63 ALZHEIMER AND (AXONAL (W) REGENERATION)

=> d l17 58-63

L17 ANSWER 58 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:193359 TOXCENTER
CP Copyright 2007 ACS
DN CA143142418O6U
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons
AU Hirata, Kazunari; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo
CS Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan.
SO Journal of Pharmacology and Experimental Therapeutics, (2005) Vol. 314, No. 1, pp. 252-259.
CODEN: JPETAB. ISSN: 0022-3565.
CY JAPAN
DT Journal
FS CAPLUS
OS CAPLUS 2005:603092
LA English
ED Entered STN: 19 Jul 2005
Last Updated on STN: 29 Aug 2006

L17 ANSWER 59 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:154827 TOXCENTER
CP Copyright (c) 2007 The Thomson Corporation
DN PREV200500203216
TI Neuroprotective role of testosterone in the nervous system
AU Bialek, Magdalena; Zaremba, Pawel; Borowicz, Kinga K.; Czuczwar, Stanislaw J. [Reprint Author]
CS Dept Pathophysiol, Skubiszewski Med Univ, Jaczewskiego 8, PL-20090, Lublin, Poland czuczwarsj@yahoo.com
SO Polish Journal of Pharmacology, (September 2004) Vol. 56, No. 5, pp. 509-518. print.
ISSN: 1230-6002.
DT Article
General Review; (Literature Review)
FS BIOSIS
OS BIOSIS 2005:211699
LA English
ED Entered STN: 7 Jun 2005
Last Updated on STN: 7 Jun 2005

L17 ANSWER 60 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:92303 TOXCENTER
CP Copyright 2007 ACS
DN CA14221386101Z
TI Neuroprotective role of testosterone in the nervous system
AU Bialek, Magdalena; Zaremba, Pawel; Borowicz, Kinga K.; Czuczwar, Stanislaw J.
CS Department of Pathophysiology, Skubiszewski Medical University, Lublin, PL 20-090, Pol..
SO Polish Journal of Pharmacology, (2004) Vol. 56, No. 5, pp. 509-518.
CODEN: PJPAE3. ISSN: 1230-6002.
CY POLAND
DT Journal
FS CAPLUS
OS CAPLUS 2005:243139
LA English
ED Entered STN: 22 Mar 2005
Last Updated on STN: 29 Nov 2005

L17 ANSWER 61 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2003:55704 TOXCENTER
CP Copyright 2007 ACS
DN CA13812162764X
TI Recent advance in adenoviral gene transfer technology for neuronal survival and ***axonal regeneration***
AU Namikawa, Kazuhiko; Kiyama, Hiroshi
CS Dep. Anatomy, Grad. Sch. Med., Osaka City Univ., Japan.
SO Saishin Igaku, (2002) Vol. 57, No. 7, pp. 1591-1600.
CODEN: SAIGAK. ISSN: 0370-8241.
CY JAPAN
DT Journal
FS CAPLUS
OS CAPLUS 2002:604210
LA Japanese
ED Entered STN: 11 Mar 2003
Last Updated on STN: 21 Feb 2006

L17 ANSWER 62 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 1997:28867 TOXCENTER
DN PubMed ID: 9017230
TI Postnatal retinal ganglion cells in vitro: protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes
AU Lucius R; Sievers J
CS Anatomisches Institut, Universitat Kiel, Germany
SO Brain research, (1996 Dec 16) Vol. 743, No. 1-2, pp. 56-62.
Journal code: 0045503. ISSN: 0006-8993.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
FS MEDLINE
OS MEDLINE 97169682
LA English
ED Entered STN: 16 Nov 2001
Last Updated on STN: 16 Nov 2001

L17 ANSWER 63 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 1996:218505 TOXCENTER
CP Copyright 2007 ACS
DN CA126070857822
TI Postnatal retinal ganglion cells in vitro: protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes
AU Lucius, Ralph; Sievers, Jobst
CS Anatomisches Institut der Universitaet Kiel, Olshausenstr. 40, Kiel, D-24118, Germany.
SO Brain Research, (1996) Vol. 743, No. 1,2, pp. 56-62.
CODEN: BRREAP. ISSN: 0006-8993.
CY GERMANY, FEDERAL REPUBLIC OF
DT Journal
FS CAPLUS
OS CAPLUS 1996:736899
LA English
ED Entered STN: 16 Nov 2001
Last Updated on STN: 18 Jun 2002

=> d l17 1-63 kwic

L17 ANSWER 1 OF 63 MEDLINE on STN
AB The dogma that the adult central nervous system (CNS) is nonpermissive to ***axonal regeneration*** is beginning to fall in the face of increased understanding of the molecular and cellular biology of axon outgrowth. It. . . . These vectors may be useful in regenerative strategies for spinal cord injury, brain injury, and neurodegenerative

diseases including Parkinson's disease, ***Alzheimer***'s disease, and Huntington's disease.

L17 ANSWER 2 OF 63 MEDLINE on STN
AB . . . injuries and diseases. After CNS injury, CSPGs are the major inhibitory component of the glial scar. Removal of CSPGs improves ***axonal regeneration*** and functional recovery. CSPGs may also be involved in the pathological processes in diseases such as epilepsy, stroke and ***Alzheimer***'s disease. Several possible methods of manipulating CSPGs in the CNS have recently been identified. The development of methods to remove. . .

L17 ANSWER 3 OF 63 MEDLINE on STN
AB Reticulon (RTN) proteins are localized to the endoplasmic reticulum (ER), and are related to intracellular membrane trafficking, apoptosis, inhibiting ***axonal regeneration***, and ***Alzheimer***'s disease. The RTN proteins are produced without an N-terminal signal peptide. Their C-terminal domain contains two long hydrophobic segments. We. . .

L17 ANSWER 4 OF 63 MEDLINE on STN
AB Axons fail to regenerate in the adult central nervous system (CNS) following injury. Developing strategies to promote ***axonal regeneration*** is therapeutically attractive for various CNS pathologies such as traumatic brain injury, stroke and ***Alzheimer***'s disease. Because the RhoA pathway is involved in neurite outgrowth, Rho-associated kinases (ROCKs), downstream effectors of GTP-bound Rho, are potentially. . .

L17 ANSWER 5 OF 63 MEDLINE on STN
AB Progressive neuronal loss in ***Alzheimer***'s disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-beta peptides (A beta). T-817MA (1-{3-[2-(1-benzothiophen-5-yl) ethoxy]. . . agent for the treatment of AD based on its neuroprotective potency against A beta-induced neurotoxicity and its effect of enhancing ***axonal regeneration*** in the sciatic nerve axotomy model. The neuroprotective effect of T-817MA against A beta(1-42) or oxidative stress-induced neurotoxicity was assessed. . .

L17 ANSWER 6 OF 63 MEDLINE on STN
AB . . . testosterone actions is neuroprotection. There are some evidences supporting the hypothesis that testosterone may act protectively in neurodegenerative disorders, e.g. ***Alzheimer***'s disease (AD), mild cognitive impairment (MCI) or depression. Androgens alter also the morphology, survival and ***axonal regeneration*** of motor neurons. These hormones accelerate the regeneration of hamster facial nerve and anterior tibialis sciatic nerve in rabbits following. . .

L17 ANSWER 7 OF 63 MEDLINE on STN
TI Modulation of ***axonal regeneration*** in neurodegenerative disease: focus on Nogo.
AB Recent work has demonstrated that ***axonal regeneration*** in the central nervous system is limited by myelin-derived Nogo binding to an axonal Nogo Receptor. The Nogo system appears. . . a physiologic role in regulating structural plasticity. The possibility that the Nogo system contributes to pathologic and compensatory plasticity in ***Alzheimer***'s Disease is considered.
CT ***Alzheimer Disease: ME, metabolism***
Alzheimer Disease: PA, pathology
Animals
Axons: ME, metabolism
*Axons: PA, pathology
*Growth Inhibitors: ME, metabolism
*Myelin Proteins: ME, metabolism
Myelin. . .

L17 ANSWER 8 OF 63 MEDLINE on STN
AB . . . estrogen in neuroprotection. Accumulated clinical evidence suggests that estrogen exposure decreases the risk and delays the onset and progression of ***Alzheimer***'s disease and schizophrenia, and may also enhance recovery from traumatic neurological injury such as stroke. Recent basic science studies show. . . the classical nuclear estrogen receptor, through which estrogen alters expression of estrogen responsive genes that play a role in apoptosis, ***axonal regeneration***, or general trophic support. Yet another possibility is that estrogen receptors in the membrane or cytoplasm alter phosphorylation cascades through. . .

L17 ANSWER 9 OF 63 MEDLINE on STN
AB Reactive oxygen species (ROS) are supposed to be involved in neurodegenerative processes like Parkinson's or ***Alzheimer***'s disease. Beside this there are an increasing number of studies indicating an involvement of ROS in traumatic brain injury. We. . . astrocytes are able to protect retinal ganglion cells against ROS-induced oxidative stress, (ii) astrocytes release soluble neurotrophic factors supporting RGC ***axonal regeneration***, and (iii) free radical production after tissue injury may partly contribute to the failure of ***axonal regeneration*** in the adult mammalian central nervous system.

L17 ANSWER 10 OF 63 MEDLINE on STN
TI Aberrant GAP-43 gene expression in ***Alzheimer***'s disease.
AB GAP-43 is a growth-associated phosphoprotein expressed at high levels in neurons during development, ***axonal regeneration***, and neuritic sprouting. GAP-43 gene expression in mature neurons is probably functionally important for the structural remodeling of synapses as required for learning and establishing new memory. The widespread aberrant neuritic growth accompanied by impaired synaptic plasticity in ***Alzheimer***'s disease (AD) suggests that abnormal GAP-43 gene expression may contribute to the cascade of neurodegeneration. In the present study, end-stage. . .
CT Check Tags: Female; Male
Aged
Aged, 80 and over
Aging: ME, metabolism
****Alzheimer Disease: GE, genetics***
Alzheimer Disease: PA, pathology
Blotting, Northern
Brain: ME, metabolism
Brain: PA, pathology
GAP-43 Protein
*Gene Expression
Humans
Immunohistochemistry
In Situ. . .

L17 ANSWER 11 OF 63 MEDLINE on STN
AB . . . molecular techniques underlying nerve growth are discussed. Possible therapeutic approaches are presented for many neurologic disorders, ranging from stroke to ***Alzheimer***'s disease to acquired immunodeficiency syndrome, based on regrowing or saving injured neurons. The clinical neurologist will become important in practical applications and research into prolonging neuronal survival and fostering ***axonal regeneration***. Over the coming years, with further research, it is anticipated that patients will be treated with these or similar modulatory. . .

L17 ANSWER 12 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on

STN
AB apoptosis, inhibiting ***axonal regeneration***, and ***Alzheimer***'s disease. The RTN proteins are produced without an N-terminal signal peptide. Their C-terminal domain contains two long hydrophobic segments. We. . .

L17 ANSWER 13 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB Axons fail to regenerate in the adult central nervous system (CNS) following injury. Developing strategies to promote ***axonal regeneration*** is therapeutically attractive for various CNS pathologies such as traumatic brain injury, stroke and ***Alzheimer***'s disease. Because the RhoA pathway is involved in neurite outgrowth, Rho-associated kinases (ROCKs), downstream effectors of GTP-bound Rho, are potentially. . .
IT . . .
brain injury: nervous system disease, injury
Brain Injuries (MeSH)
IT Diseases
stroke: vascular disease, nervous system disease
Cerebrovascular Disorders (MeSH)
IT Diseases
Alzheimer's disease: nervous system disease, behavioral and mental disorders
IT Chemicals & Biochemicals
RhoA; ROCK; Y-27632: enzyme inhibitor-drug; cofilin: dephosphorylation; H-1152:. . .

L17 ANSWER 14 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB Progressive neuronal loss in ***Alzheimer***'s disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-beta peptides (A beta). T-817MA (1-{3-[2-(1-benzothiophen-5-yl). . . agent for the treatment of AD based on its neuroprotective potency against A beta-induced neurotoxicity and its effect of enhancing ***axonal regeneration*** in the sciatic nerve axotomy model. The neuroprotective effect of T-817MA against A beta(1-42) or oxidative stress-induced neurotoxicity was assessed. . .
IT . . .
of Organisms
neuron: nervous system; central nervous system: nervous system; glial cell: nervous system; cortical neuron: nervous system
IT Diseases
Alzheimer's disease: nervous system disease, behavioral and mental disorders
IT Chemicals & Biochemicals
hydrogen peroxide; growth-associated protein 43; GSH; amyloid-beta: toxin,. . .

L17 ANSWER 15 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB. . . testosterone actions is neuroprotection. There are some evidences supporting the hypothesis that testosterone may act protectively in neurodegenerative disorders, e.g. ***Alzheimer***'s disease (AD), mild cognitive impairment (MCI) or depression. Androgens alter also the morphology, survival and ***axonal regeneration*** of motor neurons. These hormones accelerate the regeneration of hamster facial nerve and anterior tibialis sciatic nerve in rabbits following. . .
IT . . .
nervous system; laryngeal motor nucleus: nervous system; motor neuron: nervous system; pelvic autonomic neuron: nervous system, spinal cord
IT Diseases
Alzheimer's disease: behavioral and mental disorders, nervous system disease, drug therapy
Alzheimer Disease (MeSH)
IT Diseases
depression: behavioral and mental disorders, drug therapy
Depression (MeSH)
IT Diseases
mild cognitive impairment: behavioral and mental. . .

L17 ANSWER 16 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI Modulation of ***axonal regeneration*** in neurodegenerative disease: Focus on Nogo.
AB Recent work has demonstrated that ***axonal regeneration*** in the central nervous system is limited by myelin-derived Nogo binding to an axonal Nogo Receptor. The Nogo system appears. . . a physiologic role in regulating structural plasticity. The possibility that the Nogo system contributes to pathologic and compensatory plasticity in ***Alzheimer***'s Disease is considered.
IT . . .
Structures, & Systems of Organisms
axon: nervous system, plasticity, regeneration; central nervous system: nervous system; neurite: nervous system
IT Diseases
Alzheimer's disease: behavioral and mental disorders, nervous system disease
Alzheimer Disease (MeSH)
IT Chemicals & Biochemicals
Nogo: binding activity; Nogo receptor; myelin

L17 ANSWER 17 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB. . . individuals with moderate or severe white matter changes (WMC) and in those with mild or no WMC. Twenty-two patients with ***Alzheimer***'s disease (AD), nine patients with subcortical vascular dementia (SVD), and 20 normal controls were included in the study. The occurrence. . .
IT . . .
Medicine, Medical Sciences)
IT Parts, Structures, & Systems of Organisms
cerebrospinal fluid: nervous system; white matter: nervous system
IT Diseases
Alzheimer's disease: behavioral and mental disorders, nervous system disease
Alzheimer Disease (MeSH)
IT Diseases
subcortical vascular dementia: behavioral and mental disorders
IT Chemicals & Biochemicals
beta-amyloid 42: neurofilament protein; tau:. . .
IT Miscellaneous Descriptors
apolipoprotein E E4 allele inheritance; ***axonal regeneration***; white matter changes

L17 ANSWER 18 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
IT Major Concepts
Nervous System (Neural Coordination); Pharmacology
IT Parts, Structures, & Systems of Organisms
brain: nervous system
IT Diseases
Alzheimer's type senile dementia: behavioral and mental disorders, nervous system disease
IT Chemicals & Biochemicals
TEI-3356 [[(16S)-15-deoxy-16-hydroxy-16-methyl-9(O)-methano-delta-6(9alpha)-prostaglandin]: anti-amnesic effect, prostacyclin stable. .
IT Miscellaneous Descriptors

axonal regeneration; learning; memory

L17 ANSWER 19 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB Reactive oxygen species (ROS) are supposed to be involved in neurodegenerative processes like Parkinson's or ***Alzheimer***'s disease. Beside this there are an increasing number of studies indicating an involvement of ROS in traumatic brain injury. We. . . astrocytes are able to protect retinal ganglion cells against ROS-induced oxidative stress, (ii) astrocytes release soluble neurotrophic factors supporting RGC ***axonal regeneration***, and (iii) free radical production after tissue injury may partly contribute to the failure of ***axonal regeneration*** in the adult mammalian central nervous system.

L17 ANSWER 20 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI Aberrant GAP-43 gene expression in ***Alzheimer***'s disease.
AB GAP-43 is a growth-associated phosphoprotein expressed at high levels in neurons during development, ***axonal regeneration***, and neuritic sprouting. GAP-43 gene expression in mature neurons is probably functionally important for the structural remodeling of synapses as required for learning and establishing new memory. The widespread aberrant neuritic growth accompanied by impaired synaptic plasticity in ***Alzheimer***'s disease (AD) suggests that abnormal GAP-43 gene expression may contribute to the cascade of neurodegeneration. In the present study, end-stage. . .

L17 ANSWER 21 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI Disrupted beta-1-adrenoceptor-G protein coupling in the temporal cortex of patients with ***Alzheimer***'s disease.
AB. . . The efficacy of beta-1-adrenoceptor-G protein coupling was studied in postmortem temporal cortex synaptic membranes from a series of control and ***Alzheimer***'s disease subjects. For the control cases, the non-hydrolysable GTP analogue 5'-guanylylimidodiphosphate (Gpp(NH)p) gave a significant reduction in the affinity of. . . effect was attributed to the conversion of high agonist-affinity sites to a lower-affinity state and was not found for the ***Alzheimer***'s disease cases. These data indicate that a disruption of beta-1-adrenoceptor-G protein coupling occurs in the temporal cortex of ***Alzheimer***'s disease patients.
IT Miscellaneous Descriptors
AXONAL REGENERATION IMPAIRMENT; HYPEREMIA; HYPERGLYCEMIA; SENSORY CONDUCTION VELOCITY; VASA NERVORUM NEUROGENIC INFLAMMATION

L17 ANSWER 22 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI. . . The carboxy-terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of ***Alzheimer***'s disease.
AB. . . beta-1-40, beta-1-42, and beta-1-43), have been identified as the major components of the cerebral amyloid deposits which are characteristic of ***Alzheimer***'s disease. Kinetic studies of aggregation by three naturally occurring beta protein variants (beta-1-39, beta-1-40, beta-1-42) and four model peptides (beta-26-39,. . .
IT Miscellaneous Descriptors
AXONAL REGENERATION; CYCLOSPORIN A; IMMUNOSUPPRESSANT-DRUG; NERVE ANASTOMOSIS; NERVE REPAIR; NERVE TRANSPLANTATION; PERINEURIUM

L17 ANSWER 23 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AB. . . axotomized medial septal and diagonal band of Broca neurons selectively and rapidly express JLI. The role of Jun expression in ***axonal regeneration*** or neuronal death is discussed.
IT Miscellaneous Descriptors
RAT ***AXONAL REGENERATION*** NEURONAL DEATH PROTEIN
ALZHEIMER'S DISEASE TRANSCRIPTION FACTORS

L17 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB . . . injuries and diseases. After CNS injury, CSPGs are the major inhibitory component of the glial scar. Removal of CSPGs improves ***axonal regeneration*** and functional recovery. CSPGs may also be involved in the pathol. processes in diseases such as epilepsy, stroke and ***Alzheimer***'s disease. Several possible methods of manipulating CSPGs in the CNS have recently been identified. The development of methods to remove. . .

L17 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB . . . certain polypeptides and polypeptide fragments of Nogo receptor-1 (NgR1) and Nogo receptor-2 (NgR2) for promoting neurite outgrowth, neuronal survival, and ***axonal regeneration*** in CNS neurons. Previous studies have shown that the entire leucine rich repeat (LRR) region of NgR1, including the C-terminal. . . Typically, the polypeptides and polypeptide fragments of the invention act to block NgR-mediated inhibition of neuronal survival, neurite outgrowth or ***axonal regeneration*** of CNS (central nervous system) neurons by inhibiting signal transduction by the NgR complex.
ST Nogo receptor NgR1 NgR2 disulfide structure mutant neurite outgrowth; NgR Nogo receptor signaling inhibition CNS neuron ***axonal regeneration***
IT ***Alzheimer***'s disease
Axon
Central nervous system agents
Disulfide group
Gene therapy
Glaucoma (disease)
Hearing loss
Human
Mammalia
Molecular cloning
Multiple sclerosis
Parkinson's disease
(Nogo receptor (NgR) disulfide structure, NgR signaling inhibiting NgR fragments, mutants, fusion products and genetic constructs, and uses in mediating axonal growth)
IT Central nervous system
(neurons, promoting ***axonal regeneration*** in; Nogo receptor (NgR) disulfide structure, NgR signaling inhibiting NgR fragments, mutants, fusion products and genetic constructs, and uses in mediating axonal growth)

L17 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB Reticulon (RTN) proteins are localized to the endoplasmic reticulum (ER), and are related to intracellular membrane trafficking, apoptosis, inhibiting ***axonal regeneration***, and ***Alzheimer***'s disease. The RTN proteins are produced without an N-terminal signal peptide. Their C-terminal domain contains two long hydrophobic segments. We. . .

L17 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB Axons fail to regenerate in the adult central nervous system (CNS) following injury. Developing strategies to promote ***axonal regeneration*** is therapeutically attractive for various CNS pathologies such as traumatic brain injury, stroke and ***Alzheimer***'s disease. Because the RhoA pathway is involved in neurite outgrowth, Rho-associated kinases (ROCKs), downstream effectors of GTP-bound Rho, are

potentially. . .

L17 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB . . . may be used as antagonists to NgR1 ligands and, as such, may be useful in treating subjects in need of ***axonal regeneration*** (e.g., for antagonizing (e.g., reversing, decreasing, reducing, preventing, etc.) axonal growth inhibition mediated by such NgR1 ligands, and for screening. . .
IT ***Alzheimer***'s disease
Multiple sclerosis
Parkinson's disease
(treating; Nogo receptor 1 (NgR1) functional motifs and peptide mimetics and use as antagonists to NgR1 ligands for antagonizing axonal growth inhibition)

L17 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
TI Protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***
AB Described are the protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and their uses in promoting ***axonal regeneration***. The invention concerns a method of promoting the growth or regeneration of neurons, and treating disease or conditions associated with. . .
IT Protein motifs
(Ig-like domain, of NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Protein motifs
(PDZ domain, -binding motif, of NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(against NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chimeric, against NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fragments, against NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(humanized, against NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(leucine-rich repeat, NGL-1 (netrin-G1 ligand 1); protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Repeat motifs (protein)
(leucine-rich repeat, of NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(netrin, G1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Molecular association
(netrin-G1 binding to NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Signal peptides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(of NGL-1; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Axon
(outgrowth; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Analgesics
Anti-***Alzheimer***'s agents
Antiarteriosclerotics
Antiparkinsonian agents
(protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in nerve cell dysfunction)
IT Gallus domesticus
Human
Mus musculus
Protein sequences
(protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT Axon
(regeneration; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT ***Alzheimer***'s disease
Multiple sclerosis
Parkinson's disease
(treatment of; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in nerve cell dysfunction)
IT 875208-52-9
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(PDZ domain-binding motif of NGL-1; -protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT 875717-48-9D, subfragment is claimed 875717-49-0 875717-50-3
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT 875717-66-1 875717-67-2 875717-68-3
RL: PRP (Properties)
(unclaimed protein sequence; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)
IT 875612-87-6
RL: PRP (Properties)
(unclaimed sequence; protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***)

L17 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB . . . for central nervous system repair, focusing on the therapeutic use of growth factors to reduce cell loss and to enhance ***axonal regeneration*** in the context of both neurodegenerative and traumatic disorders.

ST review NGF axon nerve regeneration CNS ***Alzheimer*** disease
IT Nervous system, disease
(Huntington's chorea; growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with Huntington's disease)
IT Nervous system, disease
(amyotrophic lateral sclerosis; growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with amyotrophic lateral sclerosis)
IT ***Alzheimer***'s disease
(growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with ***Alzheimer***'s disease)
IT Parkinson's disease
(growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with Parkinson's disease)
IT Multiple sclerosis
(growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with multiple sclerosis)
IT Brain
Nerve regeneration
(growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with neurodegenerative and traumatic disorders)
IT Spinal cord, disease
(injury; growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with spinal cord injury)
IT Injury
(spinal cord; growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with spinal cord injury)
IT 9061-61-4, Nerve growth factor
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(growth factor can be used to reduce cell loss and to enhance ***axonal regeneration*** in animal model with neurodegenerative and traumatic disorders)

L17 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB Progressive neuronal loss in ***Alzheimer***'s disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-β peptides (Aβ). T-817MA was screened as. . . therapeutic agent for the treatment of AD based on its neuroprotective potency against Aβ-induced neurotoxicity and its effect of enhancing ***axonal regeneration*** in the sciatic nerve axotomy model. The neuroprotective effect of T-817MA against Aβ(1-42) or oxidative stress-induced neurotoxicity was assessed using. . .
IT ***Alzheimer***'s disease
Anti-***Alzheimer***'s agents
Oxidative stress, biological
(neuroprotective effects of T-817MA against β-amyloid- and oxidative stress-induced neurotoxicity in rat cultured central nervous system neurons)

L17 ANSWER 32 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB . . . neurogenesis, neuronal growth and regeneration, neuronal survival, and synaptic plasticity. Like neurotrophic factors, lithium and valproate promote neurite outgrowth and ***axonal regeneration*** in cultured neuronal cells and in injury models utilizing retinal cells, sciatic nerve, and spinal cord. These mood stabilizers also. . . protect cultured cells against a variety of insults and reduce neuronal loss and associated functional deficits in animal models of ***Alzheimer***'s disease, HIV-associated encephalitis and dementia, Huntington's disease, ischemia, and Parkinson's disease. Cross-sectional and longitudinal brain imaging studies show that lithium. . .
IT Disease models
(lithium, valproate showed neurotrophic action by reducing neuronal loss, associated functional deficit via ERK, P13K pathway in animal model of ***Alzheimer***'s, Parkinson's, Huntington's disease, ischemia, HIV associated encephalitis, dementia)
IT ***Alzheimer***'s disease
(mood stabilizer lithium and valproate showed neurotrophic action by reducing neuronal loss and associated functional deficit via ERK, P13K pathway activation in animal model of ***Alzheimer***'s disease)
IT Brain
(mood stabilizer lithium, valproate promoted neurogenesis, ***axonal regeneration***, reduced neuronal loss in animal model and increased brain N-acetyl aspartate, cerebral gray matter via ERK, P13K pathway activation in mood disorder patient)
IT Neuron
(mood stabilizer lithium, valproate promoted neurogenesis, neurite outgrowth and ***axonal regeneration*** via ERK, P13K pathway activation in cultured neuronal cell)
IT Nervous system agents
(mood stabilizer; lithium, valproate promoted neurogenesis, ***axonal regeneration***, reduced neuronal loss in animal model and increased brain N-acetyl aspartate, cerebral gray matter via ERK, P13K pathway activation in mood disorder patient)
IT 115926-52-8, Phosphoinositide 3-kinase 142243-02-5, Extracellular signal regulated kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mood stabilizer lithium, valproate promoted neurogenesis, ***axonal regeneration***, reduced neuronal loss in animal model and increased brain N-acetyl aspartate, cerebral gray matter via ERK, P13K pathway activation in mood disorder patient)
IT 99-66-1 7439-93-2D, Lithium, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mood stabilizer lithium, valproate promoted neurogenesis, ***axonal regeneration***, reduced neuronal loss in animal model and increased brain N-acetyl aspartate, cerebral gray matter via ERK, P13K pathway activation in mood disorder patient)

L17 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AB . . . testosterone actions is neuroprotection. There is some evidence supporting the hypothesis that testosterone may act protectively in neurodegenerative disorders, e.g. ***Alzheimer***'s disease (AD), mild cognitive impairment (MCI), or depression. Androgens alter also the morphol., survival and ***axonal regeneration*** of motor neurons. These hormones accelerate the regeneration of hamster facial nerve and anterior tibialis sciatic nerve in rabbits following. . .

L17 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
TI Modulation of ***axonal regeneration*** in neurodegenerative disease. Focus on Nogo
AB A review. Recent work has demonstrated that ***axonal regeneration*** in the central nervous system is limited by myelin-derived Nogo binding to an axonal Nogo Receptor. The Nogo system appears. . . a physiol. role in regulating structural plasticity. The possibility that the Nogo system contributes to pathol. and compensatory plasticity in ***Alzheimer***'s Disease is considered.
ST review Nogo receptor axon regeneration neurodegeneration ***Alzheimer***
IT ***Alzheimer***'s disease
Axon

Nerve regeneration
Nerve regeneration
Synaptic plasticity
(Nogo receptor in modulation of ***axonal regeneration*** in neurodegenerative disease)

IT Proteins
Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Nogo; Nogo receptor in modulation of ***axonal regeneration*** in neurodegenerative disease)

IT Nervous system, disease
(degeneration; Nogo receptor in modulation of ***axonal regeneration*** in neurodegenerative disease)

L17 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

TI Recent advance in adenoviral gene transfer technology for neuronal survival and ***axonal regeneration***

AB A review. Neuron-targeted gene transfer by adenovirus for the gene therapy of neuronal survival and ***axonal regeneration*** in the treatment of Parkinson's disease, ***Alzheimer***'s disease, malignant glioma etc. is reviewed.

IT Nerve regeneration
Nerve regeneration
(axonal; recent advance in adenoviral gene transfer technol. for neuronal survival and ***axonal regeneration***)

IT Antitumor agents
(glioma; recent advance in adenoviral gene transfer technol. for neuronal survival and ***axonal regeneration***)

IT Adenoviral vectors
Alzheimer's disease
Anti-***Alzheimer***'s agents
Antiparkinsonian agents
Gene therapy
Neuroglia, neoplasm
Parkinson's disease
Transformation, genetic
(recent advance in adenoviral gene transfer technol. for neuronal survival and ***axonal regeneration***)

L17 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

TI Apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to ***Alzheimer***'s disease

AB A review on the link between apolipoprotein E (apoE) to either one of the two hallmarks of ***Alzheimer***'s disease (AD), namely amyloid plaque formation and neurofibrillary tangles. It includes a description of apolipoprotein E (apoE) and its gene,. . . the role of apoE as a modulator of lipid homeostasis and synaptic plasticity. The well established peripheral nerve model of ***axonal regeneration*** and remyelination involving apoE and LDL receptors is presented first. The entorhinal cortex lesioning (ECL) model, which mimics certain neuropathol.. . .

ST review apolipoprotein E lipid mobilization ***Alzheimer*** disease neuron regeneration

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(APOE; apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to ***Alzheimer***'s disease)

IT Apolipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E; apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to ***Alzheimer***'s disease)

IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL; apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to ***Alzheimer***'s disease)

IT ***Alzheimer***'s disease
Human
Nerve regeneration
Nerve regeneration
Neurofibrillary tangle
Synaptic plasticity
(apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to ***Alzheimer***'s disease)

IT Brain
(entorhinal cortex; apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to ***Alzheimer***'s disease)

IT Brain
(hippocampus; apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to ***Alzheimer***'s disease)

L17 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . estrogen in neuroprotection. Accumulated clin. evidence suggests that estrogen exposure decreases the risk and delays the onset and progression of ***Alzheimer***'s disease and schizophrenia, and may also enhance recovery from traumatic neurol. injury such as stroke. Recent basic science studies show. . . the classical nuclear estrogen receptor, through which estrogen alters expression of estrogen responsive genes that play a role in apoptosis, ***axonal regeneration***, or general trophic support. Yet another possibility is that estrogen receptors in the membrane or cytoplasm alter phosphorylation cascades through. . .

IT Anti-***Alzheimer***'s agents
Cognition enhancers
Schizophrenia
(neuroprotection by estradiol and involved mechanisms)

L17 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . Immediately following the lesioning, an osmotic pump to deliver serum complement and anti-galactocerebroside IgG was implanted at T11. Subsequently, brainstem-spinal ***axonal regeneration*** was observed in exptl. animals, as assessed by retrograde neuronal labeling with Flurogold.

IT ***Alzheimer***'s disease
Parkinson's disease
(complement-dependent antibody-mediated transient demyelination for promotion of neuronal regrowth and regeneration in)

L17 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AB Reactive oxygen species (ROS) are supposed to be involved in neurodegenerative processes like Parkinson's or ***Alzheimer***'s disease. Beside this there are an increasing number of studies indicating an involvement of ROS in traumatic brain injury. We. . . astrocytes are able to protect retinal ganglion cells against ROS-induced oxidative stress, (ii) astrocytes release soluble neurotrophic factors supporting RGC ***axonal regeneration***, and (iii) free radical production after tissue injury may partly contribute to the failure of ***axonal regeneration*** in the adult mammalian central nervous system.

IT ***Alzheimer***'s disease
Astrocyte
Oxidative stress, biological
Parkinson's disease
(astrocytes against neurotoxic effects of reactive oxygen species in cocultures of cortical astrocytes with regenerating postnatal retinal ganglion cells)

L17 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

TI Aberrant GAP-43 gene expression in ***Alzheimer***'s disease

AB GAP-43 is a growth-associated phosphoprotein expressed at high levels in

neurons during development, ***axonal regeneration***, and neuritic sprouting. GAP-43 gene expression in mature neurons is probably functionally important for the structural remodeling of synapses as required for learning and establishing new memory. The widespread aberrant neuritic growth accompanied by impaired synaptic plasticity in ***Alzheimer***'s disease (AD) suggests that abnormal GAP-43 gene expression may contribute to the cascade of neurodegeneration. In the present study, end-stage. . .

ST gene GAP43 brain ***Alzheimer***

IT Brain
Neuroglia
(GAP-43 gene expression in human brain in ***Alzheimer***'s disease)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
. (GAP-43 gene expression in human brain in ***Alzheimer***'s disease)

IT Mental disorder
(***Alzheimer***'s disease, GAP-43 gene expression in human brain in ***Alzheimer***'s disease)

IT Phospholipoproteins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence)
(B-50, GAP-43 gene expression in human brain in ***Alzheimer***'s disease)

IT Nerve, disease
(degeneration, GAP-43 gene expression in human brain in ***Alzheimer***'s disease)

L17 ANSWER 41 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB . . . injuries and diseases. After CNS injury, CSPGs are the major inhibitory component of the glial scar. Removal of CSPGs improves ***axonal regeneration*** and functional recovery. CSPGs may also be involved in the pathological processes in diseases such as epilepsy, stroke and ***Alzheimer***'s disease. Several possible methods of manipulating CSPGs in the CNS have recently been identified. The development of methods to remove. . .

CT Medical Descriptors:
Alzheimer disease: ET, etiology
epilepsy: ET, etiology
eye dominance
glia
human
hypothalamus hypophysis system
learning
memory
nerve cell lesion
*nerve cell plasticity
*nerve fiber regeneration
nonhuman
priority journal
review
stroke: ET, etiology
aggrecan: EC, endogenous. . .

L17 ANSWER 42 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB . . . evidence of developmental plasticity in these ex vivo models, demonstrating emergence of injury-stimulated neuronal progenitor cells, and neurite sprouting and ***axonal regeneration*** following pathway lesioning. Neuro- and axo-genesis are emerging as significant factors contributing to brain repair following many acute and chronic. . .

CT Medical Descriptors:
Alzheimer disease: ET, etiology
Parkinson disease: ET, etiology
acute disease
amyotrophic lateral sclerosis: DT, drug therapy
anoxia
brain function
brain injury
brain slice
cell assay
cell function
cell viability
chronic disease
clinical trial
coculture
*degenerative. . .

L17 ANSWER 43 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Reticulon (RTN) proteins are localized to the endoplasmic reticulum (ER), and are related to intracellular membrane trafficking, apoptosis, inhibiting ***axonal regeneration***, and ***Alzheimer***'s disease. The RTN proteins are produced without an N-terminal signal peptide. Their C-terminal domain contains two long hydrophobic segments. We. . .

CT Medical Descriptors:
Alzheimer disease
Golgi complex
amino terminal sequence
animal cell
article
carboxy terminal sequence
cellular distribution
*endoplasmic reticulum
hydrophobicity
membrane transport
nerve fiber regeneration
nonhuman
nucleotide sequence
priority journal
protein determination
protein domain
protein family
protein localization
*cell protein:. . .

L17 ANSWER 44 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Axons fail to regenerate in the adult central nervous system (CNS) following injury. Developing strategies to promote ***axonal regeneration*** is therapeutically attractive for various CNS pathologies such as traumatic brain injury, stroke and ***Alzheimer***'s disease. Because the RhoA pathway is involved in neurite outgrowth, Rho-associated kinases (ROCKs), downstream effectors of GTP-bound Rho, are potentially. . .

L17 ANSWER 45 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB . . . interest. Studies focusing on animal and human olfactory bulb ensheathing cells (OECs) have heightened the expectations that OECs can enhance ***axonal regeneration*** and repair demyelinating diseases. Harvest of OECs from the olfactory bulb requires highly invasive surgery, which is a major obstacle.. . .

CT Medical Descriptors:
*olfactory . . . regeneration
demyelinating disease: TH, therapy
olfactory epithelium
nerve cell
culture technique
cell population
mitosis
autologous stem cell transplantation
donor
cell isolation
ex vivo study
cell lineage
phenotype
embryonal tissue
spinal cord injury: TH, therapy
diagnostic value
Alzheimer disease: DI, diagnosis
Parkinson disease: DI, diagnosis
neurologic disease: DI, diagnosis
human
nonhuman
review

L17 ANSWER 46 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AB Progressive neuronal loss in ***Alzheimer***'s disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-β peptides (Aβ). T-817MA (1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol. . . therapeutic agent for the treatment of AD based on its neuroprotective potency against Aβ-induced neurotoxicity and its effect of enhancing ***axonal regeneration*** in the sciatic nerve axotomy model. The neuroprotective effect of T-817MA against Aβ(1- 42) or oxidative stress-induced neurotoxicity was assessed. . .
CT Medical Descriptors:
*neurotoxicity
*nerve injury
*nerve fiber growth
*neuroprotection
nerve cell
central nervous system
Alzheimer disease
drug potency
nerve fiber regeneration
nerve fiber transection
disease model
oxidative stress
coculture
brain cell
glia
nerve cell culture
hippocampus
degenerative disease
nerve cell necrosis
brain slice
treatment indication
nonhuman
female
rat
animal model
animal cell
article
priority journal

*l. . .

L17 ANSWER 47 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AB . . . testosterone actions is neuroprotection. There are some evidences supporting the hypothesis that testosterone may act protectively in neurodegenerative disorders, e.g. ***Alzheimer***'s disease (AD), mild cognitive impairment (MCI) or depression. Androgens alter also the morphology, survival and ***axonal regeneration*** of motor neurons. These hormones accelerate the regeneration of hamster facial nerve and anterior tibialis sciatic nerve in rabbits following. . .
CT Medical Descriptors:
*central nervous system disease: DT, drug therapy
*central nervous system disease: PC, prevention
*neuroprotection
Alzheimer disease: DT, drug therapy
Alzheimer disease: ET, etiology
Alzheimer disease: PC, prevention
cognitive defect: DT, drug therapy
cognitive defect: PC, prevention
depression: DT, drug therapy
depression: PC, prevention
nerve fiber regeneration
hormonal regulation
hamster
facial nerve
sciatic nerve
rabbit
nerve. . .

L17 ANSWER 48 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
TI Modulation of ***axonal regeneration*** in neurodegenerative disease: Focus on Nogo.
AB Recent work has demonstrated that ***axonal regeneration*** in the central nervous system is limited by myelin-derived Nogo binding to an axonal Nogo Receptor. The Nogo system appears. . . a physiologic role in regulating structural plasticity. The possibility that the Nogo system contributes to pathologic and compensatory plasticity in ***Alzheimer***'s Disease is considered.
CT Medical Descriptors:
*nerve fiber regeneration
*degenerative disease: ET, etiology
Alzheimer disease: ET, etiology
central nervous system
neuropathology
neurite
nerve cell plasticity
human
nonhuman
human cell
animal cell
article
protein: EC, endogenous compound
protein nogo: EC, endogenous compound
myelin: EC, endogenous compound
receptor:. . .

L17 ANSWER 49 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AB . . . estrogen in neuroprotection. Accumulated clinical evidence suggests that estrogen exposure decreases the risk and delays the onset and progression of ***Alzheimer***'s disease and schizophrenia, and may also enhance recovery from traumatic neurological injury such as

stroke. Recent basic science studies show. . . the classical nuclear estrogen receptor, through which estrogen alters expression of estrogen responsive genes that play a role in apoptosis, ***axonal regeneration***, or general trophic support. Yet another possibility is that estrogen receptors in the membrane or cytoplasm alter phosphorylation cascades through. . .

CT Medical Descriptors:
*estrogen therapy
*neuroprotection
*schizophrenia: PC, prevention
*schizophrenia: DT, drug therapy
*stroke: PC, prevention
*stroke: DT, drug therapy
Alzheimer disease: PC, prevention
Alzheimer disease: DT, drug therapy
nervous system development
brain injury: PC, prevention
brain injury: DT, drug therapy
genetic transcription
glia
nerve cell
in vitro study
in vivo study
antioxidant activity
human
nonhuman
rat
animal. . .

L17 ANSWER 50 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB . . . Rho blocks the neurite growth-inhibitor effects of myelin-associated glycoprotein (MAG). These findings may have clinical applications in the stimulation of ***axonal regeneration*** following injury within the CNS, and possibly in the treatment of neurodegenerative disorders.

CT Medical Descriptors:
*nerve fiber growth
cell structure
cell motility
degenerative disease: ET, etiology
nerve fiber regeneration
Alzheimer disease: ET, etiology
human
nonhuman
human cell
animal cell
short survey
*rho factor: EC, endogenous compound
myelin associated glycoprotein: EC, endogenous compound
rho antagonist: DV, drug development
rho. . .

L17 ANSWER 51 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Reactive oxygen species (ROS) are supposed to be involved in neurodegenerative processes like Parkinson's or ***Alzheimer***'s disease. Beside this there are an increasing number of studies indicating an involvement of ROS in traumatic brain injury. We. . . astrocytes are able to protect retinal ganglion cells against ROS-induced oxidative stress, (ii) astrocytes release soluble neurotrophic factors supporting RGC ***axonal regeneration***, and (iii) free radical production after tissue injury may partly contribute to the failure of ***axonal regeneration*** in the adult mammalian central nervous system.

L17 ANSWER 52 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

TI Aberrant GAP-43 gene expression in ***Alzheimer***'s disease.

AB GAP-43 is a growth-associated phosphoprotein expressed at high levels in neurons during development, ***axonal regeneration***, and neuritic sprouting. . GAP- 43 gene expression in mature neurons is probably functionally important for the structural remodeling of synapses as required for learning and establishing new memory. The widespread aberrant neuritic growth accompanied by impaired synaptic plasticity in ***Alzheimer***'s disease (AD) suggests that abnormal GAP-43 gene expression may contribute to the cascade of neurodegeneration. In the present study, end-stage. . .

CT Medical Descriptors:
alzheimer disease
article
brain cortex
chromosome aberration
gene expression
human
human tissue
lewy body
nerve cell plasticity
nerve degeneration
nerve fiber growth
priority journal
receptor down regulation
white matter

L17 ANSWER 53 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB We have examined the possibility of promoting ***axonal regeneration*** within lesioned neural tissue using grafted artificial gel matrices. Polymeric matrices which feature a three-dimensional crosslinked macromolecular network were implanted. . . the deposition of newly synthesized extracellular molecules. This rearrangement of the brain scarring process into an organized cellular coating promoted ***axonal regeneration*** into the gels. Entrapment of embryonic neurons and embryonal carcinoma (EC)-derived neurons, within the gels, was performed to explore the. . .

CT Medical Descriptors:
*neurosurgery
*parkinson disease: SU, surgery
*transplantation
alzheimer disease: SU, surgery
animal experiment
animal tissue
controlled study
epilepsy: SU, surgery
human
human tissue
huntington chorea: SU, surgery
korsakoff psychosis: SU, surgery
nonhuman
short survey

L17 ANSWER 54 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB . . . ganglia neurons was responsive to nerve growth factor (100 ng/ml). Nerve growth factor induced an increase of initial rate of ***axonal regeneration*** and influenced the survival time of these neurons. Acetyl-L-carnitine (250 μM) did not affect the ***axonal regeneration*** but substantially attenuated the

rate of neuronal mortality. A significant difference was evident between the acetyl-L-carnitine-treated and the untreated neurons. . .

CT Medical Descriptors:
*aged
*nerve cell culture
*spinal ganglion
alzheimer disease: ET, etiology
animal cell
article
cell death
cell protection
cell survival
controlled study
drug effect
male
methodology
nerve fiber degeneration
neurotropism
nonhuman
rat
*levacecarnine: PD, pharmacology
*nerve growth factor: PD, pharmacology
*neurotropic agent: PD,. . .

L17 ANSWER 55 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AB . . . molecular techniques underlying nerve growth are discussed. Possible therapeutic approaches are presented for many neurologic disorders, ranging from stroke to ***Alzheimer***'s disease to acquired immunodeficiency syndrome, based on regrowing or saving injured neurons. The clinical neurologist will become important in practical applications and research into prolonging neuronal survival and fostering ***axonal regeneration***. Over the coming years, with further research, it is anticipated that patients will be treated with these or similar modulatory. . .

L17 ANSWER 56 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AB Progressive neuronal loss in ***Alzheimer***'s disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-beta peptides (A beta). T-817MA (1-{3-[2-(1-benzothiophen-5-yl). . . agent for the treatment of AD based on its neuroprotective potency against A beta-induced neurotoxicity and its effect of enhancing ***axonal regeneration*** in the sciatic nerve axotomy model.
The neuroprotective effect of T-817MA against A beta(1-42) or oxidative stress-induced neurotoxicity was assessed. . .
ST . . .
of Organisms
neuron: nervous system; central nervous system: nervous system; glial cell: nervous system; cortical neuron: nervous system
ST Diseases
Alzheimer's disease: nervous system disease, behavioral and mental disorders
ST Chemicals & Biochemicals
hydrogen peroxide; growth-associated protein 43; GSH; amyloid-beta: toxin,. . .

L17 ANSWER 57 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AB Progressive neuronal loss in ***Alzheimer***'s disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-beta peptides (A beta). T-817MA (1-{3-[2-(1-benzothiophen-5-yl) ethoxy]. . . agent for the treatment of AD based on its neuroprotective potency against A beta-induced neurotoxicity and its effect of enhancing ***axonal regeneration*** in the sciatic nerve axotomy model.
The neuroprotective effect of T-817MA against A beta(1-42) or oxidative stress-induced neurotoxicity was assessed. . .

L17 ANSWER 58 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AB Progressive neuronal loss in ***Alzheimer***'s disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-β peptides (Aβ). T-817MA was screened as. . . therapeutic agent for the treatment of AD based on its neuroprotective potency against Aβ-induced neurotoxicity and its effect of enhancing ***axonal regeneration*** in the sciatic nerve axotomy model.
The neuroprotective effect of T-817MA against Aβ(1-42) or oxidative stress-induced neurotoxicity was assessed using. . .

L17 ANSWER 59 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AB. . . testosterone actions is neuroprotection. There are some evidences supporting the hypothesis that testosterone may act protectively in neurodegenerative disorders, e.g. ***Alzheimer***'s disease (AD), mild cognitive impairment (MCI) or depression. Androgens alter also the morphology, survival and ***axonal regeneration*** of motor neurons. These hormones accelerate the regeneration of hamster facial nerve and anterior tibialis sciatic nerve in rabbits following. . .
CT ***Alzheimer*** Disease
Depression
Cognition Disorders
ST . . .
nervous system; laryngeal motor nucleus: nervous system; motor neuron: nervous system; pelvic autonomic neuron: nervous system, spinal cord
ST Diseases
Alzheimer's disease: behavioral and mental disorders, nervous system disease, drug therapy
Alzheimer Disease (MeSH)
ST Diseases
depression: behavioral and mental disorders, drug therapy
Depression (MeSH)
ST Diseases
mild cognitive impairment: behavioral and mental. . .

L17 ANSWER 60 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AB. . . testosterone actions is neuroprotection. There is some evidence supporting the hypothesis that testosterone may act protectively in neurodegenerative disorders, e.g. ***Alzheimer***'s disease (AD), mild cognitive impairment (MCI), or depression. Androgens alter also the morphol., survival and ***axonal regeneration*** of motor neurons. These hormones accelerate the regeneration of hamster facial nerve and anterior tibialis sciatic nerve in rabbits following. . .

L17 ANSWER 61 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
TI Recent advance in adenoviral gene transfer technology for neuronal survival and ***axonal regeneration***
AB A review. Neuron-targeted gene transfer by adenovirus for the gene therapy of neuronal survival and ***axonal regeneration*** in the treatment of Parkinson's disease, ***Alzheimer***'s disease, malignant glioma etc. is reviewed.

L17 ANSWER 62 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AB Reactive oxygen species (ROS) are supposed to be involved in neurodegenerative processes like Parkinson's or ***Alzheimer***'s disease. Beside this there are an increasing number of studies indicating an involvement of ROS in traumatic brain injury. We. . . astrocytes are able to protect retinal ganglion cells against ROS-induced oxidative stress, (ii) astrocytes release soluble neurotrophic factors supporting RGC ***axonal regeneration***, and (iii) free radical production after tissue injury may partly contribute to the failure of ***axonal regeneration*** in the adult mammalian central nervous system.

L17 ANSWER 63 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AB Reactive oxygen species (ROS) are supposed to be involved in neurodegenerative processes like Parkinson's or ***Alzheimer***'s disease. Beside this there are an increasing number of studies indicating an involvement of ROS in traumatic brain injury. We. . . astrocytes are able to protect retinal ganglion cells against ROS-induced oxidative stress, (ii) astrocytes release soluble neurotrophic factors supporting RGC ***axonal regeneration***, and (iii) free radical production after tissue injury may partly contribute to the failure of ***axonal regeneration*** in the adult mammalian central nervous system.

=> d his

(FILE 'HOME' ENTERED AT 15:48:48 ON 19 JUN 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, TOXCENTER' ENTERED AT 15:49:02 ON 19 JUN 2007

L1 12537 S AMYLOID(W)BETA(W)PEPTIDE
L2 9399 S BETA(W)AMYLOID(W)PEPTIDE
L3 13 S NOGO(W)RECEPTOR(W)ANTAGONIST
L4 0 S RETICULON(W)FAMILY(W)PEPTIDE
L5 459 S NOGO(W)RECEPTOR
L6 3 S L5 (P) (L1 OR L2)
L7 2 S NGR1(W)ANTAGONIST
L8 4 S L3 AND ALZHEIMER
L9 3 S L5 AND (L1 OR L2)
L10 10 S LINGO-1(W)ANTAGONIST
L11 0 S L10 AND (L1 OR L2)
L12 0 S L10 AND ALZHEMIMER
L13 1 S L10 AND ALZHEIMER
L14 25 S NEP"1-40"
L15 0 S L14 AND (L1 OR L2)
L16 0 S L14 AND ALZHEIMER
L17 63 S ALZHEIMER AND (AXONAL (W)REGENERATION)

=> s l17 and (l14 or l3 or l7)
L18 0 L17 AND (L14 OR L3 OR L7)

=> s l17 and (l1 or l2)
L19 7 L17 AND (L1 OR L2)

=> d l19 1-7

L19 ANSWER 1 OF 7 MEDLINE on STN
AN 2005316528 MEDLINE
DN PubMed ID: 15798005
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons.
AU Hirata Kazunari; Yamaguchi Hidetoshi; Takamura Yusaku; Takagi Akiko; Fukushima Tetsuo; Iwakami Noboru; Saitoh Akihito; Nakagawa Masaya; Yamada Tatsuo
CS Research Laboratories, Toyama Chemical Co., Ltd, 2-4-1 Shimookui, Toyama, 930-8508, Japan.. kazunari hirata@toyama-chemical.co.jp
SO The Journal of pharmacology and experimental therapeutics, (2005 Jul) Vol. 314, No. 1, pp. 252-9. Electronic Publication: 2005-03-29.
Journal code: 0376362. ISSN: 0022-3565.
CY United States
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200508
ED Entered STN: 21 Jun 2005
Last Updated on STN: 27 Aug 2005
Entered Medline: 26 Aug 2005

L19 ANSWER 2 OF 7 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2005:365391 BIOSIS
DN PREV200510151552
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons.
AU Hirata, Kazunari [Reprint Author]; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo
CS Toyama Chem Co Ltd, Res Labs, 2-4-1 Shimookui, Toyama 9308508, Japan
kazunari hirata@toyama-chemical.co.jp
SO Journal of Pharmacology and Experimental Therapeutics, (JUL 2005) Vol. 314, No. 1, pp. 252-259. http://www.jpet.org.
CODEN: JPETAB. ISSN: 0022-3565.
DT Article
LA English
ED Entered STN: 14 Sep 2005
Last Updated on STN: 14 Sep 2005

L19 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:603092 CAPLUS
DN 143:241806
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons
AU Hirata, Kazunari; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo
CS Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan
SO Journal of Pharmacology and Experimental Therapeutics (2005), 314(1), 252-259
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 7 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2005339732 EMBASE
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons.
AU Hirata K.; Yamaguchi H.; Takamura Y.; Takagi A.; Fukushima T.; Iwakami N.; Saitoh A.; Nakagawa M.; Yamada T.
CS K. Hirata, Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama, 930-8508, Japan. kazunari hirata@toyama-chemical.co.jp
SO Journal of Pharmacology and Experimental Therapeutics, (2005) Vol. 314, No. 1, pp. 252-259.
Refs: 38
ISSN: 0022-3565 CODEN: JPETAB
CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery

030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 1 Sep 2005
Last Updated on STN: 1 Sep 2005

L19 ANSWER 5 OF 7 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:250010 TOXCENTER
CP Copyright (c) 2007 The Thomson Corporation
DN PREV200510151552
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons
AU Hirata, Kazunari [Reprint Author]; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo
CS Toyama Chem Co Ltd, Res Labs, 2-4-1 Shimookui, Toyama 9308508, Japan
kazunari_hirata@toyama-chemical.co.jp
SO Journal of Pharmacology and Experimental Therapeutics, (JUL 2005) Vol. 314, No. 1, pp. 252-259. http://www.jpet.org.
CODEN: JPETAB. ISSN: 0022-3565.
DT Article
FS BIOSIS
OS BIOSIS 2005:365391
LA English
ED Entered STN: 20 Sep 2005
Last Updated on STN: 20 Sep 2005

L19 ANSWER 6 OF 7 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:229107 TOXCENTER
DN PubMed ID: 15798005
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons
AU Hirata Kazunari; Yamaguchi Hidetoshi; Takamura Yusaku; Takagi Akiko; Fukushima Tetsuo; Iwakami Noboru; Saitoh Akihito; Nakagawa Masaya; Yamada Tatsuo
CS Research Laboratories, Toyama Chemical Co., Ltd, 2-4-1 Shimookui, Toyama, 930-8508, Japan. kazunari hirata@toyama-chemical.co.jp
SO The Journal of pharmacology and experimental therapeutics, (2005 Jul) Vol. 314, No. 1, pp. 252-9. Electronic Publication: 2005-03-29.
Journal code: 0376362. ISSN: 0022-3565.
CY United States
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
FS MEDLINE
OS MEDLINE 2005316528
LA English
ED Entered STN: 30 Aug 2005
Last Updated on STN: 30 Aug 2005

L19 ANSWER 7 OF 7 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:193359 TOXCENTER
CP Copyright 2007 ACS
DN CA143142418O6U
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons
AU Hirata, Kazunari; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo
CS Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan.
SO Journal of Pharmacology and Experimental Therapeutics, (2005) Vol. 314, No. 1, pp. 252-259.
CODEN: JPETAB. ISSN: 0022-3565.
CY JAPAN
DT Journal
FS CAPLUS
OS CAPLUS 2005:603092
LA English
ED Entered STN: 19 Jul 2005
Last Updated on STN: 29 Aug 2006

=> d l17 1-57

L17 ANSWER 1 OF 63 MEDLINE on STN
AN 2007293203 IN-PROCESS
DN PubMed ID: 17503736
TI The pivotal role of RhoA GTPase in the molecular signaling of axon growth inhibition after CNS injury and targeted therapeutic strategies.
AU Gross Robert E; Mei Qi; Gutekunst Claire-Anne; Torre Enrique
CS Department of Neurosurgery, Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA..
Robert.gross@emoryhealthcare.org
NC 5K08NS046322 (NINDS)
SO Cell transplantation, (2007) Vol. 16, No. 3, pp. 245-62.
Journal code: 9208854. ISSN: 0963-6897.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 17 May 2007
Last Updated on STN: 17 May 2007

L17 ANSWER 2 OF 63 MEDLINE on STN
AN 2007251491 IN-PROCESS
DN PubMed ID: 17222456
TI The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system.
AU Galtrey Clare M; Fawcett James W
CS Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Robinson Way, Cambridge, CB2 2PY, UK.
SO Brain research reviews, (2007 Apr) Vol. 54, No. 1, pp. 1-18. Electronic Publication: 2007-01-11.
Journal code: 101300366. ISSN: 0165-0173.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 28 Apr 2007
Last Updated on STN: 15 May 2007

L17 ANSWER 3 OF 63 MEDLINE on STN
AN 2007124185 MEDLINE
DN PubMed ID: 17303085
TI Two hydrophobic segments of the RTN1 family determine the ER localization and retention.
AU Iwahashi Jun; Hamada Nobuyuki; Watanabe Hiroshi
CS Division of Infectious Diseases, Department of Infectious Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011,

Japan.. iwahashi@med.kurume-u.ac.jp
SO Biochemical and biophysical research communications, (2007 Apr 6) Vol. 355, No. 2, pp. 508-12. Electronic Publication: 2007-02-07.
Journal code: 0372516. ISSN: 0006-291X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200704
ED Entered STN: 28 Feb 2007
Last Updated on STN: 13 Apr 2007
Entered Medline: 12 Apr 2007

L17 ANSWER 4 OF 63 MEDLINE on STN
AN 2006424547 IN-PROCESS
DN PubMed ID: 16847745
TI Direct Rho-associated kinase inhibiton induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells.
AU Zhang Zhiqun; Ottens Andrew K; Larner Stephen F; Kobeissy Firas H; Williams Melissa L; Hayes Ronald L; Wang Kevin K W
CS Centers for Neuroproteomics and Biomarkers Research, University of Florida, P.O. Box 100256, 100 S. Newell Drive, Gainesville, Florida, 32610, USA.
SO Cellular & molecular biology letters, (2006) Vol. 11, No. 1, pp. 12-29.
Journal code: 9607427. ISSN: 1425-8153.
CY Poland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 19 Jul 2006
Last Updated on STN: 12 Dec 2006

L17 ANSWER 5 OF 63 MEDLINE on STN
AN 2005316528 MEDLINE
DN PubMed ID: 15798005
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons.
AU Hirata Kazunari; Yamaguchi Hidetoshi; Takamura Yusaku; Takagi Akiko; Fukushima Tetsuo; Iwakami Noboru; Saitoh Akihito; Nakagawa Masaya; Yamada Tatsuo
CS Research Laboratories, Toyama Chemical Co., Ltd, 2-4-1 Shimookui, Toyama, 930-8508, Japan.. kazunari hirata@toyama-chemical.co.jp
SO The Journal of pharmacology and experimental therapeutics, (2005 Jul) Vol. 314, No. 1, pp. 252-9. Electronic Publication: 2005-03-29.
Journal code: 0376362. ISSN: 0022-3565.
CY United States
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200508
ED Entered STN: 21 Jun 2005
Last Updated on STN: 27 Aug 2005
Entered Medline: 26 Aug 2005

L17 ANSWER 6 OF 63 MEDLINE on STN
AN 2004619048 MEDLINE
DN PubMed ID: 15591638
TI Neuroprotective role of testosterone in the nervous system.
AU Bialek M; Zaremba P; Borowicz K K; Czuczwar S J
CS Department of Pathophysiology, Skubiszewski Medical University, Jaczewskiego 8, PL 20-090 Lublin, Poland.
SO Polish journal of pharmacology, (2004 Sep-Oct) Vol. 56, No. 5, pp. 509-18.
Ref: 87
Journal code: 9313882. ISSN: 1230-6002.
CY Poland
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200507
ED Entered STN: 20 Dec 2004
Last Updated on STN: 16 Jul 2005
Entered Medline: 15 Jul 2005

L17 ANSWER 7 OF 63 MEDLINE on STN
AN 2002451827 MEDLINE
DN PubMed ID: 12212768
TI Modulation of ***axonal regeneration*** in neurodegenerative disease: focus on Nogo.
AU Strittmatter Stephen M
CS Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA.. Stephen.Strittmatter@yale.edu
SO Journal of molecular neuroscience : MN, (2002 Aug-Oct) Vol. 19, No. 1-2, pp. 117-21. Ref: 23
Journal code: 9002991. ISSN: 0895-8696.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200301
ED Entered STN: 6 Sep 2002
Last Updated on STN: 29 Jan 2003
Entered Medline: 28 Jan 2003

L17 ANSWER 8 OF 63 MEDLINE on STN
AN 2001042902 MEDLINE
DN PubMed ID: 11040417
TI Neuroprotection by estradiol.
AU Garcia-Segura L M; Azcoitia I; DonCarlos L L
CS Instituto Cajal, CSIC, Madrid, Spain.
SO Progress in neurobiology, (2001 Jan) Vol. 63, No. 1, pp. 29-60. Ref: 427
Journal code: 0370121. ISSN: 0301-0082.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200012
ED Entered STN: 22 Mar 2001
Last Updated on STN: 22 Mar 2001
Entered Medline: 7 Dec 2000

L17 ANSWER 9 OF 63 MEDLINE on STN
AN 97169682 MEDLINE
DN PubMed ID: 9017230
TI Postnatal retinal ganglion cells in vitro: protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes.
AU Lucius R; Sievers J
CS Anatomisches Institut, Universitat Kiel, Germany.
SO Brain research, (1996 Dec 16) Vol. 743, No. 1-2, pp. 56-62.
Journal code: 0045503. ISSN: 0006-8993.

CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 199704
ED Entered STN: 24 Apr 1997
Last Updated on STN: 24 Apr 1997
Entered Medline: 17 Apr 1997

L17 ANSWER 10 OF 63 MEDLINE on STN
AN 96010259 MEDLINE
DN PubMed ID: 7573369
TI Aberrant GAP-43 gene expression in ***Alzheimer***'s disease.
AU de la Monte S M; Ng S C; Hsu D W
CS Alzheimer's Disease Research Center, Neuropathology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
NC R01-NS29793 (NINDS)
SO The American journal of pathology, (1995 Oct) Vol. 147, No. 4, pp. 934-46.
Journal code: 0370502. ISSN: 0002-9440.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199511
ED Entered STN: 27 Dec 1995
Last Updated on STN: 6 Feb 1998
Entered Medline: 9 Nov 1995

L17 ANSWER 11 OF 63 MEDLINE on STN
AN 90055926 MEDLINE
DN PubMed ID: 2573331
TI Growth factors for neuronal survival and process regeneration. Implications in the mammalian central nervous system.
AU Lipton S A
CS Department of Neurology, Children's Hospital, Boston, MA 02115.
NC EY05477 (NEI)
EY06087 (NEI)
NS00879 (NINDS)
SO Archives of neurology, (1989 Nov) Vol. 46, No. 11, pp. 1241-8. Ref: 109
Journal code: 0372436. ISSN: 0003-9942.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198912
ED Entered STN: 28 Mar 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 12 Dec 1989

L17 ANSWER 12 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2007:248532 BIOSIS
DN PREV200700244493
TI Two hydrophobic segments of the RTN1 family determine the ER localization and retention.
AU Iwahashi, Jun [Reprint Author]; Hamada, Nobuyuki; Watanabe, Hiroshi
CS Kurume Univ, Sch Med, Dept Infect Med, Div Infect Dis, 67 Asahimachi, Kurume, Fukuoka 8300011, Japan
iwahashi@med.kurume-u.ac.jp
SO Biochemical and Biophysical Research Communications, (APR 6 2007) Vol. 355, No. 2, pp. 508-512.
CODEN: BBRCA9. ISSN: 0006-291X.
DT Article
LA English
ED Entered STN: 18 Apr 2007
Last Updated on STN: 18 Apr 2007

L17 ANSWER 13 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2006:539139 BIOSIS
DN PREV200600538678
TI Direct Rho-associated kinase inhibiton induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells.
AU Zhang, Zhiqun; Ottens, Andrew K.; Larner, Stephen F.; Kobeissy, Firas H.; Williams, Melissa L.; Hayes, Ronald L.; Wang, Kevin K. W. [Reprint Author]
CS Univ Florida, Ctr Neuroprote and Biomarkers Res, McKnight Brain Inst, POB 100256,100 S Newell Dr, Gainesville, FL 32610 USA
kwang@psychiatry.ufl.edu
SO Cellular & Molecular Biology Letters, (MAR 2006) Vol. 11, No. 1, pp. 12-29.
ISSN: 1425-8153.
DT Article
LA English
ED Entered STN: 18 Oct 2006
Last Updated on STN: 18 Oct 2006

L17 ANSWER 14 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2005:365391 BIOSIS
DN PREV200510151552
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons.
AU Hirata, Kazunari [Reprint Author]; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo
CS Toyama Chem Co Ltd, Res Labs, 2-4-1 Shimookui, Toyama 9308508, Japan
kazunari_hirata@toyama-chemical.co.jp
SO Journal of Pharmacology and Experimental Therapeutics, (JUL 2005) Vol. 314, No. 1, pp. 252-259. http://www.jpet.org.
CODEN: JPETAB. ISSN: 0022-3565.
DT Article
LA English
ED Entered STN: 14 Sep 2005
Last Updated on STN: 14 Sep 2005

L17 ANSWER 15 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2005:211699 BIOSIS
DN PREV200500203216
TI Neuroprotective role of testosterone in the nervous system.
AU Bialek, Magdalena; Zaremba, Pawel; Borowicz, Kinga K.; Czuczwar, Stanislaw J. [Reprint Author]
CS Dept Pathophysiol, Skubiszewski Med Univ, Jaczewskiego 8, PL-20090, Lublin, Poland
czuczwarsj@yahoo.com
SO Polish Journal of Pharmacology, (September 2004) Vol. 56, No. 5, pp. 509-518. print.
ISSN: 1230-6002 (ISSN print).
DT Article
General Review; (Literature Review)

LA English
ED Entered STN: 1 Jun 2005
Last Updated on STN: 1 Jun 2005

L17 ANSWER 16 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2002:525476 BIOSIS
DN PREV200200525476
TI Modulation of ***axonal regeneration*** in neurodegenerative disease: Focus on Nogo.
AU Strittmatter, Stephen M. [Reprint author]
CS Department of Neurology, and Section of Neurobiology, Yale University School of Medicine, P.O. Box 208018, New Haven, CT, 06510, USA
Stephen.Strittmatter@yale.edu
SO Journal of Molecular Neuroscience, (August-October, 2002) Vol. 19, No. 1-2, pp. 117-121. print.
CODEN: JMNEES. ISSN: 0895-8696.
DT Article
LA English
ED Entered STN: 9 Oct 2002
Last Updated on STN: 9 Oct 2002

L17 ANSWER 17 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2001:560175 BIOSIS
DN PREV200100560175
TI Neurofilament protein in cerebrospinal fluid: A marker of white matter changes.
AU Sjogren, M. [Reprint author]; Blomberg, M.; Jonsson, M.; Wahlund, L.-O.; Edman, A.; Lind, K.; Rosengren, L.; Blennow, K.; Wallin, A.
CS Institute of Clinical Neuroscience, Sahlgrenska University Hospital/Molndal, SE 431 80, Molndal, Sweden
magnus.sjogren@medfak.gu.se
SO Journal of Neuroscience Research, (November 1, 2001) Vol. 66, No. 3, pp. 510-516. print.
CODEN: JNREDK. ISSN: 0360-4012.
DT Article
LA English
ED Entered STN: 5 Dec 2001
Last Updated on STN: 25 Feb 2002

L17 ANSWER 18 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2000:148411 BIOSIS
DN PREV200000148411
TI Anti-amnesic effect of TEI-3356, a stable analogue of prostacyclin, assessed with amyloid beta(1-42) protein-infused rats.
AU Suwa, Yorimasa [Reprint author]; Yamada, Kiyofumi; Arai, Takami [Reprint author]; Sakurai, Katsutoshi [Reprint author]; Yoshioka, Noboru [Reprint author]; Nabeshima, Toshitaka
CS Institute for Biomedical Research, Teijin Ltd., Hino, Tokyo, 191-8512, Japan
SO Society for Neuroscience Abstracts, (1999) Vol. 25, No. 1-2, pp. 2122. print.
Meeting Info.: 29th Annual Meeting of the Society for Neuroscience. Miami Beach, Florida, USA. October 23-28, 1999. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
LA English
ED Entered STN: 19 Apr 2000
Last Updated on STN: 4 Jan 2002

L17 ANSWER 19 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 1997:75938 BIOSIS
DN PREV199799382641
TI Postnatal retinal ganglion cells in vitro: Protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes.
AU Lucius, Ralph [Reprint author]; Sievers, Jobst
CS Anatomisches Inst., Universitaet Kiel, Olshausenstr. 40, D-24118 Kiel, Germany
SO Brain Research, (1996) Vol. 743, No. 1-2, pp. 56-62.
CODEN: BRREAP. ISSN: 0006-8993.
DT Article
LA English
ED Entered STN: 26 Feb 1997
Last Updated on STN: 26 Feb 1997

L17 ANSWER 20 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 1995:511111 BIOSIS
DN PREV199598516161
TI Aberrant GAP-43 gene expression in ***Alzheimer***'s disease.
AU De La Monte, Suzanne M. [Reprint author]; Ng, Shi-Chung; Hsu, Dora W.
CS Massachusetts Gen. Hosp., MGH Cancer Cent.-MGH East, 149 13th St., 7th Floor, Charlestown, MA 02129, USA
SO American Journal of Pathology, (1995) Vol. 147, No. 4, pp. 934-946.
CODEN: AJPAA4. ISSN: 0002-9440.
DT Article
LA English
ED Entered STN: 29 Nov 1995
Last Updated on STN: 29 Nov 1995

L17 ANSWER 21 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 1993:391353 BIOSIS
DN PREV199396066653
TI Disrupted beta-1-adrenoceptor-G protein coupling in the temporal cortex of patients with ***Alzheimer***'s disease.
AU Cowburn, Richard F. [Reprint author]; Vestling, Monika; Fowler, Christopher J.; Ravid, Rivka; Winblad, Bengt; O'Neill, Cora
CS Dep. Geriatr. Med. B56, Huddinge Univ. Hosp., 141 86 Huddinge, Sweden
SO Neuroscience Letters, (1993) Vol. 155, No. 2, pp. 163-166.
CODEN: NELED5. ISSN: 0304-3940.
DT Article
LA English
ED Entered STN: 23 Aug 1993
Last Updated on STN: 23 Aug 1993

L17 ANSWER 22 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 1993:345493 BIOSIS
DN PREV199396042493
TI The carboxy-terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of ***Alzheimer***'s disease.
AU Jarrett, Joseph T.; Berger, Elizabeth P.; Lansbury, Peter T.; Jr. [Reprint author]
CS Dep. Chem., Mass. Inst. Technol., Cambridge, MA 02139, USA
SO Biochemistry, (1993) Vol. 32, No. 18, pp. 4693-4697.
CODEN: BICHAW. ISSN: 0006-2960.
DT Article
LA English
ED Entered STN: 26 Jul 1993
Last Updated on STN: 31 Aug 1993

L17 ANSWER 23 OF 63 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AN 1992:526818 BIOSIS
DN PREV199294134893; BA94:134893
TI AXOTOMIZED MEDIAL SEPTAL-DIAGONAL BAND NEURONS EXPRESS JUN-LIKE IMMUNOREACTIVITY.
AU DRAGUNOW M [Reprint author]
CS DEP PHARMACOLOGY, FACULTY MEDICINE, UNIVERSITY AUCKLAND, PRIVATE BAG, AUCKLAND, NEW ZEALAND
SO Molecular Brain Research, (1992) Vol. 15, No. 1-2, pp. 141-144.
CODEN: MBREE4. ISSN: 0169-328X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 19 Nov 1992
Last Updated on STN: 19 Nov 1992

L17 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:366937 CAPLUS
TI The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system
AU Galtrey, Clare M.; Fawcett, James W.
CS Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 2PY, UK
SO Brain Research Reviews (2007), 54(1), 1-18
CODEN: BRERD2; ISSN: 0165-0173
PB Elsevier B.V.
DT Journal
LA English

L17 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:220128 CAPLUS
DN 146:302160
TI Nogo receptor (NgR) disulfide structure, NgR signaling inhibiting NgR fragments, mutants, fusion products and genetic constructs, and uses in mediating axonal growth
IN Wen, Dingyi; Lee, Daniel H. S.; Pepinsky, R. Blake
PA Biogen Idec Ma Inc., USA
SO PCT Int. Appl., 89pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007025219	A2	20070301	WO 2006-US33369	20060825
	WO 2007025219	A3	20070531		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2005-710864P P 20050825

L17 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:217634 CAPLUS
DN 146:374466
TI Two hydrophobic segments of the RTN1 family determine the ER localization and retention
AU Iwahashi, Jun; Hamada, Nobuyuki; Watanabe, Hiroshi
CS Division of Infectious Diseases, Department of Infectious Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan
SO Biochemical and Biophysical Research Communications (2007), 355(2), 508-512
CODEN: BBRCA9; ISSN: 0006-291X
PB Elsevier
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1271018 CAPLUS
DN 146:497617
TI Direct Rho-associated kinase inhibition induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells
AU Zhang, Zhiqun; Ottens, Andrew K.; Larner, Stephen F.; Kobeissy, Firas H.; Williams, Melissa L.; Hayes, Ronald L.; Wang, Kevin K. W.
CS Centers for Neuroproteomics and Biomarkers Research and Traumatic Brain Injury Studies, Departments of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA
SO Cellular & Molecular Biology Letters (2006), 11(1), 12-29
CODEN: CMBLFF; ISSN: 1425-8153
PB University of Wroclaw, Institute of Biochemistry, Dep. of Genetic Biochemistry
DT Journal
LA English
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1176722 CAPLUS
DN 145:467114
TI Nogo receptor 1 (NgR1) functional motifs and peptide mimetics and use as antagonists to NgR1 ligands for antagonizing axonal growth inhibition
IN Doherty, Patrick; Williams, Gareth
PA Wyeth, John, and Brother Ltd., USA; King's College London
SO PCT Int. Appl., 60pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006119013	A2	20061109	WO 2006-US16217	20060428
	WO 2006119013	A3	20070315		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-675902P P 20050429

L17 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:149716 CAPLUS
DN 144:205797

TI Protein sequences of human, mouse and chicken netrin-G1 ligand NGL-1 and uses in promotion of ***axonal regeneration***
IN Lin, John; Rosenthal, Arnon
PA USA
SO U.S. Pat. Appl. Publ., 39 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006035826	A1	20060216	US 2004-917905	20040813
CA 2576526	A1	20060223	CA 2005-2576526	20050802
WO 2006020470	A2	20060223	WO 2005-US27551	20050802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1778273	A2	20070502	EP 2005-779162	20050802
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI US 2004-917905	A	20040813		
WO 2005-US27551	W	20050802		

L17 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1315447 CAPLUS
DN 144:267376
TI New strategies for CNS repair
AU Tuszynski, M. H.
CS Department of Neurosciences, Center for Neural Repair, University of California, San Diego, La Jolla, CA, 92093-0626, USA
SO Ernst Schering Research Foundation Workshop (2005), 53(Opportunities and Challenges of the Therapies Targeting CNS Regeneration), 1-10
CODEN: ESRWEL; ISSN: 0947-6075
PB Springer GmbH
DT Journal; General Review
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:603092 CAPLUS
DN 143:241806
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons
AU Hirata, Kazunari; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo
CS Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan
SO Journal of Pharmacology and Experimental Therapeutics (2005), 314(1), 252-259
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 32 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:530778 CAPLUS
DN 143:278023
TI Neurotrophic actions of mood-stabilizers: a recent research discovery and its potential clinical applications
AU Chen, Guang; Creson, Thomas; Engel, Sharon; Hao, Yanlei; Wang, Gang
CS Group on Molecular Neurotherapeutics, LMP/MAP, NIMH/NIH, Bethesda, MD, USA
SO Current Psychiatry Reviews (2005), 1(2), 173-185
CODEN: CPRUD5; ISSN: 1573-4005
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
RE.CNT 142 THERE ARE 142 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:243139 CAPLUS
DN 142:386101
TI Neuroprotective role of testosterone in the nervous system
AU Bialek, Magdalena; Zaremba, Pawel; Borowicz, Kinga K.; Czuczwar, Stanislaw J.
CS Department of Pathophysiology, Skubiszewski Medical University, Lublin, PL 20-090, Pol.
SO Polish Journal of Pharmacology (2004), 56(5), 509-518
CODEN: PJPAE3; ISSN: 1230-6002
PB Polish Academy of Sciences, Institute of Pharmacology
DT Journal; General Review
LA English
RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:694987 CAPLUS
DN 137:350109
TI Modulation of ***axonal regeneration*** in neurodegenerative disease. Focus on Nogo
AU Strittmatter, Stephen M.
CS Department of Neurology, and Section of Neurobiology, Yale University School of Medicine, New Haven, CT, 06510, USA
SO Journal of Molecular Neuroscience (2002), 19(1/2), 117-121
CODEN: JMNEES; ISSN: 0895-8696
PB Humana Press Inc.
DT Journal; General Review
LA English
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:604210 CAPLUS
DN 138:162764
TI Recent advance in adenoviral gene transfer technology for neuronal survival and ***axonal regeneration***
AU Namikawa, Kazuhiko; Kiyama, Hiroshi
CS Dep. Anatomy, Grad. Sch. Med., Osaka City Univ., Japan
SO Saishin Igaku (2002), 57(7), 1591-1600
CODEN: SAIGAK; ISSN: 0370-8241
PB Saishin Igakusha
DT Journal; General Review
LA Japanese

L17 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:486006 CAPLUS
DN 137:382829
TI Apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to ***Alzheimer***'s disease
AU Danik, Marc; Poirier, Judes
CS Douglas Hospital Research Centre, Faculty of Medicine, McGill University, Montreal, QC, Can.
SO New Comprehensive Biochemistry (2002), 35(Brain Lipids and Disorders in Biological Psychiatry), 53-66
CODEN: NCBIDL; ISSN: 0167-7306
PB Elsevier Science B.V.
DT Journal; General Review
LA English
RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:860252 CAPLUS
DN 134:110579
TI Neuroprotection by estradiol
AU Garcia-Segura, Luis Miguel; Azcoitia, Inigo; DonCarlos, Lydia L.
CS Instituto Cajal, C.S.I.C., Madrid, E-28002, Spain
SO Progress in Neurobiology (Oxford) (2000), Volume Date 2001, 63(1), 29-60
CODEN: PGNBA5; ISSN: 0301-0082
PB Elsevier Science Ltd.
DT Journal; General Review
LA English
RE.CNT 376 THERE ARE 376 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:297326 CAPLUS
DN 130:336969
TI Complement-mediated transient demyelination for promotion neuronal regeneration in the central nervous system
IN Steeves, John D.; Dyer, Jason K.; Keirstead, Hans S.
PA Can.
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921581	A1	19990506	WO 1998-CA997	19981028
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2219683	A1	19990428	CA 1997-2219683	19971028
	CA 2253078	A1	19990428	CA 1998-2253078	19981028
	CA 2253078	C	20010501		
	AU 9896179	A	19990517	AU 1998-96179	19981028
	AU 748143	B2	20020530		
	EP 1047449	A1	20001102	EP 1998-949847	19981028
	EP 1047449	B1	20030910		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001521008	T	20011106	JP 2000-517739	19981028
	US 6548061	B1	20030415	US 1998-181719	19981028
	AT 249241	T	20030915	AT 1998-949847	19981028
	PT 1047449	T	20040430	PT 1998-949847	19981028
	ES 2210829	T3	20040701	ES 1998-949847	19981028
	US 6969516	B1	20051129	US 2000-530234	20000706
PRAI	CA 1997-2219683	A	19971028		
	CA 1998-2251410	A	19981016		
	WO 1998-CA997	W	19981028		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:736899 CAPLUS
DN 126:85782
TI Postnatal retinal ganglion cells in vitro: protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes
AU Lucius, Ralph; Sievers, Jobst
CS Anatomisches Institut der Universitaet Kiel, Olshausenstr. 40, Kiel, D-24118, Germany
SO Brain Research (1996), 743(1,2), 56-62
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:971365 CAPLUS
DN 124:83841
TI Aberrant GAP-43 gene expression in ***Alzheimer***'s disease
AU De la Monte, Suzanne M.; Ng, Shi-Chung; Hsu, Dora W.
CS Harvard Medical School, Massachusetts General Hospital, Boston, MA, 02129, USA
SO American Journal of Pathology (1995), 147(4), 934-46
CODEN: AJPAA4; ISSN: 0002-9440
PB American Society for Investigative Pathology
DT Journal
LA English

L17 ANSWER 41 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2007159329 EMBASE
TI The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system.
AU Galtrey C.M.; Fawcett J.W.
CS J.W. Fawcett, Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Robinson Way, Cambridge, CB2 2PY, United Kingdom. jf108@cam.ac.uk
SO Brain Research Reviews, (2007) Vol. 54, No. 1, pp. 1-18.
Refs: 212
ISSN: 0165-0173 CODEN: BRERD2
PUI S 0165-0173(06)00109-3
CY Netherlands
DT Journal; General Review
FS 021 Developmental Biology and Teratology
008 Neurology and Neurosurgery
LA English
SL English
ED Entered STN: 11 May 2007
Last Updated on STN: 11 May 2007

L17 ANSWER 42 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights

reserved on STN
AN 2007156671 EMBASE
TI Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics.
AU Cho S.; Wood A.; Bowlby M.R.
CS S. Cho, Department of Discovery Neuroscience, Department of Wyeth Research, Princeton, NJ 08543, United States. chos1@wyeth.com
SO Current Neuropharmacology, (2007) Vol. 5, No. 1, pp. 19-33. .
Refs: 184
ISSN: 1570-159X CODEN: CNUEAN
CY Netherlands
DT Journal; General Review
FS 030 Pharmacology
037 Drug Literature Index
005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
LA English
SL English
ED Entered STN: 1 May 2007
Last Updated on STN: 1 May 2007

L17 ANSWER 43 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2007098136 EMBASE
TI Two hydrophobic segments of the RTN1 family determine the ER localization and retention.
AU Iwahashi J.; Hamada N.; Watanabe H.
CS J. Iwahashi, Division of Infectious Diseases, Department of Infectious Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan. iwahashi@med.kurume-u.ac.jp
SO Biochemical and Biophysical Research Communications, (6 Apr 2007) Vol. 355, No. 2, pp. 508-512. .
Refs: 26
ISSN: 0006-291X E-ISSN: 1090-2104 CODEN: BBRCA
PUI S 0006-291X(07)00265-3
CY United States
DT Journal; Article
FS 029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 3 Apr 2007
Last Updated on STN: 3 Apr 2007

L17 ANSWER 44 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2006487495 EMBASE
TI Direct Rho-associated kinase inhibiton induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells.
AU Zhang Z.; Ottens A.K.; Larner S.F.; Kobeissy F.H.; Williams M.L.; Hayes R.L.; Wang K.K.W.
CS K.K.W. Wang, Center for Neuroproteomics and Biomarkers Research, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, United States. kwang@psychiatry.ufl.edu
SO Cellular and Molecular Biology Letters, (2006) Vol. 11, No. 1, pp. 12-29. .
Refs: 47
ISSN: 1425-8153 E-ISSN: 1689-1392 CODEN: CMBLFF
CY Poland
DT Journal; Article
FS 030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 16 Oct 2006
Last Updated on STN: 16 Oct 2006

L17 ANSWER 45 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2006165584 EMBASE
TI The therapeutic potential of human olfactory-derived stem cells.
AU Marshall C.T.; Lu C.; Winstead W.; Zhang X.; Xiao M.; Harding G.; Klueber K.M.; Roisen F.J.
CS D. F.J. Roisen, Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, 500 South Preston Street, Louisville, KY 40202, United States. fjrois01@gwise.louisville.edu
SO Histology and Histopathology, (2006) Vol. 21, No. 4-6, pp. 633-643. .
Refs: 128
ISSN: 0213-3911 CODEN: HIHIES
CY Spain
DT Journal; General Review
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 18 Apr 2006
Last Updated on STN: 18 Apr 2006

L17 ANSWER 46 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2005339732 EMBASE
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons.
AU Hirata K.; Yamaguchi H.; Takamura Y.; Takagi A.; Fukushima T.; Iwakami N.; Saitoh A.; Nakagawa M.; Yamada T.
CS K. Hirata, Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama, 930-8508, Japan. kazunari hirata@toyama-chemical.co.jp
SO Journal of Pharmacology and Experimental Therapeutics, (2005) Vol. 314, No. 1, pp. 252-259. .
Refs: 38
ISSN: 0022-3565 CODEN: JPETAB
CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 1 Sep 2005
Last Updated on STN: 1 Sep 2005

L17 ANSWER 47 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2005037821 EMBASE
TI Neuroprotective role of testosterone in the nervous system.
AU Bialek M.; Zaremba P.; Borowicz K.K.; Czuczwar S.J.
CS S.J. Czuczwar, Dept. of Pathophysiology, Skubiszewski Medical University, Jaczewskiego 8, PL 20-090 Lublin, Poland. czuczwarsj@yahoo.com
SO Polish Journal of Pharmacology, (2004) Vol. 56, No. 5, pp. 509-518. .
Refs: 87
ISSN: 1230-6002 CODEN: PJPAE3
CY Poland
DT Journal; General Review
FS 008 Neurology and Neurosurgery
030 Pharmacology
032 Psychiatry
037 Drug Literature Index

LA English
SL English
ED Entered STN: 4 Feb 2005
Last Updated on STN: 4 Feb 2005

L17 ANSWER 48 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2002327350 EMBASE
TI Modulation of ***axonal regeneration*** in neurodegenerative disease: Focus on Nogo.
AU Strittmatter S.M.
CS S.M. Strittmatter, Department of Neurology, Section of Neurobiology, Yale University School of Medicine, P.O. Box 208018, New Haven, CT 06510, United States. Stephen.Strittmatter@yale.edu
SO Journal of Molecular Neuroscience, (2002) Vol. 19, No. 1-2, pp. 117-121. .
Refs: 23
ISSN: 0895-8696 CODEN: JMNEES
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
LA English
SL English
ED Entered STN: 10 Oct 2002
Last Updated on STN: 10 Oct 2002

L17 ANSWER 49 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2000353446 EMBASE
TI Neuroprotection by estradiol.
AU Garcia-Segura L.M.; Azcoitia I.; DonCarlos L.L.
CS L.L. DonCarlos, Department of Cell Biology, Loyola University Chicago, Stritch School of Medicine, 2160 South First Avenue, Maywood, IL 60153, United States. Idoncar@luc.edu
SO Progress in Neurobiology, (1 Jan 2001) Vol. 63, No. 1, pp. 29-60. .
Refs: 376
ISSN: 0301-0082 CODEN: PGNBA5
PUI S 0301-0082(00)00025-3
CY United Kingdom
DT Journal; General Review
FS 020 Gerontology and Geriatrics
022 Human Genetics
029 Clinical Biochemistry
003 Endocrinology
030 Pharmacology
037 Drug Literature Index
008 Neurology and Neurosurgery
LA English
SL English
ED Entered STN: 26 Oct 2000
Last Updated on STN: 26 Oct 2000

L17 ANSWER 50 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 1999382285 EMBASE
TI Rho family antagonists and their use to block inhibition of neurite growth.
AU McKerracher L.; et al.
SO Expert Opinion on Therapeutic Patents, (1999) Vol. 9, No. 11, pp. 1571-1574. .
Refs: 9
ISSN: 1354-3776 CODEN: EOTPEG
CY United Kingdom
DT Journal; (Short Survey)
FS 008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 2 Dec 1999
Last Updated on STN: 2 Dec 1999

L17 ANSWER 51 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 97020490 EMBASE
DN 1997020490
TI Postnatal retinal ganglion cells in vitro: Protection against reactive oxygen species (ROS)-induced axonal degeneration by cocultured astrocytes.
AU Lucius R.; Sievers J.
CS R. Lucius, Anatomisches Institut, Universitat Kiel, Olshausenstr. 40, D-24118 Kiel, Germany
SO Brain Research, (1996) Vol. 743, No. 1-2, pp. 56-62. .
Refs: 48
ISSN: 0006-8993 CODEN: BRREAP
PUI S 0006-8993(96)01029-3
CY Netherlands
DT Journal; Article
FS 002 Physiology
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 18 Feb 1997
Last Updated on STN: 18 Feb 1997

L17 ANSWER 52 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 95311502 EMBASE
DN 1995311502
TI Aberrant GAP-43 gene expression in ***Alzheimer***'s disease.
AU De la Monte S.M.; Ng S.-C.; Hsu D.W.
CS Cancer Center-MGH East, Massachusetts General Hospital, 149 13th St.,Charlestown, MA 02129, United States
SO American Journal of Pathology, (1995) Vol. 147, No. 4, pp. 934-946. .
ISSN: 0002-9440 CODEN: AJPAA4
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
022 Human Genetics
LA English
SL English
ED Entered STN: 11 Nov 1995
Last Updated on STN: 11 Nov 1995

L17 ANSWER 53 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 93213095 EMBASE
DN 1993213095
TI New aspects of neurotransplantation.
AU Woerly S.; Morassutti D.J.
CS Biomaterials Institute, Hopital Saint-Francois d'Assise, 10 rue de l'Espinay,Quebec, Que. G1L 3L5, Canada
SO Neurosurgical Review, (1993) Vol. 16, No. 2, pp. 93-104. .
ISSN: 0344-5607 CODEN: NSREDV
CY Germany
DT Journal; (Short Survey)
FS 008 Neurology and Neurosurgery
021 Developmental Biology and Teratology

LA English
SL English
ED Entered STN: 22 Aug 1993
Last Updated on STN: 22 Aug 1993

L17 ANSWER 54 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 92286708 EMBASE
DN 1992286708
TI Culture of dorsal root ganglion neurons from aged rats: Effects of acetyl-L-carnitine and NGF.
AU Manfridi A.; Forloni G.L.; Arrigoni-Martelli E.; Mancia M.
CS Istituto di Fisiologia Umana II, Universita degli Studi di Milano, Via Mangiagalli 32,20133 Milano, Italy
SO International Journal of Developmental Neuroscience, (1992) Vol. 10, No. 4, pp. 321-329.
ISSN: 0736-5748 CODEN: IJDND6
CY United Kingdom
DT Journal; Article
FS 001 Anatomy, Anthropology, Embryology and Histology
008 Neurology and Neurosurgery
020 Gerontology and Geriatrics
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 25 Oct 1992
Last Updated on STN: 25 Oct 1992

L17 ANSWER 55 OF 63 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 89268444 EMBASE
DN 1989268444
TI Growth factors for neuronal survival and process regeneration. Implications in the mammalian central nervous system.
AU Lipton S.A.
CS Children's Hospital, Boston, MA 02115, United States
SO Archives of Neurology, (1989) Vol. 46, No. 11, pp. 1241-1248.
ISSN: 0003-9942 CODEN: ARNEAS
CY United States
DT Journal
FS 001 Anatomy, Anthropology, Embryology and Histology
002 Physiology
005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
LA English
SL English
ED Entered STN: 12 Dec 1991
Last Updated on STN: 12 Dec 1991

L17 ANSWER 56 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:250010 TOXCENTER
CP Copyright (c) 2007 The Thomson Corporation
DN PREV200510151552
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons
AU Hirata, Kazunari [Reprint Author]; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo
CS Toyama Chem Co Ltd, Res Labs, 2-4-1 Shimookui, Toyama 9308508, Japan
kazunari_hirata@toyama-chemical.co.jp
SO Journal of Pharmacology and Experimental Therapeutics, (JUL 2005) Vol. 314, No. 1, pp. 252-259. http://www.jpet.org.
CODEN: JPETAB. ISSN: 0022-3565.
DT Article
FS BIOSIS
OS BIOSIS 2005:365391
LA English
ED Entered STN: 20 Sep 2005
Last Updated on STN: 20 Sep 2005

L17 ANSWER 57 OF 63 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:229107 TOXCENTER
DN PubMed ID: 15798005
TI A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons
AU Hirata Kazunari; Yamaguchi Hidetoshi; Takamura Yusaku; Takagi Akiko; Fukushima Tetsuo; Iwakami Noboru; Saitoh Akihito; Nakagawa Masaya; Yamada Tatsuo
CS Research Laboratories, Toyama Chemical Co., Ltd, 2-4-1 Shimookui, Toyama, 930-8508, Japan. kazunari_hirata@toyama-chemical.co.jp
SO The Journal of pharmacology and experimental therapeutics, (2005 Jul) Vol. 314, No. 1, pp. 252-9. Electronic Publication: 2005-03-29.
Journal code: 0376362. ISSN: 0022-3565.
CY United States
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
FS MEDLINE
OS MEDLINE 2005316528
LA English
ED Entered STN: 30 Aug 2005
Last Updated on STN: 30 Aug 2005

=> d his

(FILE 'HOME' ENTERED AT 15:48:48 ON 19 JUN 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, TOXCENTER' ENTERED AT 15:49:02 ON 19 JUN 2007

L1	12537	S	AMYLOID(W)BETA(W)PEPTIDE
L2	9399	S	BETA(W)AMYLOID(W)PEPTIDE
L3	13	S	NOGO(W)RECEPTOR(W)ANTAGONIST
L4	0	S	RETICULON(W)FAMILY(W)PEPTIDE
L5	459	S	NOGO(W)RECEPTOR
L6	3	S	L5 (P) (L1 OR L2)
L7	2	S	NGR1(W)ANTAGONIST
L8	4	S	L3 AND ALZHEIMER
L9	3	S	L5 AND (L1 OR L2)
L10	10	S	LINGO-1(W)ANTAGONIST
L11	0	S	L10 AND (L1 OR L2)
L12	0	S	L10 AND ALZHEMIMER
L13	1	S	L10 AND ALZHEIMER
L14	25	S	NEP"1-40"
L15	0	S	L14 AND (L1 OR L2)
L16	0	S	L14 AND ALZHEIMER
L17	63	S	ALZHEIMER AND (AXONAL (W)REGENERATION)
L18	0	S	L17 AND (L14 OR L3 OR L7)
L19	7	S	L17 AND (L1 OR L2)

=>

```
=> s l1 and l2 and function
L20         79 L1 AND L2 AND FUNCTION

=> s l1 or l2 (p) function
L21      13364 L1 OR L2 (P) FUNCTION

=> s (l1 or l2) and function
L22       3236 (L1 OR L2) AND FUNCTION

=> s l22 and (l3 orl7  or l14)
MISSING OPERATOR L3 ORL7
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l22 and (l3 or l7  or l14)
L23          0 L22 AND (L3 OR L7 OR L14)

=> d l20 70-79

L20  ANSWER 70 OF 79  TOXCENTER COPYRIGHT 2007 ACS on STN
AN   2003:73424  TOXCENTER
CP   Copyright (c) 2007 The Thomson Corporation
DN   PREV200300153993
TI   Activation of Wnt signaling rescues neurodegeneration and behavioral
     impairments induced by beta-amyloid fibrils
AU   De Ferrari, G. V.; Chacon, M. A.; Barria, M. I.; Garrido, J. L.; Godoy, J.
     A.; Olivares, G.; Reyes, A. E.; Alvarez, A.; Bronfman, M.; Inestrosa, N.
     C. [Reprint Author]
CS   Molecular Neurobiology Unit, P Catholic University of Chile, PO Box 114-D,
     Santiago, Chile  ninestr@genes.bio.puc.cl
SO   Molecular Psychiatry, (2003) Vol. 8, No. 2, pp. 195-208. print.
     ISSN: 1359-4184.
DT   Article
FS   BIOSIS
OS   BIOSIS 2003:153993
LA   English
ED   Entered STN: 1 Apr 2003
     Last Updated on STN: 1 Apr 2003

L20  ANSWER 71 OF 79  TOXCENTER COPYRIGHT 2007 ACS on STN
AN   2002:136467  TOXCENTER
CP   Copyright 2007 ACS
DN   CA13626396235M
TI   The protective effects of melatonin from oxidative damage induced by
     amyloid beta-peptide 25-35 in middle-aged rats
AU   Shen, Y. X.; Xu, S. Y.; Wei, W.; Sun, X. X.; Liu, L. H.; Yang, J.; Dong,
     C.
CS   Institute of Clinical Pharmacology, Anhui Medical University, Hefei,
     230032, Peop. Rep. China.
SO   Journal of Pineal Research, (2002) Vol. 32, No. 2, pp. 85-89.
     CODEN: JPRSE9. ISSN: 0742-3098.
CY   CHINA
DT   Journal
FS   CAPLUS
OS   CAPLUS 2002:267661
LA   English
ED   Entered STN: 18 Jun 2002
     Last Updated on STN: 2 May 2006

L20  ANSWER 72 OF 79  TOXCENTER COPYRIGHT 2007 ACS on STN
AN   2002:78163  TOXCENTER
CP   Copyright 2007 ACS
DN   CA13711153285U
TI   Suppressed expression of nicotinic acetylcholine receptors by nanomolar
     beta.-amyloid peptides in PC12 cells
AU   Guan, Z.-Z.; Miao, H.; Tian, J.-Y.; Unger, C.; Nordberg, A.; Zhang, X.
CS   Division of Molecular Neuropharmacology, Department of Clinical, Huddinge
     University Hospital, Huddinge, Swed..
SO   Journal of Neural Transmission, (2001) Vol. 108, No. 12, pp. 1417-1433.
     CODEN: JNTRF3. ISSN: 1435-1463.
CY   SWEDEN
DT   Journal
FS   CAPLUS
OS   CAPLUS 2002:228581
LA   English
ED   Entered STN: 3 Apr 2002
     Last Updated on STN: 29 Aug 2006

L20  ANSWER 73 OF 79  TOXCENTER COPYRIGHT 2007 ACS on STN
AN   2001:213180  TOXCENTER
CP   Copyright 2007 ACS
DN   CA13524339064K
TI   Amyloid beta peptide 1-40 and the
     function of rat hippocampal hemicholinium-3 sensitive choline
     carriers: effects of a proteolytic degradation in vitro
AU   Kristofikova, Zdena; Tejkalova, Hana; Klaschka, Jan
CS   Prague Psychiatric Centre, Prague, 18103/8, Czech Rep..
SO   Neurochemical Research, (2001) Vol. 26, No. 3, pp. 203-212.
     CODEN: NEREDZ. ISSN: 0364-3190.
CY   CZECH REPUBLIC
DT   Journal
FS   CAPLUS
OS   CAPLUS 2001:557510
LA   English
ED   Entered STN: 27 Nov 2001
     Last Updated on STN: 26 Mar 2002

L20  ANSWER 74 OF 79  TOXCENTER COPYRIGHT 2007 ACS on STN
AN   2001:5964  TOXCENTER
CP   Copyright 2000 Wiley-Liss, Inc.
DN   PubMed ID: 10956426
TI   Huperzine A and tacrine attenuate beta-amyloid
     peptide-induced oxidative injury
AU   Xiao X Q; Wang R; Tang X C
CS   State Key Laboratory of Drug Research, Shanghai Institute of Materia
     Medica, Chinese Academy of Sciences, Shanghai, China
SO   Journal of neuroscience research, (2000 Sep 1) Vol. 61, No. 5, pp. 564-9.
     Journal code: 7600111. ISSN: 0360-4012.
CY   United States
DT   (COMPARATIVE STUDY)
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
FS   MEDLINE
OS   MEDLINE 2001032559
LA   English
ED   Entered STN: 16 Nov 2001
     Last Updated on STN: 16 Nov 2001

L20  ANSWER 75 OF 79  TOXCENTER COPYRIGHT 2007 ACS on STN
AN   2000:192645  TOXCENTER
CP   Copyright 2007 ACS
DN   CA13324329417X
TI   Huperzine A and tacrine attenuate .beta.-amyloid
     peptide-induced oxidative injury
AU   Xiao, Xiao Qiu; Wang, Rui; Tang, Xi Can
CS   State Key Laboratory of Drug Research, Shanghai Institute of Materia
     Medica, Chinese Academy of Sciences, Shanghai, 200031, Peop. Rep. China.
```

SO Journal of Neuroscience Research, (2000) Vol. 61, No. 5, pp. 564-569.
CODEN: JNREDK. ISSN: 0360-4012.
CY CHINA
DT Journal
FS CAPLUS
OS CAPLUS 2000:655982
LA English
ED Entered STN: 16 Nov 2001
Last Updated on STN: 21 Dec 2004

L20 ANSWER 76 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2000:180205 TOXCENTER
CP Copyright 2007 ACS
DN CA13408098483T
TI β-Amyloid augments platelet aggregation. Reduced activity of familial angiopathy-associated mutants
AU Wolozin, B.; Maheshwari, S.; Jones, C.; Dukoff, R.; Wallace, W.; Racchi, M.; Nagula, S.; Shulman, N. R.; Sunderland, T.; Bush, A.
CS Section on Geriatric Psychiatry, NIMH, Bethesda, MD, 20892, USA.
SO Molecular Psychiatry, (1998) Vol. 3, No. 6, pp. 500-507.
CODEN: MOPSFQ. ISSN: 1359-4184.
CY UNITED STATES
DT Journal
FS CAPLUS
OS CAPLUS 2000:569427
LA English
ED Entered STN: 16 Nov 2001
Last Updated on STN: 5 Mar 2002

L20 ANSWER 77 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2000:124293 TOXCENTER
CP Copyright 2007 ACS
DN CA13221277675N
TI β-Amyloid1-42 binds to α7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology
AU Wang, Hoau-Yan; Lee, Daniel H. S.; D'Andrea, Michael R.; Peterson, Per A.; Shank, Richard P.; Reitz, Allen B.
CS R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477-0776, USA.
SO Journal of Biological Chemistry, (2000) Vol. 275, No. 8, pp. 5626-5632.
CODEN: JBCHA3. ISSN: 0021-9258.
CY UNITED STATES
DT Journal
FS CAPLUS
OS CAPLUS 2000:156752
LA English
ED Entered STN: 16 Nov 2001
Last Updated on STN: 16 Apr 2002

L20 ANSWER 78 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 1997:217243 TOXCENTER
CP Copyright 2007 ACS
DN CA12807071065X
TI 17β-Estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by ***amyloid .beta.-peptide*** and iron
AU Keller, Jeffrey N.; Germeyer, Ariane; Begley, James G.; Mattson, Mark P.
CS Sanders-Brown Research Center on Aging, University of Kentucky, Lexington, KY, USA.
SO Journal of Neuroscience Research, (1997) Vol. 50, No. 4, pp. 522-530.
CODEN: JNREDK. ISSN: 0360-4012.
CY UNITED STATES
DT Journal
FS CAPLUS
OS CAPLUS 1997:774254
LA English
ED Entered STN: 16 Nov 2001
Last Updated on STN: 5 Jun 2002

L20 ANSWER 79 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 1997:206759 TOXCENTER
CP Copyright 2007 ACS
DN CA12724329848Q
TI β-Amyloid-induced cerebrovascular endothelial dysfunction
AU Thomas, Tom; McLendon, Chris; Sutton, E. Truitt; Thomas, George
CS Departments of Psychiatry and Physiology, College of Medicine, Univ. South Florida, Tampa, FL, 33613, USA.
SO Annals of the New York Academy of Sciences, (1997) Vol. 826, No. Cerebrovascular Pathology in Alzheimer's Disease, pp. 447-451.
CODEN: ANYAA9. ISSN: 0077-8923.
CY UNITED STATES
DT Journal
FS CAPLUS
OS CAPLUS 1997:700729
LA English
ED Entered STN: 16 Nov 2001
Last Updated on STN: 18 Jun 2002

=> d l20 1-69

L20 ANSWER 1 OF 79 MEDLINE on STN
AN 2006023704 MEDLINE
DN PubMed ID: 16303255
TI Transgenic mice over-expressing human beta-amyloid have functional nicotinic alpha 7 receptors.
AU Spencer J P; Weil A; Hill K; Hussain I; Richardson J C; Cusdin F S; Chen Y H; Randall A D
CS Neurology and GI CEDD, GlaxoSmithKline, Harlow, Essex CM19 5AW, UK..
jon p spencer@gsk.com
SO Neuroscience, (2006 Feb) Vol. 137, No. 3, pp. 795-805. Electronic Publication: 2005-11-21.
Journal code: 7605074. ISSN: 0306-4522.
CY United States
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200604
ED Entered STN: 14 Jan 2006
Last Updated on STN: 13 Apr 2006
Entered Medline: 12 Apr 2006

L20 ANSWER 2 OF 79 MEDLINE on STN
AN 2002690364 MEDLINE
DN PubMed ID: 12450488
TI Alzheimer's disease and the basal forebrain cholinergic system: relations to ***beta-amyloid peptides***, cognition, and treatment strategies.
AU Auld Daniel S; Kornecook Tom J; Bastianetto Stephane; Quirion Remi
CS Douglas Hospital Research Centre, 6875 Blvd Lasalle, Verdun, Que, Canada H4H 1R3.
SO Progress in neurobiology, (2002 Oct) Vol. 68, No. 3, pp. 209-45. Ref: 504
Journal code: 0370121. ISSN: 0301-0082.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
General Review; (REVIEW)

LA English
FS Priority Journals
EM 200303
ED Entered STN: 14 Dec 2002
Last Updated on STN: 6 Mar 2003
Entered Medline: 5 Mar 2003

L20 ANSWER 3 OF 79 MEDLINE on STN
AN 2002327989 MEDLINE
DN PubMed ID: 12071472
TI The protective effects of melatonin from oxidative damage induced by ***amyloid beta-peptide*** 25-35 in middle-aged rats.
AU Shen Y X; Xu S Y; Wei W; Sun X X; Liu L H; Yang J; Dong C
CS Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China.. shenyuxi@mail.hf.ah.cn
SO Journal of pineal research, (2002 Mar) Vol. 32, No. 2, pp. 85-9.
Journal code: 8504412. ISSN: 0742-3098.
CY Denmark
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200211
ED Entered STN: 20 Jun 2002
Last Updated on STN: 11 Dec 2002
Entered Medline: 8 Nov 2002

L20 ANSWER 4 OF 79 MEDLINE on STN
AN 2002327706 MEDLINE
DN PubMed ID: 12070316
TI Charge states rather than propensity for beta-structure determine enhanced fibrillogenesis in wild-type Alzheimer's ***beta-amyloid peptide*** compared to E22Q Dutch mutant.
AU Massi Francesca; Klimov D; Thirumalai D; Straub John E
CS Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA.
NC R01 NS 41356-01 (NINDS)
SO Protein science : a publication of the Protein Society, (2002 Jul) Vol. 11, No. 7, pp. 1639-47.
Journal code: 9211750. ISSN: 0961-8368.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200308
ED Entered STN: 19 Jun 2002
Last Updated on STN: 11 Dec 2002
Entered Medline: 19 Aug 2003

L20 ANSWER 5 OF 79 MEDLINE on STN
AN 2001126187 MEDLINE
DN PubMed ID: 11137881
TI Beta-amyloid (1-42) affects MTT reduction in astrocytes: implications for vesicular trafficking and cell functionality.
AU Kerokoski P; Soininen H; Pirttila T
CS Department of Neuroscience and Neurology, University of Kupio, Finland.. petri.kerokoski@uku.fi
SO Neurochemistry international, (2001 Feb) Vol. 38, No. 2, pp. 127-34.
Journal code: 8006959. ISSN: 0197-0186.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200102
ED Entered STN: 22 Mar 2001
Last Updated on STN: 22 Mar 2001
Entered Medline: 22 Feb 2001

L20 ANSWER 6 OF 79 MEDLINE on STN
AN 2001101045 MEDLINE
DN PubMed ID: 11119646
TI Energy landscape theory for Alzheimer's ***amyloid beta-peptide*** fibril elongation.
AU Massi F; Straub J E
CS Department of Chemistry, Boston University, Boston, Massachusetts 02115, USA.
SO Proteins, (2001 Feb 1) Vol. 42, No. 2, pp. 217-29.
Journal code: 8700181. ISSN: 0887-3585.
CY United States
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LA English
FS Priority Journals
EM 200102
ED Entered STN: 22 Mar 2001
Last Updated on STN: 22 Mar 2001
Entered Medline: 1 Feb 2001

L20 ANSWER 7 OF 79 MEDLINE on STN
AN 2001032559 MEDLINE
DN PubMed ID: 10956426
TI Huperzine A and tacrine attenuate ***beta-amyloid peptide***-induced oxidative injury.
AU Xiao X Q; Wang R; Tang X C
CS State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
SO Journal of neuroscience research, (2000 Sep 1) Vol. 61, No. 5, pp. 564-9.
Journal code: 7600111. ISSN: 0360-4012.
CY United States
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200011
ED Entered STN: 22 Mar 2001
Last Updated on STN: 22 Mar 2001
Entered Medline: 30 Nov 2000

L20 ANSWER 8 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2007:315288 BIOSIS
DN PREV200700315208
TI Abeta Peptide and Alzheimer's Disease: Celebrating a Century of Research.
AU Barrow, CJ [Editor]; Small, DH [Editor]
CS Ocean Nutr Canada, Dartmouth, NS, Canada
SO Barrow, CJ [Editor]; Small, DH [Editor]. (2007) Abeta Peptide and Alzheimer's Disease: Celebrating a Century of Research.
Publisher: SPRINGER, 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES.
ISBN: 978-1-85233-961-6(H).
DT Book
LA English
ED Entered STN: 24 May 2007

Last Updated on STN: 24 May 2007

L20 ANSWER 9 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2006:252694 BIOSIS
DN PREV200600251494
TI Transgenic mice over-expressing human beta-amyloid have functional nicotinic alpha 7 receptors.
AU Spencer, J. P. [Reprint Author]; Weil, A.; Hill, K.; Hussain, I.; Richardson, J. C.; Cusdin, F. S.; Chen, Y. H.; Randall, A. D.
CS GlaxoSmithKline Inc, Neurol and GI CEDD, Harlow CM19 5AW, Essex, UK
jon p spencer@gsk.com
SO Neuroscience, (2006) Vol. 137, No. 3, pp. 795-805.
CODEN: NRSCDN. ISSN: 0306-4522.
DT Article
LA English
ED Entered STN: 26 Apr 2006
Last Updated on STN: 26 Apr 2006

L20 ANSWER 10 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2003:390477 BIOSIS
DN PREV200300390477
TI beta-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex.
AU Dougherty, John J.; Wu, Jianlin; Nichols, Robert A. [Reprint Author]
CS Department of Pharmacology and Physiology, College of Medicine, Drexel University (formerly MCP Hahnemann University), 245 North 15th Street, Philadelphia, PA, 19102, USA
robert.nichols@drexel.edu
SO Journal of Neuroscience, (July 30 2003) Vol. 23, No. 17, pp. 6740-6747. print.
ISSN: 0270-6474 (ISSN print).
DT Article
LA English
ED Entered STN: 27 Aug 2003
Last Updated on STN: 27 Aug 2003

L20 ANSWER 11 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2003:153993 BIOSIS
DN PREV200300153993
TI Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils.
AU De Ferrari, G. V.; Chacon, M. A.; Barria, M. I.; Garrido, J. L.; Godoy, J. A.; Olivares, G.; Reyes, A. E.; Alvarez, A.; Bronfman, M.; Inestrosa, N. C. [Reprint Author]
CS Molecular Neurobiology Unit, P Catholic University of Chile, PO Box 114-D, Santiago, Chile
ninestr@genes.bio.puc.cl
SO Molecular Psychiatry, (2003) Vol. 8, No. 2, pp. 195-208. print.
ISSN: 1359-4184 (ISSN print).
DT Article
LA English
ED Entered STN: 26 Mar 2003
Last Updated on STN: 26 Mar 2003

L20 ANSWER 12 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2002:423365 BIOSIS
DN PREV200200423365
TI Charge states rather than propensity for beta-structure determine enhanced fibrillogenesis in wild-type Alzheimer's ***beta-amyloid peptide*** compared to E22Q Dutch mutant.
AU Massi, Francesca; Klimov, D.; Thirumalai, D.; Straub, John E. [Reprint author]
CS Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, MA, 02215, USA
straub@bu.edu
SO Protein Science, (July, 2002) Vol. 11, No. 7, pp. 1639-1647. print.
ISSN: 0961-8368.
DT Article
LA English
ED Entered STN: 7 Aug 2002
Last Updated on STN: 7 Aug 2002

L20 ANSWER 13 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2002:260830 BIOSIS
DN PREV200200260830
TI The protective effects of melatonin from oxidative damage induced by ***amyloid beta-peptide*** 25-35 in middle-aged rats.
AU Shen, Y. X. [Reprint author]; Xu, S. Y.; Wei, W.; Sun, X. X.; Liu, L. H.; Yang, J.; Dong, C.
CS Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, China
shenyuxi@mail.hf.ah.cn
SO Journal of Pineal Research, (March, 2002) Vol. 32, No. 2, pp. 85-89. print.
CODEN: JPRSE9. ISSN: 0742-3098.
DT Article
LA English
ED Entered STN: 24 Apr 2002
Last Updated on STN: 24 Apr 2002

L20 ANSWER 14 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2001:98544 BIOSIS
DN PREV200100098544
TI beta-Amyloid (1-42) affects MTT reduction in astrocytes: Implications for vesicular trafficking and cell functionality.
AU Petri, Kerokoski [Reprint author]; Hilkka, Soininen; Tuula, Pirttila
CS Department of Neuroscience and Neurology, University of Kuopio, 70211, Kuopio, Finland
petri.kerokoski@uku.fi
SO Neurochemistry International, (February, 2001) Vol. 38, No. 2, pp. 127-134. print.
CODEN: NEUIDS. ISSN: 0197-0186.
DT Article
LA English
ED Entered STN: 21 Feb 2001
Last Updated on STN: 15 Feb 2002

L20 ANSWER 15 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2001:92592 BIOSIS
DN PREV200100092592
TI Energy landscape theory for Alzheimer's ***amyloid beta-peptide*** fibril elongation.
AU Massi, Francesca; Straub, John E. [Reprint author]
CS Department of Chemistry, Boston University, Boston, MA, 02215, USA
straub@bu.edu
SO Proteins, (February 1, 2001) Vol. 42, No. 2, pp. 217-229. print.
CODEN: PSFGEY. ISSN: 0887-3585.
DT Article
LA English
ED Entered STN: 21 Feb 2001
Last Updated on STN: 12 Feb 2002

L20 ANSWER 16 OF 79 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2000:411441 BIOSIS
DN PREV200000411441
TI Huperzine A and tacrine attenuate ***beta-amyloid peptide***-induced oxidative injury.
AU Xiao, Xiao Qiu; Wang, Rui; Tang, Xi Can [Reprint author]
CS State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 294 Tai-yuan Road, Shanghai, 200031, China
SO Journal of Neuroscience Research, (September 1, 2000) Vol. 61, No. 5, pp. 564-569. print.
CODEN: JNREDK. ISSN: 0360-4012.
DT Article
LA English
ED Entered STN: 27 Sep 2000
Last Updated on STN: 8 Jan 2002

L20 ANSWER 17 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:452213 CAPLUS
DN 146:516772
TI β-Sheet Structured β-Amyloid(1-40) Perturbs Phosphatidylcholine Model Membranes
AU De Planque, Maurits R. R.; Raussens, Vincent; Contera, Sonia Antoranz; Rijkers, Dirk T. S.; Liskamp, Rob M. J.; Ruysschaert, Jean-Marie; Ryan, John F.; Separovic, Frances; Watts, Anthony
CS Biomembrane Structure Unit, Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK
SO Journal of Molecular Biology (2007), 368(4), 982-997
CODEN: JMOBAK; ISSN: 0022-2836
PB Elsevier Ltd.
DT Journal
LA English
RE.CNT 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 18 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:152774 CAPLUS
DN 146:160667
TI Chronic but not acute intracerebroventricular administration of ***amyloid .beta.-peptide***(25-35) decreases somatostatin content, adenylate cyclase activity, somatostatin-induced inhibition of adenylate cyclase activity, and adenylate cyclase I levels in the rat hippocampus
AU Burgos-Ramos, E.; Hervas-Aguilar, A.; Puebla-Jimenez, L.; Boyano-Adanez, M. C.; Arilla-Ferreiro, E.
CS Grupo de Neurobioquimica, Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad de Alcala, Alcala de Henares, Spain
SO Journal of Neuroscience Research (2007), 85(2), 433-442
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 19 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1205062 CAPLUS
DN 146:161107
TI Aβ-immunotherapy for Alzheimer's disease using mannan- ***amyloid -beta peptide*** immunoconjugates
AU Ghochikyan, Anahit; Petrushina, Irina; Lees, Andrew; Vasilevko, Vitaly; Movsesyan, Nina; Karapetyan, Adrine; Agadjanyan, Michael G.; Cribbs, David H.
CS Department of Immunology, The Institute for Molecular Medicine, Huntington Beach, CA, USA
SO DNA and Cell Biology (2006), 25(10), 571-580
CODEN: DCEBE8; ISSN: 1044-5498
PB Mary Ann Liebert, Inc.
DT Journal
LA English
RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1092969 CAPLUS
DN 146:225706
TI Control of ***amyloid-.beta.-peptide*** qeneration by subcellular trafficking of the β-amyloid precursor protein and β-secretase
AU Walter, Jochen
CS Department of Neurology, University of Bonn, Bonn, D-53127, Germany
SO Neurodegenerative Diseases (2006), 3(4-5), 247-254
CODEN: NDEIA6; ISSN: 1660-2854
PB S. Karger AG
DT Journal; General Review
LA English
RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 21 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1087762 CAPLUS
DN 146:57527
TI Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism
AU Shen, Yuequan; Joachimiak, Andrzej; Rosner, Marsha Rich; Tang, Wei-Jen
CS Ben-May Institute for Cancer Research, The University of Chicago, Chicago, IL, 60637, USA
SO Nature (London, United Kingdom) (2006), 443(7113), 870-874
CODEN: NATUAS; ISSN: 0028-0836
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:686944 CAPLUS
DN 146:24646
TI The role of nitric oxide in neurodegenerative diseases and dementia
AU Fang, Marong; Wang, Mingwei; Qing, Renshi; Zhang, Lihong; Li, Jicheng; Yew, David T.
CS Department of Anatomy, Medical School of Zhejiang University, Peop. Rep. China
SO Current Trends in Neurology (2005), 1, 81-90
CODEN: CTNUAA; ISSN: 0972-8252
PB Research Trends
DT Journal; General Review
LA English
RE.CNT 107 THERE ARE 107 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:580664 CAPLUS
DN 145:373539
TI Lipid rafts and Alzheimer's disease
AU Urano, Yasuomi; Hamakubo, Takao

CS Department of Biochemistry, Dartmouth Medical School, Hanover, NH, 03755, USA
SO Foods & Food Ingredients Journal of Japan (2006), 211(5), 428-434
CODEN: FFIJER; ISSN: 0919-9772
PB FFI Janaru
DT Journal; General Review
LA Japanese

L20 ANSWER 24 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:509120 CAPLUS
DN 145:40563
TI Sex-dependent Actions of ***Amyloid Beta Peptides*** on Hippocampal Choline Carriers of Postnatal Rats
AU Kristofikova, Z.; Ricny, J.; Kozmikova, I.; Ripova, D.; Zach, P.; Klaschka, J.
CS Prague Psychiatric Center, Prague, 181 03 8, Czech Rep.
SO Neurochemical Research (2006), 31(3), 351-360
CODEN: NEREDZ; ISSN: 0364-3190
PB Springer
DT Journal
LA English
RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 25 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:234583 CAPLUS
DN 144:310455
TI Anti-human ***amyloid .beta. peptide*** antibodies with impaired effector ***function*** for treating Alzheimer's disease, Down syndrome cerebral amyloid angiopathy, Parkinson's disease and Aβ peptide-associated diseases
IN Rosenthal, Arnon; Pons, Jaume; Ho, Wei-Hsien; Grimm, Jan Markus
PA USA
SO U.S. Pat. Appl. Publ., 76 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006057701	A1	20060316	US 2005-194989	20050801
	US 2006057702	A1	20060316	US 2005-195207	20050801
	AU 2005290250	A1	20060406	AU 2005-290250	20050801
	CA 2575663	A1	20060406	CA 2005-2575663	20050801
	WO 2006036291	A2	20060406	WO 2005-US27295	20050801
	WO 2006036291	A3	20060720		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1781704	A2	20070509	EP 2005-778628	20050801
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	US 2004-592494P	P	20040730		
	US 2005-653197P	P	20050214		
	US 2005-676093P	P	20050429		
	WO 2005-US27295	W	20050801		

L20 ANSWER 26 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:96274 CAPLUS
DN 144:485636
TI The role of an astrocytic NADPH oxidase in the neurotoxicity of ***amyloid beta peptides***
AU Abramov, Andrey Y.; Duchen, Michael R.
CS Department of Physiology, University College London, London, WC1E 6BT, UK
SO Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences (2005), 360(1464), 2309-2314
CODEN: PTRBAE; ISSN: 0962-8436
PB Royal Society
DT Journal; General Review
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 27 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:38538 CAPLUS
DN 144:230912
TI Transgenic mice over-expressing human β-amyloid have functional nicotinic alpha 7 receptors
AU Spencer, J. P.; Weil, A.; Hill, K.; Hussain, I.; Richardson, J. C.; Cusdin, F. S.; Chen, Y. H.; Randall, A. D.
CS Neurology and GI CEDD, GlaxoSmithKline, Essex, CM19 5AW, UK
SO Neuroscience (San Diego, CA, United States) (2006), 137(3), 795-805
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 28 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:903694 CAPLUS
DN 143:303830
TI The chick embryo appears as a natural model for research in beta-amyloid precursor protein processing
AU Carrodeguas, J. A.; Rodolosse, A.; Garza, M. V.; Sanz-Clemente, A.; Perez-Pe, R.; Lacosta, A. M.; Dominguez, L.; Monleon, I.; Sanchez-Diaz, R.; Sorribas, V.; Sarasa, M.
CS Laboratory of Neurobiology, Department of Anatomy, Embryology and Genetics, University of Zaragoza, Zaragoza, E-50013, Spain
SO Neuroscience (Oxford, United Kingdom) (2005), 134(4), 1285-1300
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier Ltd.
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 29 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:198438 CAPLUS
DN 142:424135
TI Insulin protects against ***amyloid .beta.-peptide*** toxicity in brain mitochondria of diabetic rats
AU Moreira, Paula I.; Santos, Maria S.; Sena, Cristina; Seica, Raquel; Oliveira, Catarina R.
CS Center for Neuroscience of Coimbra, Department of Zoology, Faculty of Sciences and Technology, University of Coimbra, Coimbra, 3004-517, Port.
SO Neurobiology of Disease (2005), 18(3), 628-637
CODEN: NUDIEM; ISSN: 0969-9961

PB Elsevier
DT Journal
LA English
RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 30 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1024659 CAPLUS
DN 142:152749
TI Signal transduction during ***amyloid-.beta.-peptide*** neurotoxicity: role in Alzheimer disease
AU Fuentealba, Rodrigo A.; Farias, Ginny; Scheu, Jessica; Bronfman, Miguel; Marzolo, Maria Paz; Inestrosa, Nibaldo C.
CS Centro FONDAP de Regulacion Celular y Patologia "Joaquin Luco", MIFAB, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile
SO Brain Research Reviews (2004), 47(1-3), 275-289
CODEN: BRERD2; ISSN: 0165-0173
PB Elsevier B.V.
DT Journal; General Review
LA English
RE.CNT 163 THERE ARE 163 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 31 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:100490 CAPLUS
DN 140:124840
TI Methods for detecting parenchymal plaques in vivo
IN Poduslo, Joseph F.; Curran, Geoffrey L.; Wengenack, Thomas M.
PA USA
SO U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 542,537, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004022736	A1	20040205	US 2003-351777	20030127
PRAI	US 2000-542537	B2	20000404		
	US 2002-427821P	P	20021120		

L20 ANSWER 32 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:826200 CAPLUS
DN 139:360646
TI Influence of Hydrophobic Teflon Particles on the Structure of ***Amyloid .beta.-Peptide***
AU Giacomelli, Carla E.; Norde, Willem
CS INFIQC Departamento de Fisicoquimica, Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Cordoba, 5000, Argent.
SO Biomacromolecules (2003), 4(6), 1719-1726
CODEN: BOMAF6; ISSN: 1525-7797
PB American Chemical Society
DT Journal
LA English
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 33 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:701932 CAPLUS
DN 139:301297
TI Stereoselective Interactions of Peptide Inhibitors with the ***.beta.-Amyloid Peptide***
AU Chalifour, Robert J.; McLaughlin, Richard W.; Lavoie, Louis; Morissette, Celine; Tremblay, Nadine; Boule, Marie; Sarazin, Philippe; Stea, Dino; Lacombe, Diane; Tremblay, Patrick; Gervais, Francine
CS Neurochem Inc., Saint-Laurent, QC, H4S 2A1, Can.
SO Journal of Biological Chemistry (2003), 278(37), 34874-34881
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 34 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:346501 CAPLUS
DN 139:114944
TI Cholesterol Distribution in the Golgi Complex of DITNC1 Astrocytes Is Differentially Altered by Fresh and Aged ***Amyloid .beta.-Peptide***-(1-42)
AU Igbavboa, Urule; Pidcock, Justine M.; Johnson, Leslie N. A.; Malo, Todd M.; Studniski, Ann E.; Yu, Su; Sun, Grace Y.; Wood, W. Gibson
CS Veterans Affairs Medical Center and the Department of Pharmacology, Education and Clinical Center, Geriatric Research, University of Minnesota School of Medicine, Minneapolis, MN, 55417, USA
SO Journal of Biological Chemistry (2003), 278(19), 17150-17157
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 35 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:893187 CAPLUS
DN 138:269080
TI Alzheimer's disease and the basal forebrain cholinergic system: relations to ***.beta.-amyloid peptides***, cognition, and treatment strategies
AU Auld, Daniel S.; Kornecook, Tom J.; Bastianetto, Stephane; Quirion, Remi
CS Douglas Hospital Research Centre, Verdun, QC, H4H 1R3, Can.
SO Progress in Neurobiology (Oxford, United Kingdom) (2002), 68(3), 209-245
CODEN: PGNBA5; ISSN: 0301-0082
PB Elsevier Science Ltd.
DT Journal; General Review
LA English
RE.CNT 504 THERE ARE 504 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 36 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:508402 CAPLUS
DN 137:212549
TI Charge states rather than propensity for β-structure determine enhanced fibrillogenesis in wild-type Alzheimer's ***.beta.-amyloid peptide*** compared to E22Q Dutch mutant
AU Massi, Francesca; Klimov, D.; Thirumalai, D.; Straub, John E.
CS Department of Chemistry, Boston University, Boston, MA, 02215, USA
SO Protein Science (2002), 11(7), 1639-1647
CODEN: PRCIEI; ISSN: 0961-8368
PB Cold Spring Harbor Laboratory Press
DT Journal
LA English
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 37 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:267661 CAPLUS

DN 136:396235
TI The protective effects of melatonin from oxidative damage induced by ***amyloid beta-peptide*** 25-35 in middle-aged rats
AU Shen, Y. X.; Xu, S. Y.; Wei, W.; Sun, X. X.; Liu, L. H.; Yang, J.; Dong, C.
CS Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, Peop. Rep. China
SO Journal of Pineal Research (2002), 32(2), 85-89
CODEN: JPRSE9; ISSN: 0742-3098
PB Blackwell Munksgaard
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 38 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:228581 CAPLUS
DN 137:153285
TI Suppressed expression of nicotinic acetylcholine receptors by nanomolar .***beta***.-***amyloid peptides*** in PC12 cells
AU Guan, Z.-Z.; Miao, H.; Tian, J.-Y.; Unger, C.; Nordberg, A.; Zhang, X.
CS Division of Molecular Neuropharmacology, Department of Clinical, Huddinge University Hospital, Huddinge, Swed.
SO Journal of Neural Transmission (2001), 108(12), 1417-1433
CODEN: JNTRF3; ISSN: 1435-1463
PB Springer-Verlag Wien
DT Journal
LA English
RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 39 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:557510 CAPLUS
DN 135:339064
TI ***Amyloid beta peptide*** 1-40 and the ***function*** of rat hippocampal hemicholinium-3 sensitive choline carriers: effects of a proteolytic degradation in vitro
AU Kristofikova, Zdena; Tejkalova, Hana; Klaschka, Jan
CS Prague Psychiatric Centre, Prague, 18103/8, Czech Rep.
SO Neurochemical Research (2001), 26(3), 203-212
CODEN: NEREDZ; ISSN: 0364-3190
PB Kluwer Academic/Plenum Publishers
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 40 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:80286 CAPLUS
DN 134:264528
TI β-Amyloid (1-42) affects MTT reduction in astrocytes: implications for vesicular trafficking and cell functionality
AU Kerokoski, Petri; Soininen, Hilkka; Pirttila, Tuula
CS Department of Neuroscience and Neurology, University of Kuopio, Kuopio, 70211, Finland
SO Neurochemistry International (2001), 38(2), 127-134
CODEN: NEUIDS; ISSN: 0197-0186
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 41 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:59884 CAPLUS
DN 134:250689
TI Energy landscape theory for Alzheimer's ***amyloid .beta .-peptide*** fibril elongation
AU Massi, Francesca; Straub, John E.
CS Department of Chemistry, Boston University, Boston, MA, 02215, USA
SO Proteins: Structure, Function, and Genetics (2001), 42(2), 217-229
CODEN: PSFGEY; ISSN: 0887-3585
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 42 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:655982 CAPLUS
DN 133:329417
TI Huperzine A and tacrine attenuate ***.beta.-amyloid peptide***-induced oxidative injury
AU Xiao, Xiao Qiu; Wang, Rui; Tang, Xi Can
CS State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 200031, Peop. Rep. China
SO Journal of Neuroscience Research (2000), 61(5), 564-569
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 43 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:569427 CAPLUS
DN 134:98483
TI β-Amyloid augments platelet aggregation. Reduced activity of familial angiopathy-associated mutants
AU Wolozin, B.; Maheshwari, S.; Jones, C.; Dukoff, R.; Wallace, W.; Racchi, M.; Nagula, S.; Shulman, N. R.; Sunderland, T.; Bush, A.
CS Section on Geriatric Psychiatry, NIMH, Bethesda, MD, 20892, USA
SO Molecular Psychiatry (1998), 3(6), 500-507
CODEN: MOPSFQ; ISSN: 1359-4184
PB Stockton Press
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 44 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:156752 CAPLUS
DN 132:277675
TI β-Amyloid1-42 binds to α7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology
AU Wang, Hoau-Yan; Lee, Daniel H. S.; D'Andrea, Michael R.; Peterson, Per A.; Shank, Richard P.; Reitz, Allen B.
CS R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477-0776, USA
SO Journal of Biological Chemistry (2000), 275(8), 5626-5632
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 45 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:774254 CAPLUS
DN 128:71065
TI 17β-Estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by ***amyloid .beta.-peptide*** and iron
AU Keller, Jeffrey N.; Germeyer, Ariane; Begley, James G.; Mattson, Mark P.
CS Sanders-Brown Research Center on Aging, University of Kentucky, Lexington, KY, USA
SO Journal of Neuroscience Research (1997), 50(4), 522-530
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 46 OF 79 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:700729 CAPLUS
DN 127:329848
TI β-Amyloid-induced cerebrovascular endothelial dysfunction
AU Thomas, Tom; McLendon, Chris; Sutton, E. Truitt; Thomas, George
CS Departments of Psychiatry and Physiology, College of Medicine, Univ. South Florida, Tampa, FL, 33613, USA
SO Annals of the New York Academy of Sciences (1997), 826(Cerebrovascular Pathology in Alzheimer's Disease), 447-451
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal
LA English
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 47 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2007178627 EMBASE
TI β-Sheet Structured β-Amyloid(1-40) Perturbs Phosphatidylcholine Model Membranes.
AU de Planque M.R.R.; Raussens V.; Contera S.A.; Rijkers D.T.S.; Liskamp R.M.J.; Ruysschaert J.-M.; Ryan J.F.; Separovic F.; Watts A.
CS M.R.R. de Planque, Biomembrane Structure Unit, Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, United Kingdom. m.deplanquel@physics.ox.ac.uk
SO Journal of Molecular Biology, (11 May 2007) Vol. 368, No. 4, pp. 982-997.
Refs: 90
ISSN: 0022-2836 CODEN: JMOBAK
PUI S 0022-2836(07)00255-0
CY United Kingdom
DT Journal; Article
FS 029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 1 May 2007
Last Updated on STN: 1 May 2007

L20 ANSWER 48 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2006379200 EMBASE
TI Fragment 31-35 of ***.beta.-amyloid peptide*** induces neurodegeneration in rat cerebellar granule cells via bax gene expression and caspase-3 activation. A crucial role for the redox state of methionine-35 residue.
AU Misiti F.; Clementi M.E.; Tringali G.; Vairano M.; Orsini F.; Pezzotti M.; Navarra P.; Giardina B.; Pozzoli G.
CS G. Pozzoli, Institute of Pharmacology, Catholic University School of Medicine, Largo F. Vito 1, 00168 Rome, Italy. giacomopozzoli@rm.unicatt.it
SO Neurochemistry International, (2006) Vol. 49, No. 5, pp. 525-532.
Refs: 46
ISSN: 0197-0186 CODEN: NEUIDS
PUI S 0197-0186(06)00149-5
CY United Kingdom
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 29 Aug 2006
Last Updated on STN: 29 Aug 2006

L20 ANSWER 49 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2006017457 EMBASE
TI Transgenic mice over-expressing human β-amyloid have functional nicotinic alpha 7 receptors.
AU Spencer J.P.; Weil A.; Hill K.; Hussain I.; Richardson J.C.; Cusdin F.S.; Chen Y.H.; Randall A.D.
CS J.P. Spencer, Neurology and GI CEDD, GlaxoSmithKline, Harlow, Essex CM19 5AW, United Kingdom. jon_p_spencer@gsk.com
SO Neuroscience, (2006) Vol. 137, No. 3, pp. 795-805.
Refs: 49
ISSN: 0306-4522 CODEN: NRSCDN
PUI S 0306-4522(05)01150-4
CY United Kingdom
DT Journal; Article
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 26 Jan 2006
Last Updated on STN: 26 Jan 2006

L20 ANSWER 50 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2004505779 EMBASE
TI Assessment of the bioactivity of antibodies against ***.beta.-amyloid peptide*** in vitro and in vivo.
AU Mohajeri M.H.; Gaugler M.N.M.; Martinez J.; Tracy J.; Li H.; Crameri A.; Kuehnle K.; Wollmer M.A.; Nitsch R.M.
CS M.H. Mohajeri, Division of Psychiatry Research, University of Zurich, August Forel Strasse 1, CH-8008 Zurich, Switzerland. mohajeri@bli.unizh.ch
SO Neurodegenerative Diseases, (2004) Vol. 1, No. 4-5, pp. 160-167.
Refs: 33
ISSN: 1660-2854 CODEN: NDEIA6
CY Switzerland
DT Journal; Article
FS 008 Neurology and Neurosurgery
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English
ED Entered STN: 9 Dec 2004
Last Updated on STN: 9 Dec 2004

L20 ANSWER 51 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2003411455 EMBASE
TI β-amyloid induces paired helical filament-like tau filaments in

tissue culture.
AU Ferrari A.; Hoerndli F.; Baechi T.; Nitsch R.M.; Gotz J.
CS J. Gotz, Division of Psychiatry Research, University of Zurich, August Forel Strasse 1, 8008 Zurich, Switzerland. goetz@bli.unizh.ch
SO Journal of Biological Chemistry, (10 Oct 2003) Vol. 278, No. 41, pp. 40162-40168. .
Refs: 28
ISSN: 0021-9258 CODEN: JBCHA3
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 6 Nov 2003
Last Updated on STN: 6 Nov 2003

L20 ANSWER 52 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2002420945 EMBASE
TI Alzheimer's disease and the basal forebrain cholinergic system: Relations to ***.beta.-amyloid peptides***, cognition, and treatment strategies.
AU Auld D.S.; Kornecook T.J.; Bastianetto S.; Quirion R.
CS R. Quirion, Douglas Hospital Research Centre, 6875 Blvd. Lasalle, Verdun, Que. H4H IR3, Canada. quirem@douglas.mcgill.ca
SO Progress in Neurobiology, (2002) Vol. 68, No. 3, pp. 209-245. .
Refs: 504
ISSN: 0301-0082 CODEN: PGNBA5
PUI S 0301-0082(02)00079-5
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 12 Dec 2002
Last Updated on STN: 12 Dec 2002

L20 ANSWER 53 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2002312730 EMBASE
TI Intracellular amyloid-β1-42, but not extracellular soluble ***amyloid-.beta. peptides***, induces neuronal apoptosis.
AU Kienlen-Campard P.; Miolet S.; Tasiaux B.; Octave J.-N.
CS J.-N. Octave, Universite Catholique de Louvain, FARL/ UCL 54 10, Av Hippocrate 54, B-1200 Brussels, Belgium. octave@nchm.ucl.ac.be
SO Journal of Biological Chemistry, (3 May 2002) Vol. 277, No. 18, pp. 15666-15670. .
Refs: 47
ISSN: 0021-9258 CODEN: JBCHA3
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 26 Sep 2002
Last Updated on STN: 26 Sep 2002

L20 ANSWER 54 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2002221516 EMBASE
TI Charge states rather than propensity for β-structure determine enhanced fibrillogenesis in wild-type Alzheimer's ***.beta.-amyloid peptide*** compared to E22Q Dutch mutant.
AU Massi F.; Klimov D.; Thirumalai D.; Straub J.E.
CS J.E. Straub, Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, United States. straub@bu.edu
SO Protein Science, (2002) Vol. 11, No. 7, pp. 1639-1647. .
Refs: 36
ISSN: 0961-8368 CODEN: PRCIEI
CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 11 Jul 2002
Last Updated on STN: 11 Jul 2002

L20 ANSWER 55 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2002132603 EMBASE
TI The protective effects of melatonin from oxidative damage induced by ***amyloid beta-peptide*** 25-35 in middle-aged rats.
AU Shen Y.X.; Xu S.Y.; Wei W.; Sun X.X.; Liu L.H.; Yang J.; Dong C.
CS Y.X. Shen, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, China. shenyuxi@mail.hf.ah.cn
SO Journal of Pineal Research, (2002) Vol. 32, No. 2, pp. 85-89. .
Refs: 24
ISSN: 0742-3098 CODEN: JPRSE
CY United Kingdom
DT Journal; Article
FS 003 Endocrinology
008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 25 Apr 2002
Last Updated on STN: 25 Apr 2002

L20 ANSWER 56 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2001019961 EMBASE
TI Energy landscape theory for Alzheimer's ***amyloid .beta .-peptide*** fibril elongation.
AU Massi F.; Straub J.E.
CS J.E. Straub, Department of Chemistry, Boston University, Boston, MA 02215, United States. straub@bu.edu
SO Proteins: Structure, Function and Genetics, (1 Feb 2001) Vol. 42, No. 2, pp. 217-229. .
Refs: 36
ISSN: 0887-3585 CODEN: PSFGEY
CY United States
DT Journal; Conference Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
LA English
SL English
ED Entered STN: 25 Jan 2001

Last Updated on STN: 25 Jan 2001

L20 ANSWER 57 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2001010030 EMBASE
TI β-Amyloid (1-42) affects MTT reduction in astrocytes: Implications for vesicular trafficking and cell functionality.
AU Kerokoski P.; Soininen H.; Pirttila T.
CS P. Kerokoski, Department of Neuroscience/Neurology, University of Kuopio, PO Box 1627, 70211 Kuopio, Finland. petri.kerokoski@uku.fi
SO Neurochemistry International, (1 Feb 2001) Vol. 38, No. 2, pp. 127-134. Refs: 36
ISSN: 0197-0186 CODEN: NEUIDS
PUI S 0197-0186(00)00071-1
CY United Kingdom
DT Journal; Article
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English
ED Entered STN: 1 Feb 2001
Last Updated on STN: 1 Feb 2001

L20 ANSWER 58 OF 79 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
AN 2000314251 EMBASE
TI Huperzine A and tacrine attenuate ***.beta.-amyloid peptide***-induced oxidative injury.
AU Xiao Qiu Xiao; Wang R.; Xi Can Tang
CS Prof. X.C. Tang, State Key Lab. of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 294 Tai-yuan Road, Shanghai 200031, China. xctang@mail.shcnc.ac.cn
SO Journal of Neuroscience Research, (1 Sep 2000) Vol. 61, No. 5, pp. 564-569. Refs: 37
ISSN: 0360-4012 CODEN: JNREDK
CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
LA English
SL English
ED Entered STN: 21 Sep 2000
Last Updated on STN: 21 Sep 2000

L20 ANSWER 59 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2007:108272 TOXCENTER
CP Copyright (c) 2007 The Thomson Corporation
DN PREV200700315208
TI Abeta Peptide and Alzheimer's Disease: Celebrating a Century of Research
AU Barrow, CJ [Editor]; Small, DH [Editor]
CS Ocean Nutr Canada, Dartmouth, NS, Canada
SO Barrow, CJ [Editor]; Small, DH [Editor]. (2007) Abeta Peptide and Alzheimer's Disease: Celebrating a Century of Research. Ref: SPRINGER, 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES. ISBN: 978-1-85233-961-6 (H).
DT Book
FS BIOSIS
OS BIOSIS 2007:315288
LA English
ED Entered STN: 28 May 2007
Last Updated on STN: 28 May 2007

L20 ANSWER 60 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2007:66414 TOXCENTER
CP Copyright 2007 ACS
DN CA14612225706T
TI Control of ***amyloid-.beta.-peptide*** generation by subcellular trafficking of the β-amyloid precursor protein and β-secretase
AU Walter, Jochen
CS Department of Neurology, University of Bonn, Bonn, D-53127, Germany.
SO Neurodegenerative Diseases, (2006) Vol. 3, No. 4-5, pp. 247-254. CODEN: NDEIA6. ISSN: 1660-2854.
CY GERMANY, FEDERAL REPUBLIC OF
DT Journal
FS CAPLUS
OS CAPLUS 2006:1092969
LA English
ED Entered STN: 13 Mar 2007
Last Updated on STN: 13 Mar 2007

L20 ANSWER 61 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2007:44125 TOXCENTER
CP Copyright 2007 ACS
DN CA14609160667J
TI Chronic but not acute intracerebroventricular administration of ***amyloid .beta.-peptide***(25-35) decreases somatostatin content, adenylate cyclase activity, somatostatin-induced inhibition of adenylate cyclase activity, and adenylate cyclase I levels in the rat hippocampus
AU Burgos-Ramos, E.; Hervas-Aguilar, A.; Puebla-Jimenez, L.; Boyano-Adanez, M. C.; Arilla-Ferreiro, E.
CS Grupo de Neurobioquimica, Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad de Alcala, Alcala de Henares, Spain.
SO Journal of Neuroscience Research, (2007) Vol. 85, No. 2, pp. 433-442. CODEN: JNREDK. ISSN: 0360-4012.
CY SPAIN
DT Journal
FS CAPLUS
OS CAPLUS 2007:152774
LA English
ED Entered STN: 13 Feb 2007
Last Updated on STN: 20 Feb 2007

L20 ANSWER 62 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2007:40872 TOXCENTER
CP Copyright 2007 ACS
DN CA14609161107P
TI Aβ-immunotherapy for Alzheimer's disease using mannan- ***amyloid -beta peptide*** immunoconjugates
AU Ghochikyan, Anahit; Petrushina, Irina; Lees, Andrew; Vasilevko, Vitaly; Movsesyan, Nina; Karapetyan, Adrine; Agadjanyan, Michael G.; Cribbs, David H.
CS Department of Immunology, The Institute for Molecular Medicine, Huntington Beach, CA, USA.
SO DNA and Cell Biology, (2006) Vol. 25, No. 10, pp. 571-580. CODEN: DCEBE8. ISSN: 1044-5498.
CY UNITED STATES
DT Journal
FS CAPLUS
OS CAPLUS 2006:1205062
LA English
ED Entered STN: 13 Feb 2007
Last Updated on STN: 27 Feb 2007

L20 ANSWER 63 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2006:238254 TOXCENTER

CP Copyright 2007 ACS
DN CA146020246462
TI The role of nitric oxide in neurodegenerative diseases and dementia
AU Fang, Marong; Wang, Mingwei; Qing, Renshi; Zhang, Lihong; Li, Jicheng; Yew, David T.
CS Department of Anatomy, Medical School of Zhejiang University, Peop. Rep. China.
SO Current Trends in Neurology, (2005) Vol. 1, pp. 81-90.
CODEN: CTNUAA. ISSN: 0972-8252.
CY CHINA
DT Journal
FS CAPLUS
OS CAPLUS 2006:686944
LA English
ED Entered STN: 18 Jul 2006
Last Updated on STN: 5 Jun 2007

L20 ANSWER 64 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2006:200141 TOXCENTER
CP Copyright 2007 ACS
DN CA14503040563E
TI Sex-dependent Actions of ***Amyloid Beta Peptides*** on Hippocampal Choline Carriers of Postnatal Rats
AU Kristofikova, Z.; Ricny, J.; Kozmikova, I.; Ripova, D.; Zach, P.; Klaschka, J.
CS Prague Psychiatric Center, Prague, 181 03 8, Czech Rep..
SO Neurochemical Research, (2006) Vol. 31, No. 3, pp. 351-360.
CODEN: NEREDZ. ISSN: 0364-3190.
CY CZECH REPUBLIC
DT Journal
FS CAPLUS
OS CAPLUS 2006:509120
LA English
ED Entered STN: 6 Jun 2006
Last Updated on STN: 11 Jul 2006

L20 ANSWER 65 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2006:144712 TOXCENTER
CP Copyright 2007 ACS
DN CA14417310455P
TI Anti-human ***amyloid .beta. peptide*** antibodies with impaired effector ***function*** for treating Alzheimer's disease, Down syndrome cerebral amyloid angiopathy, Parkinson's disease and Aβ peptide-associated diseases
AU Rosenthal, Arnon; Pons, Jaume; Ho, Wei-Hsien; Grimm, Jan Markus
PI US 2006057701 A1 16 Mar 2006
SO (2006) U.S. Pat. Appl. Publ., 76 pp.
CODEN: USXXCO.
CY UNITED STATES
DT Patent
FS CAPLUS
OS CAPLUS 2006:234583
LA English
ED Entered STN: 4 Apr 2006
Last Updated on STN: 25 Dec 2006

L20 ANSWER 66 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2005:79199 TOXCENTER
CP Copyright 2007 ACS
DN CA14223424135Y
TI Insulin protects against ***amyloid .beta.-peptide*** toxicity in brain mitochondria of diabetic rats
AU Moreira, Paula I.; Santos, Maria S.; Sena, Cristina; Seica, Raquel; Oliveira, Catarina R.
CS Center for Neuroscience of Coimbra, Department of Zoology, Faculty of Sciences and Technology, University of Coimbra, Coimbra, 3004-517, Port..
SO Neurobiology of Disease, (2005) Vol. 18, No. 3, pp. 628-637.
CODEN: NUDIEM. ISSN: 0969-9961.
CY PORTUGAL
DT Journal
FS CAPLUS
OS CAPLUS 2005:198438
LA English
ED Entered STN: 8 Mar 2005
Last Updated on STN: 29 Aug 2006

L20 ANSWER 67 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2004:271381 TOXCENTER
CP Copyright 2007 ACS
DN CA14209152749Q
TI Signal transduction during ***amyloid-.beta.-peptide*** neurotoxicity: role in Alzheimer disease
AU Fuentealba, Rodrigo A.; Farias, Ginny; Scheu, Jessica; Bronfman, Miguel; Marzolo, Maria Paz; Inestrosa, Nibaldo C.
CS Centro FONDAP de Regulacion Celular y Patologia "Joaquin Luco", MIFAB, Facultad de Ciencias Biologicas, Pontificia Universidad Catolica de Chile, Santiago, Chile.
SO Brain Research Reviews, (2004) Vol. 47, No. 1-3, pp. 275-289.
CODEN: BRERD2. ISSN: 0165-0173.
CY CHILE
DT Journal
FS CAPLUS
OS CAPLUS 2004:1024659
LA English
ED Entered STN: 7 Dec 2004
Last Updated on STN: 22 Feb 2005

L20 ANSWER 68 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2003:223404 TOXCENTER
CP Copyright 2007 ACS
DN CA13920301297H
TI Stereoselective Interactions of Peptide Inhibitors with the ***.beta.-Amyloid Peptide***
AU Chalifour, Robert J.; McLaughlin, Richard W.; Lavoie, Louis; Morissette, Celine; Tremblay, Nadine; Boule, Marie; Sarazin, Philippe; Stea, Dino; Lacombe, Diane; et al.
CS Neurochem Inc., Saint-Laurent, QC, H4S 2A1, Can..
SO Journal of Biological Chemistry, (2003) Vol. 278, No. 37, pp. 34874-34881.
CODEN: JBCHA3. ISSN: 0021-9258.
CY CANADA
DT Journal
FS CAPLUS
OS CAPLUS 2003:701932
LA English
ED Entered STN: 9 Sep 2003
Last Updated on STN: 27 Feb 2007

L20 ANSWER 69 OF 79 TOXCENTER COPYRIGHT 2007 ACS on STN
AN 2003:102003 TOXCENTER
CP Copyright 2007 ACS
DN CA13818269080Y
TI Alzheimer's disease and the basal forebrain cholinergic system: relations to ***.beta.-amyloid peptides***, cognition, and treatment strategies
AU Auld, Daniel S.; Kornecook, Tom J.; Bastianetto, Stephane; Quirion, Remi
CS Douglas Hospital Research Centre, Verdun, QC, H4H 1R3, Can..
SO Progress in Neurobiology (Oxford, United Kingdom), (2002) Vol. 68, No. 3, pp. 209-245.

CODEN: PGNBA5. ISSN: 0301-0082.
CY CANADA
DT Journal
FS CAPLUS
OS CAPLUS 2002:893187
LA English
ED Entered STN: 29 Apr 2003
Last Updated on STN: 22 Nov 2005

=>